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Chapter 1 – Design and Synthesis of a Core-Modified Oximidine Analogue 
 
 The natural products oximidine I and II are potent and selective anticancer 
agents at nanomolar concentrations. They were isolated in 1999 from the 
fermentation broth of Pseudomonas sp. Q52002 by Hayakawa and co-workers. Their 
structures and potent cytotoxicity are similar to the recently discovered natural 
products salicylihalamides, apicularens, and lobatamides, which are members of the 
benzolactone enamide family.  
 In order to explore the biological activity of oximidine II, we have 
investigated the formation of the triene macrocycle of oximidine using a RCM 
procedure, and the reductive copper-mediated macrocycle formation. We observed 
the limitation of RCM for the formation of the triene macrocycle. The chiral pool 
approach, using D-glucal, was explored as an alternative route to prepare the cis-
diene for RCM. The reductive copper-mediate protocol provided a better result. To 
facilitate the preparation of oximidine analogs, we also have chosen a simplified 
scaffold based on a quantitative structure-activity relationship (QSAR) analysis using 
the comparative molecular similarity indices analysis (CoMSIA) model reported by 
Georg et al. in 2006. We prepared by total synthesis oximidine analogues that carry a 
vinyl sulfone, a boronic acid and an !-keto oxadiazole instead of the enamide side 
chain. 
 
Chapter 2 – Novel Oximidine Analogues with Improved Stability as Anticancer 
Agents 
 Structure-activity relationship (SAR) studies for the benzolactone enamide 
family, including oximidine II, have demonstrated that the enamide side chain is 
crucial for their anticancer activity. However, it is believed that the enamide will be 
labile under physiological conditions. This has led to our hypothesis that the 
replacement of the enamide moiety with a stable warhead will allow the discovery of 
novel anticancer agents with improved pharmacokinetics.  
 We selected three different warheads that are likely to be stable under 
physiological conditions and that could undergo nucleophilic addition like the 
enamide. All new analogs were tested for cell growth inhibition against four human 
cancer cell lines: leukemia (HL-60), breast (MCF-7), and melanoma (SK-MEL-28 
and SK-MEL-5). The results showed that these analogs were micromolar inhibitors in 
the range of 20 µM – 60 µM, except for the !-keto oxadiazole that did not display 
cytotoxicity toward any of the cell lines.  
 
 
Chapter 3 – Novel Endotoxin-Sequestering Compounds with Terepthalaldehyde-bis-
Guanylhydrazone Scaffolds 
 Lipopolyamines bind to the lipid A moiety of lipopolysaccharide, a 
constituent of Gram-negative bacterial membranes, and neutralize its toxicity in 
animal models of endotoxic shock. In an effort to identify non-polyamine scaffolds 
with similar endotoxin-recognizing features, we had observed an unusually high 
frequency of hits containing guanylhydrazone scaffolds in high-throughput screens. 
We now describe the syntheses and preliminary structure-activity relationships in a 
homologous series of bis-guanylhydrazone compounds decorated with hydrophobic 
functionalities. These first-generation compounds bind and neutralize 
lipopolysaccharide with a potency comparable to that of polymyxin B, a peptide 
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Chapter 1  
Design and Synthesis of a Core-Modified Oximidine Analogue 
 
1.1 Introduction 
 Natural products from plants, bacteria, fungi, and marine microorganisms 
have been used for drug discovery campaigns for decades. Due to the unique and 
diverse structures, they provided lead compounds for the treatment of cancer, 
microbial infections, inflammation, hypercholesteremia, and tissue rejection in organ 
transplantation. It has been estimated that over 58% of all FDA approved drugs are 
derived from natural products (parent compounds, derivatives, analogues, and 
mimic).1 The natural products class of macrolactones, usually originating from 
polyketide pathways, have been reported to possess a large spectrum of biological 
activity such as insecticidal, antibiotic, and anticancer. These properties account for 
the conformational equilibrium between preorganization and flexibility to direct the 
appropriate orientation of polar and non-polar groups to the biological binding 
pocket.2, 3 
 Macrocyclic benzolactone enamides such as salicylihalamides,3, 4 lobatamides, 
5, 6 apicularen,7 and oximidines8-10 show a unique cytotoxicity profile towards the NCI 
60-cell line, suggesting a novel mechanism.  Mammalian vacuolar ATPase (V-
ATPase) enzymes have been identified as the biological target of these natural 
products. The natural products oximidines I and II are potent and selective anticancer 
agents at nanomolar concentrations. They were isolated in 1999 from the 
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1, (-)-salicylihalamide A: 17E






































 6, lobatamide A: R = H, 25Z, E-oxime ether 
 7, lobatamide B: R = H, 25Z, Z-oxime ether 
 8, lobatamide C: R = H, 25E, E-oxime ether 
 9, lobatamide D: R = OH, 25Z, E-oxime ether 
10, lobatamide E: R = OH, 25Z, Z-oxime ether 
11, lobatamide F: R = OH, 25E, E-oxime ether
 3, oximidine I: C12-C13 = !-epoxide, R = OH, 18Z
 4, oximidine II: C12-C13 = Z-olefin, R = OH, 18Z 
 5, oximidine III: C12-C13 = !-epoxide, R = H, 18E
14, apicularen A: R = H 





Figure 1. Macrocycle benzolactone enamide family 
 
 This class of compounds has drawn great interest in the synthetic and medicinal 
chemistry community due to their unique biological activity as well as intriguing 
molecular structure. The 12-membered macrocycle with a triene system in oximidine 
II, and the vinylic epoxide in oximidine I are the key synthetic challenge. Commonly 
used macrocyclization procedures including macrolactonization, ring closing 
metathesis (RCM) allowed the formation of the 12-membered ring only in modest 
yield.11-13 To add to the challenge, all natural products of this class contain an acid 
sensitive enamide side chain.13 A tremendous effort has been devoted to the 
development of new synthetic methodologies for the preparation of this class of 
 
3 
compounds.11-15 A brief review of each approach and total synthesis is included in 
this chapter. 
 
1.2 Previous synthetic studies of oximidines 
1.2.1 The Maier Approach
11
  
 Maier and Scheufler reported the synthesis of a macrocycle model system 
lacking the conjugated diene/triene by using as key synthetic steps a sequence 

















1) 80% AcOH, 90%
2. LiOH, MeOH,

























19 20 21  
Scheme 1. Maier and Scheufler approach 
 
The Stille coupling of vinyl stannane 16 with triflate 17 provided styrene 18. After 
acetal deprotection and ester hydrolysis, the intermediate was subjected to 
Yamaguchi macrolactonization to provide a mixture of lactones 20 and 21 in a 3:2 





































Scheme 2. Maier and Scheufler Approach for Yamaguchi macrolactonization 
 
The preference for a 12-membered ring product, 23, over an 11-membered ring 
product, 25, was driven by both thermodynamic and kinetic factors.18, 19 Interestingly, 
macrocyclization attempts with a di-protected alcohol led to much lower yield.  
 
1.2.2 The Coleman Approach
12
 
 Coleman and Garg used the Miura-modified Castro-Stephens reaction20 for 
the coupling of a vinyl iodide and an alkyne to form enyne or dienyne 12-membered 
macrocycles.12 The reactions of the intermediates 26, 29, and 32 with a catalytic 
amount of CuI, triphenylphosphine and K2CO3 in DMF at 120 °C provided the 
desired products in modest yield; however, the epoxide lactone 35 failed to deliver 
the desired product, Scheme 3. This might be due to the instability of the epoxide.  
The resulting intermediates were subjected to Boland reduction21 to afford the (E,Z)-
diene 28, 34 and (E,Z,Z)-triene 31 macrocycles. The modest yield for the copper-
mediated macrocyclization might be due to the strain of the ring system. 
 
5 
Computational modeling of 30 (MMX force field) showed an out-of-plane bending of 







































































Scheme 3. Coleman and Garg approach 
 
1.2.3 The Taylor Approach
14
 
 Taylor’s group reported the first synthesis of the epoxide-containing 
macrolactone of oximidine I by using the intramolecular Horner–Wadsworth–

























































43 44 45  
Scheme 4. Taylor approach toward the epoxy macrocycle of oximidine I 
 
The commercially available 3-butyn-1-ol was used to prepare the cis-epoxy alcohol 
39 in eight steps, and the phosphonate aryl acid 41 was prepared from methyl 2-
methylbenzoate in three steps. After Yamaguchi-type activation of the aryl-acid 41, 
the alcohol 39 was added to obtain the intermediate 42 in 70% yield. The acetate 
group of 42 was cleaved in the presence of CsCO3 and Et3N in MeOH at 0 °C to 
provide the primary alcohol 43. Subsequent Swern oxidation furnished aldehyde 44 in 
good yield. The macrolactone containing epoxide 45 was obtained in 25% from the 
HWE intramolecular olefination using KOtBu and 18-crown-6.  
 
1.2.4 The Porco Synthesis of Oximidine II
13
 
 The first total synthesis of oximidine II was reported by Porco and Wang in 
2003. The RCM25-28 was used for the macrocycle formation of a well defined bis-
 
7 
diene to construct a highly constrained triene core. The retrosynthetic analysis 






































Figure 2. Porco and Wang’s retrosynthetic analysis of oximidine II 
 
Copper-mediated amidation29 of (Z)-vinyl iodide 47 and amide 46 was used for the 
late stage installation of the enamide side chain. The main task was to deliver the 
macrocyclic triene from bis-diene intermediate 48 using RCM. Transesterification30 
between salicylate 50 and diene-alcohol 49 would generate the macrocycle precursor 













     DMF, 94%
2. cat. OsO4, NMO
   THF/H2O 
3. K2CO3, Pb(OAc)4




OPMB 1. tert-BuLi, allyldiphenylphosphine













Scheme 5. Porco and Wang diene-alcohol synthesis. 
  
 Their asymmetric total synthesis began with the preparation of the diene-
alcohol 49 from the enantioenriched alcohol 53, Scheme 5. The Brown asymmetric 
allylation31 of aldehyde 51 and allyl methoxymethyl ether 52 with (+)-!-
methoxydiisopinocamphenylborane gave (S,S)-triol 53 as a single diastereomer with 
90% ee. Silylation of the secondary alcohol 53, followed by the dihydroxylation and 
cis-diol cleavage afforded aldehyde 54 which underwent Yamamoto’s protocol31 to 
obtain (Z)-diene and upon desilylation provided cis-diene 49.   
The diene-acetonide 50 was prepared by the homologation of (E)-crotonaldehyde 55 
to afford dienyl stannane32 56 which was coupled with known triflate33, 34 57 under 
Stille coupling conditions, Scheme 6.35 Treatment of alcohol 49 with NaHMDS 
followed by the addition of acetonide 50 afforded the sodium phenolate intermediate 



























Scheme 6. Porco and Wang bis-diene synthesis 
 
The TBS group was strategically placed in order to force a specific conformation 
which facilitates the macrocycle formation under kinetic control.13, 36-38 In the absence 
of TBS, they never observed the product of macrocyclization and only oligomeric 









































         Grubbs's 
2nd Generation Catalyst
 
Scheme 7. Porco and Wang RCM approach for macrocycle triene formation 
 
The first generation Grubbs’s catalyst was ineffective under several reaction 
conditions while the second generation Grubbs’s catalyst was able to catalyze the 
macrocycle formation in 48% overall yield (39% for the first cycle and 9% for the 
second cycle). Further experimentation showed that prolonged reaction times resulted 
in decomposition of both starting material and product. It is worth noting that using 
bis-diene 63 with Grubbs’s 1st or 2nd generation catalysts led to a stable complex 64 
 
11 
from the reaction of ruthenium with the trans-diene with no further progress of the 
reaction, Scheme 8. Thus the installation of a trans-methyl group on the trans-diene 


















Scheme 8. Porco and Wang synthesis of the stable Ru-complex 
 
 To complete the total synthesis, the triene macrocycle 60 was subjected to DDQ 
oxidative cleavage of the PMB ether and the resulting alcohol was oxidized with 
pyridinium dichromate. The crude aldehyde was converted to the vinyl iodide 65 as a 
single isomer using the Stork-Zhao protocol39 which utilizes the light sensitive 
iodomethyl(triphenyl)phosphonium iodide salt. Deprotection of the methoxymethyl 









































 Scheme 9. Porco and Wang completion of the total synthesis of oximidine II 
 
 After several model studies, (Z)-vinyl iodide 47 was coupled with oxime amide 
46 using a stoichiometric amount of copper (II) thiophene carboxylate (CuTC),40 
N,N-dimethylethylene diamine and K2CO3.
29 The crude amide was desilylated with a 
buffered solution of HF/pyridine to afford oximidine II (4) in 44% yield over the final 
two steps.  
 
1.2.5 The Porco Synthesis of Oximidine III
41
 
 The synthesis of oximidine III, bearing an epoxide at C12-C13 is even more 
challenging as demonstrated by the model studies conducted by Coleman and 
Taylor.12, 14 Porco and Wang reported the first total synthesis of oximidine III using 






































68, R2 = H
69, R2 = (CH2)3CH=CH2
70, R2 = H






72, R1 = cis-Me
73, R1 = trans-Me
74, R1 = cis-
iPr
 
Figure 3. Porco and Wang’s retrosynthetic analysis of oximidine III 
 
 The retrosynthetic analysis is a similar to the one for oximidine II, Figure 3. 
Based on their experience with the synthesis of oximidine II, they expected that the 
ruthenium would react first with the epoxy-ene terminus of the intermediate 68 to 
form the desired macrocycle. The synthon 69 was also considered since it would 
allow a Relay ring-closing metathesis (RRCM) and overcome the slow initiation step 











70, R2 = H








4 steps O O
O
R1
72, R1 = cis-Me
73, R1 = trans-Me
74, R1 = cis-
iPr  
Scheme 10. Porco and Wang synthesis of alcohols and salicylates 
 
The enantio-pure epoxide 75 was generated through a hydrolytic kinetic 
resolution using Jacobsen’s protocol44 and was then converted to epoxy-ene alcohol 
and epoxy-diene alcohol fragments 70 and 72 in six steps. The salicylate fragment 72, 
73, and 74 were prepared in four steps starting with the coupling between triflate 57 
and vinyl stannane 76. The RCM precursors were generated from the 
transesterifications of the salicylates and the alcohols, followed by protection of the 
phenolic hydroxy group.  
 After extensive experimentation for both RCM and RRCM, they found that 
RRCM gave yields in the range of 30-71% yield when either Grubbs’s 2nd generation 
catalyst or Hoveyda-Grubbs’s 2nd generation catalyst were used. Instead, RCM 
occurred in 12-15% yield with both catalysts. The best result, at 71% yield, was 
obtained when 78 was used with Hoveyda-Grubbs’s 2nd generation catalyst as shown 
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78 79  
Scheme 11. Porco and Wang RRCM to provide macrocycle of oximidine III 
 
Similar transformations, as employed for the synthesis oximidine II, were used to 
complete the total synthesis oximidine III. 
 
1.2.6 The Molander Synthesis
45
 
  Molander and Dehmel reported a formal synthesis of oximidine II in 2004 by 
synthesizing triene core 80. The initial proposal is illustrated in the retrosynthetic 
analysis, Figure 4. Their success relied on a key macrolactonization step via 












































Figure 4. Molander and Dehmel’s retrosynthetic analysis of oximidine II 
  
The precursor 81 of the Suzuki macrocyclization has all required double bonds and 
upon reaction it will be converted into 80, an intermediate in the Porco’s total 
synthesis. In a similar fashion to Porco’s synthesis, a transesterification will be used 
to couple the salicylate 82 and the alcohol 83. The diastereoselective chelation-
controlled addition of an organometallic nucleophile derived from 84 and a !-chiral 




















































58% three steps 58% two steps
85%
 
Scheme 12. Molander and Dehmel first generation approach 
  
 The synthesis began with the preparation of 84 in three steps employing a 
double Sonogashira coupling with cis-1,2-dichloroethylene.51-53 The alcohol 87 was 
prepared by the addition of zinc acetylide to aldehyde54 85 (Carreira’s protocol)55-58 in 
the presence of stoichiometric (+)-N-methylephedrine (NME). The resulting alcohol 
was protected with MOMCl and the selective hydrogenation of the less hindered 
alkyne followed by the reductive cleavage of the benzylidene acetal (by the 
coordination of DIBAL to the MOM group)59 provided selectively the secondary 
alcohol 83. Base-mediated transesterification between alcohol 83 and salicylate 82 
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was followed by the desilylation of TIPS group to give 88.  The resulting 88 was 
converted into triflate 89 uneventfully; however, after extensive efforts the 
hydroboration of the terminal alkyne was unsuccessful. 
 Therefore it was necessary to change slightly the synthetic sequence. The 
transesterification between salicylate 92 and alcohol 91 gave the ester 93 followed by 
hydroboration using Snieckus’s reagent60 to provide the precursor 95 for the 
macrocyclization. Optimization of the intramolecular Suzuki-Miyaura coupling gave 
42% yield in two steps from alkyne 96. To complete the formal synthesis of 
oximidine II, protecting group manipulations provided the triene-macrocycle 80 


































2) DDQ, buffer pH 7
72% two steps
1) 2,5-dimethylhexa-2,4-diene
    BH3•DMS then H2O











99% two steps 42%
 
Scheme 13. Molander and Dehmel completion of the formal synthesis of oximidine II 
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1.2.7 The Georg Synthesis of Oximidine II
15, 61 
 In 2003, Georg and co-workers reported a model study towards the synthesis 
of oximidine I and II using the modified Castro-Stephens conditions previously 
reported by Coleman and Garg for the ring closing step, in Scheme 14.15 The reaction 
did not yield the expected C8-C9 trans double bond product, a cis double bond of 98 
was formed as a major product instead accompanied by 3% yield of the unexpected 
99 (unpublished data). A coupling constant of C8-C9 of 98 at 12 Hz and a strong nOe 
between C8 and C9 was observed which suggested a Z-olefin geometry while Coleman 






















97 98, 31% 99, 3%  
Scheme 14. Georg and Haack approach using Castro-Stephens macrocyclization 
 
 This led to the hypothesis that under Castro Stephens conditions, an E to Z 
isomerization of the triene occurred under the specific reaction conditions – one 
equivalent of 97, 0.10 equivalents CuI, 0.20 equivalents PPh3, 1.75 equivalents 
K2CO3 in 0.005 M anhydrous DMF heated at 110 °C for 26 h. However, there was no 
clear explanation for the formation of the triene macrocycle 99 at that time. It was 
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concluded that the isomerization of the desired product was governed by 
thermodynamic driving force. This hypothesis is supported by DFT and MP2 
calculations, Figure 5.15 The results showed that the relative energy of the alkyne 
containing macrocycle 100 is lower than that of 101 by 11-16 kcal/mol. Interestingly, 
the reduced triene 102 containing the cis C8-C9 double bond has higher energy than 
the (E,Z,Z)-macrocycle 103 by 2-5 kcal/mol. Furthermore, the ene-enyne macrocycle 
105 with an E double bond at C8-C9 showed a lower energy than macrocycle 104 by 

















Figure  5. Georg and Haack conformational analysis 
  
 After extensive studies on the formation of the unexpected triene 99, Georg 
and Schneider developed a novel copper-mediated reductive coupling under Castro-
Stephens conditions, which was found to be effective towards the total synthesis of 

















Scheme 15. Georg and Schneider Isomerization of E to Z-alkene 
 
They observed that both Z- and E-dienyne isomer products were obtained from the 
treatment of 106 during the Castro-Stephens reaction in the absence of light. 1H NMR 
studies showed that the E-dienyne 107 product was converted to the Z-dienyne 108 
after 8 h in a CDCl3 solution at 0 °C. This evidence suggested that the Castro-
Stephens reaction is stereospecific. Reductions of dienyne 109 under the Boland 
reduction gave the (E,Z,Z)-triene 110 as predicted from computer modeling. 











109 110  
Scheme 16. Georg and Schneider Boland reductions 
 
They proposed that the triene may be formed upon addition of a reducing 
agent in the presence of the copper catalyst during the Castro-Stephens coupling. 
Copper hydrides were considered since they are well known in the literature to reduce 
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alkynes to cis-alkenes. The in situ generation of Cu-H  (Stryker’s protocol)62 provided 
















Scheme 17. Georg and Schneider in situ generation of Cu-H under Castro-Stephens  
 
After considerable investigations, they discovered that sodium formate can be 
used as a hydride source for the copper-mediated reductive intramolecular coupling 
as shown in Scheme 18. As a copper source, both CuI and Cu(OAc)2 are effective for 
















Scheme 18. Georg and Schneider reductive Castro-Stephens to provide triene core 
 
Mechanistically, they proposed that the dienyne adduct of the Castro-Stephens 
reaction was coordinated to the Cu-H species forming a !-complex, preventing the 
isomerization of C8-C9 E to Z. The hydride transfer took place to the sp2 carbon of 
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the alkyne to give a "1 "#Cu complex which can easily undergo protonolysis to give 






















Scheme 19. Georg and Schneider deuterated-sodium formate experiments 
 
The deuterated-sodium formate gave only mono deuterium species at either 
C10 or C11, Scheme 19.  
 Georg and Schneider applied the novel copper-mediated reductive coupling to 
the total synthesis of oximidine II for the formation of the requisite triene 110 as 
shown in the retrosynthetic analysis, Figure 6. The installation of the enamide can be 
done through a copper-mediated amination using Porco’s protocol. The secondary 
alcohol could be synthesized from the commercially available 1,3-propanediol. 
Sharpless asymmetric dihydroxylation (SAD)63-65 would provide the desired cis-diol. 



















































Figure 6. Georg and Schneider’s retrosynthetic analysis of oximidine II 
  
 Their total synthesis began with the preparation of the secondary alcohol 114 
as shown in Scheme 20. The 1,3-diol was converted to the diol 117 in five steps, 
involving silylation, oxidation to aldehyde, HWE Wittig homologation, and SAD. 
The primary alcohol 118 was obtained in five steps after protecting group 
manipulations. Oxidation of alcohol 118 with Dess-Martin periodinane gave aldehyde 
intermediate 119 and was followed with the Peterson Olefination and desilylation to 
provide the desired enyne 121. After deprotection of PMB group using DDQ, 










































Scheme 20. Georg and Schneider synthesis of alcohol 114 
 
 The required vinyl iodide salicylate 115 was synthesized from the known 
triflate 57 and vinyl(trimethyl)silane under Heck coupling conditions to provide silyl 
salicylate 123 (Scheme 21). Iododesilylation (Kishi’s protocol)69 led to the desired 























 The transesterification between alcohol 114 and vinyl iodide salicylate 115 
followed by the in situ methylation gave the intermediate 111. The reductive copper-
mediated coupling of 111 gave the triene macrocycle 110. Protecting group 
manipulations, oxidation and Stork-Zhao Wittig homologation gave the Z-vinyl 









































Scheme 22. Georg and Schneider completion of the total synthesis of oximidine II 
 
 
1.3 Synthesis of the macrocyclic core structure of oximidine II and congeners 
 
1.3.1 Attempt to improve of Porco and Wang’s route 
Due to the high cytotoxicity and selectivity of oximidine II, we aimed at 
exploring the Structure-Activity Relationships (SAR) of this natural product in the 
enamide region. The first task was to synthesize the requisite triene macrocycle 124 
by applying known procedures. We hypothesized that Porco’s protocol13 could be 
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improved by subjecting the triene 126 to RCM, which would generate a more flexible 
macrocycle as shown in our retrosynthetic analysis. The third conjugate double bond 
could be introduced by oxidative cleavage of a selenium species to form the desired 
triene core structure 124.70 The alcohol 127 would be synthesized using Molander’s 































Figure 7. Retrosynthesis to improve the RCM  
 
The synthesis of the alcohol diene 127 was adopted from Molander’s 
protocol45 and started with the (S)-1,2,4-butanetriol to provide the desired diene in 
nine steps (Scheme 23).  Butanetriol was protected as 1,3-benzylacetal 130 and the 
primary alcohol was oxidized to give the corresponding aldehyde (Swern oxidation). 
The diastereoselective addition of the terminal alkyne to aldehyde 131 proceeded 
uneventfully in the presence of (+)-NME to provide the desired diastereomer in good 
 
28 
yield.45, 57 The resulting alcohol was protected with MOMCl and the following 
hydrolysis of the primary acetate provided a colorless crude oil, which was then 
subjected to partial hydrogenation to give cis-propargyl alcohol 132.45  Oxidation of 
propagyl alcohol 132 with IBX provided the aldehyde which was subjected to Wittig 
homologation with trimethyl phosphonium ylide to give the desired diene 133. 
Reductive cleavage of benzylidene acetal 133 with DIBAL yielded the desired 
product 127 in good yield; however, TLC showed quantitative conversion to the 

























1) i) oxalyl chloride
     DMSO, -78 oC 
    ii) Et3N
2)  i) (+)-NME
     Zn(OTf)2, NEt3



















Scheme 23. Synthesis of alcohol diene 127  
 
The precursor of the macrocyclic core was synthesized as shown in Scheme 
24. The 2,6-dihydroxybenzoic acid was treated with acetone and thionyl chloride to 
give the hydroxy acetonide which was further reacted with triflic anhydride followed 
by methyl cuprate coupling to afford methyl salicylate 135.71 The intermediate was 
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treated with n-BuLi and diphenyl diselenide to afford 136.70 The selenide was then 
alkylated with allyl bromide, and the resulting intermediate was subjected to 





























    SO2Cl2, 53%
2)  Tf2O, Py., 90%
MeLi (4 equiv),
CuI (2 equiv)













Scheme 24. Synthesis of RCM precursor 
 
 The transesterification of salicylate 5013 and alcohol 127, and in situ silylation 
with TBSCl provided the bis-diene 137, Scheme 25. We assumed that the 
intermediate 137 containing a benzyl protecting group should behave in a similar way 
















Scheme 25. Synthesis of bis-diene 137 
 
 Ring closing metathesis of bis-diene 137 with 2nd generation Grubbs’s catalyst 
(59) proceeded only with low yield, Scheme 26. Screening of other catalysts did not 
increase the yield of macrocycle formation. Better results were obtained when 126 
was reacted with the 2nd generation Grubbs’s catalyst to afford the diene product 125 
in 22% yield. The following oxidative cleavage70 occurred in 27% yield to give the 






































1.3.2 Synthesis of the homolog macrocyclic triene 
 Even though a higher yield for macrocycle formation of the diene 124 
macrocycle was observed, the overall yield for triene formation was much lower than 
Porco’s approach. Thus we decided to use Porco’s protocol to prepare our desired 










     DMF, 71%(140)
2. cat. OsO4, NMO
   THF/H2O 
3. K2CO3, Pb(OAc)4

































Scheme 27. Synthesis of the homolog macrocyclic triene core 
 
 The alcohol 139 was synthesized in a similar manner as described by Porco and 
Wang as shown in Scheme 27. The synthesis began with a Brown asymmetric 
allylation to provide secondary alcohol 139.13 The adduct 139 was silylated with 
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TBSCl, and subjected to dihydroxylation and oxidative cleavage to give aldehyde 
141. Using Yamamoto’s protocol, the aldehyde was converted to alcohol 142. The 
required alcohol 142 was obtained after the deprotection of the TBS group. The 
transesterification between salicylate 50 and alcohol 142 and in situ silylation gave 
the intermediate 143. The RCM with Grubbs’s 2nd generation catalyst gave the 
requisite triene 144 accompanied by an oligomeric product.  
 
1.3.3 Chiral pool approach 
 A chiral pool approach was used to prepare alcohol 149. The hydroxyl O-ethyl 
glycoside 146 was prepared from tri-O-acetyl-D-glucal (Glucal) in three steps using 
known chemistry, involving a Ferrier rearrangement73-75 by reaction with anhydrous 


















1. EtOH, cat. SnCl4
2. MeOH, cat. NaOMe
3. i) Bu2SnO, toluene, reflux
    ii) BnBr, TBABr
64% over three steps
1. MOMCl, i-Pr2NEt
2. Zn(NO3)2, MeCN, 60 °C







148 149  
Scheme 28. Chiral pool approach to prepare alcohol 149 
 
After methanolysis with sodium methoxide to remove the acetyl groups, the resulting 
primary alcohol was protected with the benzyl group to afford a colorless oil in 64% 
yield over three steps with only one flash chromatography column. The resulting 
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hydroxyl glycoside 146 was protected with MOMCl. Hydrolysis of the ethyl acetal 
group in the presence of Zn(NO3)2 revealed the hemiacetal.
76 Wittig homologation 
provided a cis-diene 147 in 38% yield. The secondary alcohol product was subjected 
to the Mitsunobu reaction77 to install the desired configuration of the hydroxyl group.  
The desired product 149 was obtained as single isomer in gram scale after the 
hydrolysis of the p-nitrobenzoyl moiety in 82% yield.78 Large-scale preparation of 
diene 146 was achieved in eight steps from 20 grams of glucal. 
 The transesterification between alcohol 149 and salicylate 50 gave the 




















 Scheme 29.  Synthesis of RCM precursor    
           
Unfortunately, the RCM with the new cis-diene gave unsatisfactory results as seen 
earlier with a maximum yield of 15-17% yield by increasing the amount of the 2nd 








Table 1. RCM yield with 2nd generation Grubbs’s catalyst in DCM 
_________________________________________________ 
 
   % Catalyst         time          151, yield             amount 
_________________________________________________ 
       5%            80 min           9%            12.2 mg 
    15%             80 min         17%            10.9 mg 
     20%            80 min          11%             7.2 mg 
________________________________________ 
 
1.3.4 Intramolecular reductive copper-mediated macrocycle formation 
 While we were investigating the RCM approach, the novel reductive copper-
mediated macrocycle formation was developed in our lab by Georg and Schneider.61 
We decided to use this methodology for the preparation of the triene core structure of 
oximidine II needed for our SAR studies. We envisioned using the alcohol 153 
(Scheme 30) prepared by Brown asymmetric allylation13, 31 to produce the required 
alcohol 114.61 
 The synthesis began with the Brown asymmetric allylation of aldehyde 152, 
Scheme 30, to provide the desired secondary alcohol 153. The silylation and 
dihydroxylation followed by oxidative cleavage gave the aldehyde 155 which was 
used directly for the Peterson olefination.61 The desilylation with TBAF gave diol 157 













     DCM, 100% (154)
2. cat. OsO4, NMO
   THF/H2O 
3. K2CO3, Pb(OAc)4



























Scheme 30. Synthesis of diol 157 using Brown asymmetric allylation 
 
The two-step procedure to propare aldehyde 155 was replaced with an 
ozonolysis procedure as shown in Scheme 31. After reductive work-up with 
dimethylsulfide, the aldehyde 155 was placed under high vacuum to give an opaque 
oily material which was subjected directly to Peterson olefination without further 
purification. The crude was subjected to desilylation with TBAF to give diol 157 in 
51% over three steps. The silylation of the primary alcohol adduct gave the common 
intermediate 114 generated during the Georg and Schneider synthesis. 
TIPS
TIPS
























Scheme 31. Synthesis of common alcohol intermediate 114  
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 Transesterification product 111 was prepared according to the reported 
procedure, Scheme 32.61 The intermediate 111 was subjected to the reductive copper-
mediated macrocycle formation in the presence of trimethylphosphite to provide the 
triene macrocycle 110 in a comparable yield to the previous report, using triphenyl 























Scheme 32. Formation of the triene macrocycle  
 
 
1.3.5 Simplified analogue strategy 
To facilitate the preparation of oximidine analogues, we have chosen a 
simplified scaffold approach based on three-dimensional quantitative structure-
activity relationship (3D-QSAR) analysis using the comparative molecular similarity 
indices analysis (CoMSIA) model reported by Georg and co-workers.79  
 A 3D-QSAR model consists of a mathematical equation describing potency as a 
function of 3D interactive fields around aligned training set compounds presumed to 
be the biologically active structures.80, 81 This correlation is derived from a series of 
superimposed conformations, one for each molecule in the set that includes 3D spatial 
changes of interactive field values and the biological activity of molecules. The most 
common methods to calculate 3D descriptors are comparative molecular field 
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analysis (CoMFA)82 and comparative molecular similarity indices analysis 
(CoMSIA).83 Both CoMFA and CoMSIA are based on the assumption that changes in 
binding affinities of ligands are related to changes in molecular properties, thus 
correlating molecular properties with the experimental biological activity. CoMFA 
derives a 3D-QSAR model by systematically sampling the steric (van der Waals 
interactions) and electrostatic interactions (Coulombic interactions) at regularly 
spaced grid points surrounding a specific target protein; meanwhile, CoMSIA uses a 
Gaussian type function to avoid the extreme values generated by Lennard-Jones and 
Coulombic functions. The Gaussian function also results in smoother, less fragmented 
surfaces in the final model representation.83 
The advantage of 3D-QSAR methods is that there is no need for initial active-
site information and it can be used to investigate a variety of enzyme-inhibitor 
interactions. The 3D-QSAR can be used for the virtual screening of potential drug 
candidates as well as to improve the potency of existing compounds.84, 85 
The development of 3D-QSAR of V-ATPase inhibitors was derived from the 
CoMSIA model by including 23 known mammalian V-ATPase inhibitors in the 
training set, including benzoate and benzolactone (salicylihalamides, lobatamides, 
lobatamide analogues, and oximidines).79 The model showed a good correlation with 
bovine ATPase IC50 data (R
2 = 0.968, Q2 = 0.553). It also showed reliability for 
prediction of human kidney V-ATPase inhibition by lobatamide compounds (R = 
0.862). The electronic terms appear to dominate, with a normalized weight (0.735) 
nearly three times of steric (0.265). The result also showed that the lactone ring in 
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salicylihalamide might, in concert with the enamide double bond, play a critical 
compensatory role in the activity. It showed that the salicylihalamide appears to 
exhibit fairly optimal electrostatics; its activity may be improved by making 
adjustment for the steric factor. In particular, it may be possible to explore a slightly 
bulkier group such as ethyl or t-butyl to replace the methyl group on the lactone ring 
to enhance the interaction with a steric favorable region. 
For our simplified core structure generation, the test scaffolds were designed 
based on the ease of preparation and the availability of starting material, Figure 8. We 
refined our proposed molecules into 3D structures using SYBYL to full molecular 
mechanics convergence using the Tripos Force Field86 and Gasteriger-Marsili 
charges. The resulting structures were then flexibly aligned using Surflex87 to the 
putatively bioactive conformation of salicylihalamide derived from the CoMSIA 
study of Georg and co-workers.79 Finally, Gasteiger-Marsili charges were assigned to 
these resulting structures88 and their positions and orientations within the CoMSIA 
field were refined via the field-alignment algorithm implemented within the 
QSAR/CoMSIA module of SYBYL89 using default settings. The summarized results 
were obtained and analyzed by Dr. Gerald Lushington (Molecular Graphics & 








































































158 159 160 161
162 163 164 165
166 167 168

















Table 2. CoMSIA/QSAR predicted IC50 values for V-ATPase inhibition of proposed 
structures using oximidines and lobatamides as controls 
    
Molecule predicted IC50  (nM) 
    
Oximidine I, (3) 2.02 
Oximidine II, (4) 1.47 
Lobatamide A, (6) 4.91 
Lobatamide B, (7) 4.56 
Lobatamide D, (9) 2.28 
Lobatamide E, (10) 2.14 

















The predicted IC50 of the proposed structures showed equipotent inhibition toward V-
ATPases relative to lobatamides or oximidines.  The general scaffolds of these 























Figure 9. General scaffolds of evaluated structures  
 
Among the four, we chose scaffold 176 which can be prepared in a few steps. The 


















  53, n = 1
139, n = 2  
Figure 10. Retrosynthetic analysis of simplified scaffold 
 
The ring closing metathesis is the key step that allows the formation of a macrocycle 
from a linear intermediate resulting from transesterification of salicylate 177 with 
alcohols 53, and 139. 
 The synthesis of salicylate 177 is shown in Scheme 33. The hydrostannylation 
of 4-pentyn-1-ol gave trans-vinylstannane in good yield.90 The crude NMR showed 
exclusively trans-alkene; however, the attempt to purify the product on a silica 
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column led to the isomerization and low yield. This might be due to the acid sensitive 
nature of the vinylstannane. Parikh-Doering oxidation91 of vinylstannane was 
followed by Wittig reaction to give the crucial intermediate for Stille coupling.92 The 
desired salicylate 177 was obtained in 93% over four steps when palladium tetrakis 
was used as a catalyst while the lower yield of 52% was obtained with the Pd2(dba)3 








triflate 57, Pd(PPh3)4, LiCl, 70 °C
    Bu3SnH, Pd2(dba)3, (Cy)3PHBF4, 
    i-Pr2NEt, 0 °C, 4!h
1. SO3•Py., DMSO, Et3N
2. t-BuOK, MePPh3Br
93%  over four steps
 
Scheme 33. Synthesis of salicylate 177 
 
The alcohol 53 and 139 were prepared in one step by Brown asymmetric allylation 











  51, n = 1
138, n = 2
52
80%n n
  53, n = 1, 80%
139, n = 2, 88%  




The transesterification between salicylate 177 and alcohols 53, 139 proceeded 
uneventfully in the presence of NaHMDS and THF. Upon TBS protection of the 
phenolic hydroxyl group, intermediate 181 and 182 were subjected to RCM to yield 
the thermodynamically favored products 183 and 184 in 61%, and 69% yield. The 
two pairs of J coupling values at 15-16 Hz suggested the formation of E,E-bis-diene 












183, n = 1, 61%, three steps





  53, n = 1
139, n = 2
1. NaHMDS 
    salicylate 177
2. TBSCl, imidazole
  181, n = 1
  182, n = 2  
Scheme 35. Completion of the synthesis of simplified macrocycles 
 
The attempt to deprotect the MOM group of 184 using CBr4 led to the isolation of the 
desired product 185 and diol 186, Scheme 36.13 The diol 186 was recrystallized from 
a mixture of diethyl ether and hexanes and analyzed by X-ray crystallography. The X-
ray data was obtained and analyzed by Dr. Victor Young (X-ray Crystallographic 
Facility, Department of Chemistry, University of Minnesota). The OTEP drawing of 

















+CBr4, i-PrOH, 70 °C
185, 54% 186, 45%184  






Figure 11. OTEP drawing of E,E-bis-diene macrocycle 
 
1.4 Conclusion 
 In conclusion, we have investigated the formation of the triene macrocycle of 
oximidine using a RCM procedure, and the reductive copper-mediated macrocycle 
formation. We observed the limitation of the RCM reaction for the formation of the 
triene macrocycle. The chiral pool approach, using D-glucal, was explored as an 
alternative route to prepare the cis-diene for the RCM reaction. The reductive copper-
mediate protocol provided a better result. Macrocycles containing a simplified triene 
core were designed based on CoMSIA/QSAR analysis, and prepared using the RCM 
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reaction. We anticipated that the change in the triene core would not affect the 
activity of these analogues, which would show similar potencies when compared with 
macrocycles containing the original oximidine core. This will be discussed further in 






















Novel Oximidine Analogues with Improved Stability as Anticancer Agents 
 
2.1 Biological Significance of V-ATPases 
 V-ATPases are a class of enzymes that reguate intraorganellar acidity by 
translocating protons from cytoplasm to the lumen, using the energy from the 
hydrolysis of the ATP.93-95 The electrochemical gradient generated from this process 
provides a driving force for the movement of ions and solutes into the vacuole. V-
ATPases are distributed throughout eukaryotic cells and tissues, and are located on 
the membranes of vacuoles, lysosomes, and other components of the endo membrane 
systems.96-98  
These enzymes play a crucial role for a variety of physiological functions 
including membrane and organellar protein sorting, neurotansmitter uptake, cellular 
degradations, and receptor recycling. In various intracellular compartments including 
endosomes, lysosomes, and secretory vesicles, V-ATPases function in processes such 
as receptor-mediated endocytosis,99 intracellular targeting of lysosomal enzymes,100 
protein processing and degradation,94 and the coupled transport of small molecules.101 
  V-ATPases are involved in acid secretion, bone degradation, 
homeostatis of cytoplasmic pH, and sperm maturation.102, 103 V-ATPases present in 
the apical membrane of type-A renal intercalated cells play a role in maintaining the 
acid-base balance of kidney cells.104 Metabolic acidosis is caused by a defect in renal 
acidification resulting from the mutation of human genes.105, 106 In bone, resorption 
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and remodeling is conducted by osteoclasts which possess V-ATPases on their 
plasma membrane.107-109 Acidification of the bone surface leads to dissolving the 
bone matrix and activating osteoclast-secreted acid hydrolases. The high acid 
production rates from metabolism in macrophages and neutrophis are neutralized by 
the action of V-ATPases.98, 103 
V-ATPases have been proposed to take part in tumor metastasis by secreting 
lysosomal enzymes to degrade the extracellular matrix, which is essential for 
metastatic invasion. High glycolysis rates inside cancer cells lead to a large amount of 
acid production; however, an alkaline cytoplasmic pH is necessary for cancer cell 
survival. To survive in this harsh environment, tumor cells must upregulate V-
ATPases to pump extra protons out of cellular space. Immunocytochemical 
experiments revealed that V-ATPases in human breast cancer cell lines are expressed 
more in highly metastatic than in low metastatic cells.110  
Based on these findings, V-ATPases have attracted considerable attentions as 










2.2 Structure of V-ATPases 
 V-ATPases are large multisubunit complexes consisting of two domains, an 
ATP-hydrolyic domain (V1), made of peripherally associated subunits, and a proton-
translocation domain (V0), made of membrane-bound subunits.
97, 111 The V1 domain 
(640 kDa) is comprised of eight different subunits (A-H) that control the hydrolysis 
of ATP. The V0 (260 kDa) is an integral complex of six different subunits (a, c, c’, 
c’’, e, and d) which are responsible for proton translocation. The mammalian cells 








Figure 12. Schematic struture of V-ATPase 
 
The V1 ATP-driven rotor consists of three copies of the A and B subunits, two 
copies of the E and G subunits, one or two copies of subunit H and a single copy of 
each of the remaining subunits. The subunits A and B form a hexamer of nearly 400 
kDa which serves as the ATP binding sites at one of the two types of interface of the 
A and B subunits. The other subunits form one of two types of stalks — peripheral 
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and central. They connect the V1 and V0 domains. The central stalk, the D subunit, 
functions as a rotor to couple the energy from the hydrolysis of ATP to the rotation of 
a ring of proteolipid subunits in V0. 
112 
 
Table 3. Subunit Composition of a Typical Mammalian V-ATPase113 
        
Subunit Molecular Mass Number of Domain 
 (kDa) Subunits  
    
A 70 3 V1 
B 60 3 V1 
C 40 1 V1 
D 34 1 V1 
E 33 1 V1 
F 14 1 V1 
G 13 2 V1 
H 15 1 V1 
a 100 1 V0 
d 38 1 V0 
c 16 5 or 6 V0 
c' 16 5 or 6 V0 
c" 23 1 V0 
    
 
The V0 domain is composed of four or five copies of subunit c and a single 
copy of each of the remaining subunits. The complexation of proteolipid subunits (c, 
c’, and c”) forms a highly hydrophobic ring in the transmembrane region. Its subunits 
contain a single buried glutamate residue located in transmembrane helix-4 (TM4) of 
subunit c and c’, and TM3 of subunit c” that are responsible for harboring the proton 
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to be transported across the membrane via reversible protonation. The subunit d, 
tightly bound peripheral subunit, is located on top of the proteolipid ring, providing 
the connection between the central stalk V1 and V0. It plays a role in either reversible 
dissociation or coupling of proton transport. The subunit a (100 kDa) has a 
hydrophilic N-terminal domain that is oriented toward the cytoplasmic region and a 
C-terminal domain that contains eight or nine transmembrane helices. The C-terminus 
TM7 contains arginine that is required for proton influx. The highly hydrophobic 
subunit e is located in the transmembrane domain. 
The rotary mechanism of proton transport is driven by the proton gradient 
associated with ATP hydrolysis.98 Protons enter from the cytoplasm through the hemi 
channel subunit a and they protonate the glutamine residues on the subunit c and c”. 
The energy released from ATP hydrolysis allows the rotation of the rotor. This forces 
the realignment of the protein to allow the interaction between the protonated 
glutamine side chains and a crucial arginine residue in TM7. Protons are shuttled into 
the luminal hemi-channel of subunit a from the protonation of arginine and released 
into the organelle to complete the catalytic cycle. 
There are three types of ATPases which differ in function, structure, and type 
of ions they transport, namely P-ATPases, F-ATPases and V-ATPases.114-116 P-
ATPases are found in bacteria, fungi and in eukaryotic cells. They are very different 
from V-ATPases and form smaller enzyme complexes. Their role is to transport 
different cations, Na+, K+, Ca+, across membranes. From electron microscopy, F-
ATPases and V-ATPases have a similar overall shape. They transport protons across 
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membranes and consist of distinct peripheral and integral domains that are connected 
by at least two stalks. However, V-ATPases show a more complex structure in the V1 
domain. F-ATPases are located mostly in mitochondria, chloroplasts, and bacterial 
plasma membranes, and are responsible for the synthesis of ATP. V-ATPases are 
found elsewhere in the cell and convert ATP to ADP to drive a catalytic cycle.  
  The V-ATPases have several subunit isoforms. There are at least four 
distinct subunit a isoforms, a1, a2, a3, a4.117-119 The subunit isoform a3 is a 
component of plasma membrane V-ATPase, essential for bone resorption. It is also 
expressed highly in the heart and liver. The subunit isoform a4 is found in the kidney 
only. In human, two isoforms of subunit E are known, E1 and E2, but only E1 is 
expressed in the testis.120, 121 The E1 isoform is required for acidification of luminal 
pH of testis-specific compartments and is involved directly in male fertility. 
Malfunction of V-ATPase isoforms may cause certain diseases. Mutations in the a3 
isoform result in deficient bone resorption and osteoporosis.122 In cancer, highly 
invasive MDA-MB231 human breast cancer cells express V-ATPases at the cell 
surface.123 In contrast the poorly invasive MCF7 cell line is characterized by high 
expression of subunit a4 which is considered responsible for increased acidity at the 








2.3 Inhibitors of V-ATPase  
 The unique architectures of V-ATPases and their critical roles in living cells 
have drawn interest in both the scientific and medical communities. In the past two 
decades, much effort has been spent in the search for substrates that can specifically 
bind to V-ATPases. Both natural products and synthetic small molecules have been 
identified as V-ATPase inhibitors.  
  Bafilomycin A1 (187) was first isolated in 1983 from Streptomyces 
griseus on the basis of its antifungal and antibacterial activity, Figure 13.46 It was 
found later by Bowman et al. that these bafilomycins, A1, B1, C1, more selectively 
inhibited V-ATPase than P-ATPase and had no effect on F-ATPase.124 Another group 
of related macrolides was initially identified as immunosuppressive compounds. They 
were isolated from Streptomyces diastatochromogenes and named concanamycins 
because they inhibited the proliferation of concanavalin-A-stimulated T-cells.125 They 
were found to be V-ATPase inhibitors more potent than bafilomycins.126 Given their 
selectivity, bafilomycins and connamycins macrolides have been used extensively as 
probes to study the physiological roles of V-ATPases. 
 The treatment of human tumor cell lines A431 with bafilomycin A1 showed that 
the inhibition of the acidification process in lysosomes prevented protein 
degradation.127 A possible involvement of plasma membrane V-ATPase in cell 
proliferation was observed when mouse, rat, and human cell lines were treated with 
bafilomycin A1 and concanamycin A1 and A4B.
128 Bafilomycin A1 inhibited the 
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growth of human pancreatic cancer cells, Capan-1, through apoptosis.129 This 
inhibition was observed at nanomolar concentration and was dose-dependent. The 
study using affinity chromatography with the immobilized bafilomycin C1 showed 
that the c subunit of V0 was the binding site.
130 This result was confirmed by the 
recent photoaffinity experiments of concanamycin A bearing radioactive tracer 125I at 
C23 as shown in 192.131 It was found that both bafilomycins and concanamycins bind 
to the same site at subunit c of V0, since the photolabeling could not replace the 


















187, bafilomycin A1, R = H
188, bafilomycin B1, R =


























190, concanamycin A, R = NH2CO































2.3.1 SARs of Bafilomycins and Concanamycins 
 Extensive SARs of both concanamycins and bafilomycins have been conducted 
and have led to the identification of the essential structural features responsible for 
the biological activity. One of the structural requirements essential for the biological 
activity is the distinctive intramolecular hydrogen bonding between the lactone and 
hemiketal moieties for optimal inhibition. This is proved by the three- to four-fold 























































194 195 196  
Figure 14. Analogues of Concanamycin F  
 
The presence of a small acetyl group at C9, 199, of concanamycin A as well as C7 
and C21, 197 and 198, of bafilomycin A1 was tolerated while the opening of the 
macrocyclic ring caused a total loss of activity (Figure 15).133 The amino analogue at 




















187, bafilomycin A1, R
1 = H, R2 = H
197, R1 = Acetyl, R2 = Acetyl





















190, concanamycin A, R1 = H
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199, R1 = Acetyl
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Figure 15. Analogues of bafilomycin A1 and concanamycin A  
 
However, the acid analogue 200 from the fragmentation of the pyran ring in 
bafilomycin A1 was devoid of activity (Figure 16).
102 The sulfonamides 201 and 202 
retained high potency with improvement of the selectivity. It is worth noting that the 


















































Figure 16. Acid and sulfonamide analogues of bafilomycin A1 
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Table 4. Inhibition of V-ATPase and in vivo activity* of concanamycin C (191), 
bafilomycin A1 (186), and analogues 
Compound  V-ATPase assays, IC50 (nM)       In vivo assays (mol kg
-1
) 
  Bone Brain Ratio Potency 
Toxicity 
threshold Ratio 
             
186 0.36 0.84 2.4 0.5 0.4 0.8 
191 0.35 0.58 1.7 >0.1 0.025 <0.25 
201 0.58 3.3 5.7 2.7 25 9.3 
202 0.92 3.6 3.9 6.2 20 3.2 
 
* The prevention of the retinoid-induced hypercalcaemia in thyroparathyrodectomized rats 
 
 
 Due to the complexity of the natural products bafilomycins and 
concanamycins, studies have been conducted to identify small molecules with the 
same critical structure feature, the C1-C7 fragment, of the complex macrolides. The 
new molecular bioactive entities have an indole core where the NH-group is a mimic 
of the C7 hydroxyl group of bafilomycins (Figure 17).134 The lead compound 203 
showed weak inhibition of chicken osteoclast V-ATPase at IC50 30 µM. Then 
systematic optimizations of the aromatic ring by addition of lipophilic and electron-
withdrawing groups led to the discovery of 5,6-dichloroindole analogues 205 with an 
IC50 1.9 µM. The potency was improved when the ester was converted into the amide 
containing a basic nitrogen, compound 204 (IC50 = 180 nM). The conformationally 
constrained piperidine derivative 206 (SB 242784) showed nanomolar inhibition of 
human osteoclast at 3.4 nM.102  Recently, the indolyl analogue 207, NiK-12192, has 
been reported to synergize topotecan in both topotecan sensitive and topotecan-
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resistant tumor xenografts.135 In addition, it has been reported that NiK-12192 
inhibited cell migration and invasion by affecting cell motility and cell adhesion. Oral 
administration of NiK-12192 to mice bearing human lung tumor xenografts (NCI 






































Figure 17. Small molecules mimicking bafilomycins  
 
2.3.2 Benzolactone Enamide Family 
2.3.2.1 Salicylihalamides, Oximidines, and Lobatamides 
 The growing family of V-ATPase inhibitors known as the benzolactone 
enamides contains diverse molecular features of a benzo-fused macrolactone bearing 
an N-acylated enamide side-chain (Figure 1). Members of this family include: (1) 
salicylihalamides A and B,3, 4 (2) oximidines8-10 I, II, and III (3) the lobatamides.5, 6 
Testing in the NCI 60-cell line panel revealed that the melanoma cell lines were the 
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most sensitive panel with this natural product family. Subsequent COMPARE 
analysis revealed that these compounds target V-ATPases.137 The unique feature of 
this natural product family is their selectivity toward mammalian V-ATPases. They 
were shown to inhibit human kidney, liver, and osteoclast V-ATPase in membrane 
preparations at low- to sub-nanomolar concentrations, but were inactive against V-
ATPases of fungi. In addition, the benzolactone enamide family also included CJ-
13,350 and CJ-13,357,138 isolated from fungi metabolites, and apicularen A and B, 
isolated from myxobacterial genus Chondromyces.7  
 Salicylihalamides A and B were isolated from the marine sponge Haliclona sp. 
by Boyd and co-workers in 1977 at the National Cancer Institute (NCI).138 The 
isolation was hampered by the instability of the compounds in acidic media. The 
active compounds were identified as (-)-salicylihalamide A and (-)-salicylihalamide 
B. A ligand competitive assay revealed that salicylihalamides bind in a site different 
from the bafilomycins/concanamycins pocket.139 This explains the unique selectivity 
profile of the benzolactone enamide family.  
 It is suspected that the benzolactone enamide members are irreversible 
inhibitors. The attempts to use the tritiated pentyloxy side chain analogue 208 in De 
Brabander’s group showed only a small amount of radiolabeled V-ATPase after 
observing full inhibition, Figure 18. This inferred that the inhibition process might 
proceed from the capture of a reactive N-acyliminium ion, upon the protonation of the 
enamide unit, by a protein residue of V-ATPases. Then hydrolysis can take place to 



































































Figure 18. Proposed inhibitory process of benzolactone enamides139 
 
 Oximidines I, II, and III were isolated from Pseudomonas sp. by Hayakawa 
and coworkers.8-10 These molecules inhibited the growth of oncogene-transformed 
cell lines of 3Y1, with adenovirus E1A, v-H-ras, and v-src oncogenes at nanomolar 
concentrations. By flow cytometric analysis, oximidines were found to arrest the cell 
cycle of ras- and src-transformed 3Y1 cells at the G1 phase and to increase the 
expression of p21 at protein and mRNA levels.8, 9 Thus, it was suggested that the 
inhibition of V-ATPase could induce p21 expression. The same observation was 
found when human colon cancer cells DLD-1 were treated with the potent V-ATPase 
inhibitor, bafilomycin A1.
140 The protein p21 plays a role in cell cycle regulation, by 
inhibiting cyclin-dependent kinases (Cdk) required for progression from the G1 to the 
S phase.141 It is also involved in the inhibition of DNA replication by inhibiting 
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proliferating-cell nuclear antigen to activate DNA polymerase. The expression of the 
p21 protein is critical for either tumor suppressor p53-mediated G1 arrest or 
apoptosis. Apoptosis is defined by morphologic changes, such as condensation and 
margination of chromatin concomitant with cell shrinkage. Oximidine III was found to 
be more potent than oximidine I by three to eight folds in normal and transformed 
3Y1 rat fibroblasts. This suggests a significant effect of the 14-hydroxyl group or the 
enamide geometry. 
 Lobatamides A-F have been isolated from several collections of Aplidium and 
related species; from shallow water Australian collections of Aplidium lobatum, from 
a deep water collection of Aplidium sp., and from an unidentified Philippine 
ascidian.5, 6 These compounds are different in oxime and !24-25 double bond geometry 
and hydroxylation at C30. The COMPARE analyses revealed a high correlation of 
their cytotoxic panels with salicylihalamide A’s cytotoxic profile.137 Their cytotoxic 
activities are in the low nanomolar range for sensitive cell lines and micromolar 
potency for resistance cell lines. Lobatamide A was also found from the extraction of 
Pseudomonas sp. cultured from an Indonesian soil sample.142 This occurrence of the 
same compound in different sources suggests the possibility of their biosynthesis in 







2.3.2.2 CJ compounds and Apicularens 
 It was found that an increasing level of cholesterol together with a high 
concentration of low-density lipoprotein (LDL) contributes to the development and 
progression of atherosclerosis. Thus it would be desirable to decrease the level of 
circulating LDL by upregulate LDL receptors. CJ-13,350 and CJ-13,357, isolated from 
the fungus Mortierella verticillata ATCC 42662, were found to enhance the 
expression of the LDL receptor gene in human hepatocytes.138 Their activities in the 
assay were 100 nM indicating that the geometry of the oxime has little effect on the 
activity. These compounds showed no activity on tubulin polymerization, lysosomal 
pH or cholesterol synthesis.  
 A final pair of microbial macrolides are Apicularens A and B, which were 
isolated from culture extracts of the myxobacterium Chondromyces robustus by the 
Höfle group.7 Apicularen A was highly cytotoxic for cultivated human and animal 
cancer cells but showed no antimicrobial activity. The N-acetyl-glucosamine 
glycoside apicularen B was distinctly less cytotoxic in micromolar concentration and 
showed weak activity against a few Gram-positive bacteria. The COMPARE analysis 
of apicularen A in the NCI-60 screen produced a profile of selective cytotoxicity 








2.3.2.3 Related Enamide Macrocycles 
 A recent reported enamide-bearing polyketide of V-ATPase inhibitor, 
palmerolide A (216), was isolated from Synoicum adareanum, a circumpolar tunicate 
found in the shallow waters around Anvers Island on the Antarctic Peninsula.143 It 
inhibited bovine V-ATPase at IC50 of 2 nM. Palmerolide A showed high selectivity 
toward melanoma cancer cells (e.g., UACC-62, IC50 = 18 nM); meanwhile, it showed 
a much weaker cytotoxicity by three orders of magnitude relative to other cell lines. 

































217, (-)-zampanolide 218, (-)-dactylolide216, palmerolide A  
Figure 19. Related enamide macrocycles 
  
 Another hemiaminal-containing macrocycle, (-)-zampanolide (217), was 
isolated from marine sponge Fasciospongia rimosa collected near the island of 
Okinawa. The compound exhibited potent cytotoxicity at nanomolar concentrations 
against the P388, A549, HT29, and MEL28 cell lines.144 The synthesized (-)-
dactylolide (218) was found to have weak cell growth inhibition across an NCI 60-
cell line screen by 2-3 orders of magnitude less than (-)-zampanolide.145 This 
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illuminated the critical importance of the N-acyl hemiaminal side chain of the natural 
product for bioactivity. Even though there is no report related to V-ATPase inhibition, 
this evidence suggested that the hydrolyzed intermediate of the enamide moiety in the 
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Figure 20. Benzolactone natural products 
 
  In addition, the lack of the enamide moiety in benzolactone-containing 
natural products such as (-)-zearalenone,145, 146 lasiodiplodin,147 monocillin,148 and 
radicicol148 resulted in inactivity toward V-ATPases. This infers that an enamide side-
chain may be critical for binding to the biological target either for lipophilic 









2.3.2.4 SARs of Benzolactone Enamide Family 
Extensive SARs of the benzolactone enamides have been conducted in an 
effort to simplify the synthesis, to define the mode of action, and the mode of binding. 
The first series of salicylihalamide analogues was designed the by DeBrabander’s 
group with the aim of studying the role of the enamide side chain, Table 5.139, 149 









Entry         Structure          V-ATPase IC50 (nM)     SK-MEL-5 IC50 (µM)       Binding Mode       Ref. 
____________________________________________________________________ 
1   (-)-salicylihalamide A              < 1.0                             0.06                      irreversible        
139, 149             
2   (+)-salicylihalamide                    270                            NA                 NA                
139, 149
 
                  R 
3            hexyl                                    1.0                       0.38                     irreversible             
139, 149        
4          C CPh
 
                              < 1.0                              0.3                     irreversible              
139, 149
 
5          C CBu                                  1.0                              0.3                          NA                
139, 149
                   
6        O(CH2)5Me                              1.6                               0.5                    irreversible            
139, 149
 
7        S(CH2)5Me                               1.8                              0.45                         NA              
139, 149
 
8        farnesyloxy                          > 1000                              1.5                           NA                         
139, 149
                                  
__________________________________________________________________________________ 
 
 It is assumed that the Z,Z-diene moiety of the side chain might be responsible 
for the interaction with the V-ATPase binding pocket. The modified side chain 
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analogues of entry 3-7, Table 5, showed inhibitory activity equipotent with (-)-
salicylihalamide A, with an irreversible binding mode toward a bovine brain V-
ATPase. However, there is a limitation of the substituent group as seen from the weak 
inhibition of the fanesyloxy analogue (entry 8). It should be noted that the 
cytotoxicity of these analogues are at least ten-fold less potent than the natural 
product, despite their similar potency in the V-ATPase assay. 
 
Table 6. Salicylihamide analogues and biological activity 
____________________________________________________________________ 
Entry         Structure                          V-ATPase IC50 (nM)     SK-MEL-5 IC50 (µM)              Ref. 
____________________________________________________________________ 
1   (-)-salicylihalamide A                               < 1.0                             0.06                                                      
150
                                                                         
2   (+)-salicylihalamide                                     270                              NA                                    
150
 









3          R1 = H, R2 = Bz                               300                                1                                                            
150
 
4          R1 = Bz, R2 = H                                  180                             > 20                                                         
150
 








                       3.0                                  8                             
150
 













The benzyl alcohol analogues entry 3 and 4, Table 6, are significantly less active than 
the parent compounds. This implies the involvement of a crucial hydrogen bonding 
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between salicylihalamide and the V-ATPase. The saturated macrolide analogue of 
entry 5 appeared to retain significant potency while the carbamide lacking the double 
bond of entry 6 showed a ten-fold lower activity.  
 
Table 7. Salicylihamide analogues and biological activity 
____________________________________________________________________ 
Entry         Structure                              V-ATPase IC50 (nM)               Cytoxicity                  Ref. 
____________________________________________________________________ 
1   (-)-salicylihalamide A                               < 1.0                         GI50 = 38-81 nM                  
150
 
2   (+)-salicylihalamide                                  270                                    NA                          
150
 





                         NA                          GI50 = 110-870 nM                     
150 





                         NA                           GI50 = 370-880 nM                  
150
 







                                 4.5                          IC50 = 0.20-1.03 µM         
151
      











The simplified analogues lacking the hydroxyl and methy groups as shown in entry 3 
and 4, Table 7, were about 3-10 times less potent than (-)-salicylihalamide A. This 
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suggested that the macrocyclic double bond is important but not critical for the 
activity. The ether analogue of entry 5 retained inhibition similar to the natural 
product, but was weakly cytotoxic. It is worth noting that the removal of substituents 
and the endocyclic double bond attenuates the biological activity. The !,#-
unsaturated ketone derivative (entry 6) was a potent reversible inhibitor for V-
ATPase inhibition. This was in agreement with the mechanistic proposal that the 
nucleophile intermediate is necessary for the activity of benzolactone enamide.  
  With regard to the critical role of the enamide moiety based on SARs of 
salicylihalamide A, several analogues of apicularen have been prepared by Maier’s 
group and Nicolaou’s group. Similar results were found in apicularen analogues. The 
variations in the acyl part of the enamide are tolerated with a certain chain length as 
observed by DeBrabander’s group. The analogues of entry 5 and 7, Table 8, with 
short substituent groups showed weak cytostatic affects relative to their congeners, 
but without the enamide there is no activity (entry 3). The acetylated analogue of 
entry 4 showed a small change in the activity; however, the glycosidated apicularen B 
showed total loss of activity. The $17,18 (Z)-apicularen A isomer (entry 2) showed a 
100-fold reduced cytotoxicity. This might suggest that trans geometry orchestrates 







Table 8. Apicularen analogues against 1A9 human ovarian carcinoma cell lines 
____________________________________________________________________ 
Entry                 Structure         IC50 value                             Ref. 
____________________________________________________________________ 
1                     apicularen A                          0.78 ± 0.4 nM                                   152  
2     $17,18 (Z)-apicularen A                         70.7 ± 10.4 nM                                    
152
 






                               > 20 µM, SK-MEL-5                            
153 









                                                          3.2 nM                                                                                  
152
 









                               > 1500 nM                                               
152
 









                     30.3 ± 4.6 nM                                             
152
 










                           805.5 ± 145 nM                                              
152
 















The intermediate open-chain analogue entries 3-5 (Table 9) showed significant 
potency for cell inhibitions; however, they are ten-fold less potent than their 
corresponding macrolides.  
 
Table 9. Apicularen analogues against 1A9 human ovarian carcinoma cell lines 
____________________________________________________________________ 
Entry                 Structure                      IC50 value (nM)                         Ref. 
____________________________________________________________________ 
1                     apicularen A                                                0.78 ± 0.4                                                         
152
 









                                                                                  3.2                                                                                    
152
 










                                                           35                                                                                      
152   











                             357                                                  
152
 
















  Maier’s group showed that the 11-deoxy analogue, Table 10, retained 
cytotoxicity similarly to apicularen A and it showed better activity against drug 
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resistant cell lines than apicularen A. This observation suggested that the 11-OH is 
not responsible for the cytotoxicity and the inactivity of apicularen B, glycosidated at 
C11, might result from the steric factor. 
 
Table 10. Cytotoxicity values of benzolactone enamides154 
____________________________________________________________________ 
Cell line      Origin         Specicies    apicularen A     11-deoxy analogue      (-)-salicylihalamide A        
























L-929    connective tissue     mouse         6.8                             19                                        57 
Y1         connective tissue      rat              2.3                               8.2                                     23 
KB-3-1  cervix carcinoma     human        2.3                               7.1                                       6.8                    
KB-V1   multiple drug-re-     human      15.9                               2.4                                       9.1 
               sistant cell line 
________________________________________________________________________________ 
 
 Due to the important role of the enamide side chain, all of the simplified 
lobatamide analogues bear the enamide side chain as shown in Table 11. The 
simplified macrolide of entry 2 showed a 600-fold drop in activity, indicating that the 
ring size and substitution of the macrolactone are important. Salicylate compounds 
(entries 3 and 5) with minor modifications were found to bind weakly to V-ATPase, 
whereas the N-methylated analogue (entry 6) showed much less activity. Also the 




Table 11. Lobatamide analogues against bovine V-ATPase 
____________________________________________________________________ 
Entry                 Structure     IC50 value (µM)                                          Ref. 
____________________________________________________________________ 
1                     Lobatamide C                   0.002                                           155  











                                                 1.2                                              
155
 











3                   R1 = H, R2 = H, R3 = H   25% inhibition at 20 µM; higher concentration not soluble
155
 
4                R1 = Me, R2 = H, R3 = H                         no effect                                         
155
 
5                R1 = H, R2 = Me, R3 = H                             1.3                                              
155
 
6                   R1 = H, R2 = H, R3 = Me                          200                                                  
155
 













7               R = Me                                                        0.1                                                155  
8               R = Prenyl                                                   0.06                                              156 











Me                           0.01                                              157 


















These results indicate the importance of both free hydroxyl and NH functionalities for 
hydrogen-bonding interactions. The increase of lipophilicity from a methyl group 
(entry 7) to a prenyl group (entry 8) showed an improvement of the activity. 
Interestingly, the primary alcohol of entry 9 showed high potency for V-ATPase 
inhibition close to the activity of natural product lobatamide c whereas the 
benzophenone photoaffinity labeling congener of entry 10 showed good inhibition at 
IC50 of 100 nM.
157 The benzophenone photoprobe was selected due to its stability, 
mild conditions required for photoactivation (350-360 nm, n !!*), and selectivity 
towards weak C-H "-bonds. 
 
2.3.3 Novel Oximidine Analogues with Improvement of Stability  
The SARs conducted on benzolactone enamides have demonstrated that the 
enamide side chain is crucial for their anti-cancer activity. However, it is believed 
that the enamide is labile under physiological conditions. In fact, the isolation of 
salicylihalamides was not a straightforward process, hampered by the instability of 
the compounds in acidic conditions.4 In synthetic protocols for the preparation of 
compounds of the benzolactone family, the enamide side chain is always installed at 
the end.13, 61, 92 Our hypothesis is that the replacement of the enamide with a stable 
warhead can allow the discovery of novel anti-cancer agents with improved 
pharmacokinetic stability.  
 We chose three different warheads stable under physiological conditions that 
could undergo nucleophilic addition like an enamide; namely vinyl sulfone, boronic 
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acid and %-ketone oxadiazole, Figure 21. Based on a CoMSIA/QSAR analysis, we 
have designed, prepared and evaluated analogues of oximidine II possessing a 
modified macrocyclic structure that carries a vinyl sulfone, a boronic acid and an %-
keto oxadiazole instead of the enamide side chain, Figure 21. Based on the result of 
the cytotoxicity of the sulfone containing macrocycle we decided to prepare the 










































223, n = 1





225, n = 1




Figure 21. Oximidine II analogues with stable warheads 
 
The ethyl spacer between the vinyl sulfone and the macrocycle was chosen to 
keep the same distance between the N-acyliminium moiety (generated under the 
acidic condition from the protonation of an enamide)139 and the macrocycle. 
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However, this spacer can be tuned for length and flexibility, to optimize the 
biological activity of this class of analogues.  
 
2.3.3.1 Irreversible Inhibitor 
 The vinyl sulfone is known to serve as an irreversible inhibitor towards cysteine 
proteases such as papain,158 cruzaine,159 cathepsin V,160 Staphylococcus aureus 
sortase,161 and proteasome.162 Hanzlik and coworkers designed highly potent 
irreversible protease inhibitors bearing a vinyl sulfone moiety.158 The irreversible 
inhibitory activity results from the formation of covalent bonds with thiol in the 
active site of the cysteine proteases. This could allow the investigation of the binding 
pocket at the molecular level.160  
 The unique property of the vinyl sulfone is that under physiological conditions 
it does not undergo nucleophilic addition, while once at the active site of the target, 
strategic hydrogen bond interactions activate the reactive site.163 We designed this 
class of inhibitor, assuming that the acidic environment surrounding the V-ATPase 
would activate the electrophilic vinyl sulfone moiety towards Michael addition.  
 
2.3.3.2 Reversible Inhibitor 
 Boronic acids have been used extensively as reversible inhibitors due to their 
Lewis acidity to interconvert between sp2 and sp3 allowing binding to nucleophiles 
such as alcohols and amines. In fact, boronic acids are functional groups often present 
in inhibitors that mimic the transition state of hydrolytic enzymes. Compounds 
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containing boronic acid are known to reversibly inhibit serine protease, including 
thrombin,164 dipeptidyl peptidase,165 elastase,166 fatty acid amide hydrolase 
(FAAH),167 and bortezomib (Velcade),168 which was the first FDA approved 
proteasome inhibitor and is in clinical use for the treatment of multiple myeloma and 
mantle cell lymphoma.169 
 Even though 1,3,4-oxadiazoles are present in a wide range of biologically active 
molecules, including antimicrobial, anti-fungal, anti-inflammatory, and antihypertensive, 
the %-keto oxadiazole moiety is still under-explored in medicinal chemistry.170-172 
Recently, a series of proteasome inhibitors containing an %-keto oxadiazole warhead 
were reported as selective and reversible inhibitors toward human prostate cancer at 
subnanomolar concentrations.173 %-Keto oxadiazole containing compounds have been 
developed as FAAH inhibitors.174, 175 The crystal structures of FAAH bound to %-
ketooxazoles showed the presence of a tetrahedral intermediate resulting from a 
covalent bond between serine and the ketone.176  
Based on our CoMSIA/QSAR result, we believe that the designed 
macrocycles 183, and 184 are valid templates for the preparation of novel active 
analogues. The proposed inhibitory mechanisms of these novel compounds toward 


































































vinyl sulfone irreversible Inhibitor
boronic acid reversible inhibitor










2.3.4 Preparations of vinyl sulfone V-ATPase irreversible inhibitors 
 The novel analogues were prepared by attaching the simplified core structures 
described in Chapter 1 to the side chains mentioned above. For this preliminary SAR, 
phenyl vinyl sulfone was chosen to serve as the lipophilic moiety to interact with the 
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target as predicted from our CoMSIA/QSAR model. The vinyl phenylsulfone 




























183, n = 1
184, n = 2
DDQ, 
DCM:H2O (10:1)
232, n = 1, 50%
233, n = 2, 63%
1. SO3•Py, DMSO, Et3N
2. NaH, diethyl [(phenylsulfonyl)
    methyl]phosphonate
234, n = 1, 48% two steps
235, n = 2, 65% two steps
4M HCl, MeOH
223, n = 1, 82%








Scheme 37. Preparations of vinyl sulfone inhibitors of simplified macrocycles 
 
 Deprotection of the PMB group by oxidative cleavage with DDQ gave alcohols 
232 and 233. The resulting products were oxidized under Parikh-Doering conditions 
to give the aldehyde intermediates. Treatment of the HWE reagent prepared from the 
oxidation of commercially available diethyl [(phenylthio)-methyl]phosphonate with 
H2O2
177
 with NaH and the corresponding aldehydes afforded vinyl phenylsulfones 
234, and 235 in good yield. The acidic cleavage of the MOM and TBS groups with 
diluted HCl provided the final vinyl phenylsulfones 223 and 224. 
 Similar routes were used to prepare the vinyl phenylsulfone analogues of 
oximidine II. The triene macrocycle 110 was prepared using the reductive copper-
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mediated macrocycle formation already mentioned in chapter 1. The deprotection of 
the TBDPS group using TBAF provided the corresponding alcohol 236 which 
underwent oxidation with PDC to afford the required aldehyde. The intermediate was 
treated with the HWE reagent to provide vinyl phenylsulfone 237. The mild acidic 
cleavage of the MOM-ether with carbon tetrabromide (CBr4) in warm i-PrOH gave 
the secondary alcohol 238. This CBr4 mixture of reagents generated a small amount 
of hydrobromic acid that facilitated the deprotection. Following the procedure of 
Georg and Schneider, treatment of aryl methyl ether 238 with BCl3 gave the desired 











1. PDC, MS 4 Å, DCM
2. NaH, diethyl [(phenylsulfonyl)


















Scheme 38. Preparation of a vinyl phenylsulfone analogue of oximidine II 
 
The synthesis of the homolog vinyl phenylsulfone 226 began with the triene 
macrocycle 144 generated by total synthesis using the RCM reaction as mentioned in 
Chapter 1. The oxidative cleavage of the PMB ether 144 using DDQ provided the 
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alcohol 239. This intermediate was subjected to PDC oxidation to provide the 
corresponding aldehyde. The vinyl phenylsulfone 240 was obtained by treatment of 
HWE reagent with NaH and aldehyde. Using the previous mild acidic cleavage 
condition, global deprotection of both TBS and MOM ether groups provide vinyl 












1. PDC, MS 4 Å, DCM
2. NaH, diethyl [(phenylsulfonyl)















Scheme 39. Preparation of a vinyl phenylsulfone homolog analogue of oximidine II  
 
2.3.5 Biological evaluation of vinyl phenylsulfones 
 According to the NCI 60-cell screen, the melanoma cell lines were found to be 
the most sensitive to oximidine II. The cell-cytotoxic assay was conducted by Dr. 
Defeng Tian at the HTS laboratory, Institute for Therapeutics Discovery and 
Development, University of Minnesota. The SK-MEL-5 was used in our cytotoxicity 
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assay to evaluate the biological activity of the synthesized vinyl phenylsulfone 
analogues 223, 224, 225, and 226. Taxol, colchicine, oximidine I (natural product 
from extraction), and synthesized oximidine II (courtesy of Georg and Schneider, 
total synthesis) were used as positive control experiments. The result of cell inhibition 
of SK-MEL-5 revealed that all of our vinyl phenylsulfones were micromolar 
inhibitors, IC50 in the range of 20-60 µM; while the natural product oximidine I and 
the synthesized oximidine II showed an IC50 of about 60 nM, estimated from graph, 
Table 12. 
  However, our analogues containing the simplified core structure were 
equipotent to the triene core structure of the oximidine II. This result supported our 
hypothesis guided by CoMSIA/QSAR. The cytotoxicity of these analogues might 
result from the presence of the vinyl sulfone which irreversibly inhibits the enzyme. 
The replacement of the phenyl group at the vinyl sulfone with other substituents 












Table 12. Cell growth inhibition of vinyl phenylsulfone analogues 

















































2.3.6 Ongoing Project 
 Based on the comparable biological activity of the vinyl sulfones with the 
simplified core and the vinyl sulfones with the oximidine II triene core, we decided to 
use the simplified macrocycle to explore the SAR of the boronic acid and the %-keto 
oxadiazole. Both compounds were tested as crude products without further 
purification.  ESI/HRMS analysis showed only one peak corresponding to the desired 
molecular ion. This initial task was performed to verify the activity of this class of 
compounds. Further studies are ongoing, including the complete characterization of 
these compounds. 
 
2.3.6.1 Preparation of %-keto oxadiazole V-ATPase reversible inhibitor 
The preparation of the %-keto oxadiazole began with the common 
intermediate alcohol 233, Scheme 41. The phenyl moiety attached to the oxadiazole 
was chosen for our preliminary SARs to serve as a lipophilic portion able to bind to 
the enzyme. The 2-phenyl-1,3,4-oxadiazole was prepared from the condensation of 
phenyl hydrazide and triethylorthoformate under microwave irradiation without any 
solvent at 80 °C using Nafion&NR50 (a perfluorinated polymer with sulfonic acid 












Scheme 40. Preparation of 2-phenyl-1,3,4-oxadiazole 
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The alcohol 233 was oxidized under Parikh-Doering conditions to give an 
aldehyde intermediate. The aldehyde was treated with lithiated oxadiazole to provide 
a diastereomeric mixture of alcohols.173 The resulting alcohols were oxidized with 
DMP to provide the %-keto oxadiazole 244. The global deprotection of TBS and 















1. SO3•Py, DMSO, Et3N
2. n-BuLi, 243, MgBr2•OEt2
3. Dess-Martin 
















Scheme 41.  Preparation of the %-keto oxadiazole analogue 
 
2.3.6.2 Preparation of a boronic acid V-ATPase reversible inhibitor 
 The 3-methylbutane moiety of %-amino boronic acid 228, Scheme 43, was 
assumed to promote the lipophilic interaction of the inhibitor with the binding pocket 
of the V-ATPase as predicted from the CoMSIA/QSAR. The analogue 228 was 
prepared from the coupling of the acid 250 and %-amino boronic ester 249, Scheme 
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43. The asymmetric copper-catalyzed borylation on the corresponding N-
butanesulfinyl aldimine of 245 (Ellman’s protocol)179 was used to prepared the 
required %-amino (R)-boronic ester 248, Scheme 42. The butane sulfinyl was cleaved 
under mild acidic conditions using 4M HCl in a dioxane and methanol mixture to 
































Scheme 42. Synthesis of an %-amino (R)-boronic ester 
 
 The oxidation of alcohol 232 with [bis(acetoxy)iodo]benzene (BAIB) and 
2,2,6,6-tetramethyl-1-piperidinyloxyl (TEMPO) provided the required acid 250.180 
The amine 249 was coupled with the acid 250 using TBTU according to the 
Millennium protocol, and without purification subsequently hydrolyzed under 
biphasic conditions utilizing iso-butylboronic acid as a pinacol sequestering agent to 


















1. amine 249, i-Pr2NEt, TBTU
2. 4M HCl, MeOH










Scheme 43. Preparation of the boronic acid analogue 
 
2.3.6.3 Biological evaluation of the vinyl sulfone, %-keto oxadiazole and boronic 
acid analogues 
 All new analogues of %-keto oxadiazole 265, boronic acid 266, and vinyl 
sulfone 261 and 262 were tested for cell growth inhibition on four human cancer cell 
lines using taxol and colchicine as positive controls for leukemia (HL-60), breast 
(MCF-7), and melanoma (SK-MEL-28 and SK-MEL-5) cell lines. The results showed 
that these analogues were micromolar inhibitors in vitro, greater than 20 µM, Table 
13 and Table 14, except for the %-ketone oxadiazole that did not display any 
cytotoxicity in HL-60 cell lines (Table 13). Even though the %-keto oxadiazole 
analogue showed loss of cytotoxicity, it emphasized the necessity of the enamide as 
well as the suitable warhead architecture for biological activity. On the other hand, 
the loss of cytotoxicity of the %-keto oxadiazole might result from the presence of the 
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large phenyl group on the oxadiazole moiety. The activity of the compounds 
containing nucleophiles (vinyl sulfone and boronic acid) supports the proposed 
mechanism.  
 
Table 13. Cell growth inhibition of leukemia HL-60 cell lines 
 




















































Table 14. Cell growth inhibition of melanoma (SK-MEL-28 and SK-MEL-5) and 
breast (MCF-7) cell lines  
 












































 In conclusion, a series of novel V-ATPase inhibitors with acid stable warheads 
(boronic acid, %-ketone oxadiazole, and sulfone) were designed, prepared and 
evaluated for their cytotoxicity. It was found that at least the simplified core structure 
analogues derived from CoMSIA/QSAR of vinyl phenylsulfones were equipotent to 
the triene core of oximidine II towards SK-MEL-5 cell lines.  
 The biological activity of this class of V-ATPase inhibitors could be improved 
since both vinyl sulfone and boronic acid are weakly cytotoxic against leukemia (HL-
60), breast (MCF-7), and melanoma (SK-MEL-28 and SK-MEL-5) cells in the range 
of 20-60 µM. These results indicate that we are headed in the right direction for the 



















Bacteria are classified into two groups based on their appearance after 
treatment with the Gram stain.181 The bacteria that stain purple when treated with the 
crystal violet stain are called Gram positive, while those that do not retain the violet 
stain and turn red or pink after the addition of a counterstain (commonly safranin) are 
the Gram negative bacteria. This different response to the stain is due to the 
composition of their cell walls. Gram-positive bacteria have a relatively thick layer of 
peptidoglycan surrounding their plasma membrane, whereas Gram-negative bacteria 
have a thin layer of peptidoglycan covered by an outer membrane.  
 






































The outer membrane of Gram-negative bacteria is composed of lipopolysaccharide 
(LPS), large molecules that contribute to the structural integrity of the bacteria and 
protect them from certain types of chemical attacks.182 
LPS molecules are made of a lipid and a polysaccharide joined by a covalent 
bond. The polysaccharide includes two regions, the O-antigen, with a high level of 
diversity in structure and composition, and a core region, which is relatively well 
conserved and similar in large groups of bacteria.182 Lipid A is a common 
amphipathic constituent of the LPS of all Gram-negative bacteria and is composed of 
a hydrophilic, negatively charged bisphosphorylated diglucosamine backbone, and a 
hydrophobic domain of six (E. coli) or seven (Salmenella) acyl chains in amide and 
ester linkages, Figure 23.183 LPS acts as an endotoxin, and induces a strong response 
from the normal animal immune system.184-186 LPS triggers the release of 
inflammatory cytokines, in particular TNF", interleukin-1# and IL-6.187, 188 It is the 
uncontrolled and precipitous systemic inflammatory response that ultimately results 
in the fatal shock syndrome characterized by endothelial damage, coagulopathy, loss 
of vascular tone, myocardial dysfunction, tissue hypoperfusion, and multiple organ 
failure.189-191  
Despite tremendous advances in antimicrobial chemotherapy, the incidence 
and mortality due to Gram-negative sepsis continues to escalate worldwide.192, 193 It is 
the number one cause of death in the intensive care unit, with a current estimate of at 
least 750,000 cases per year, and 215,00 fatalities in the United States annually.194 
The healthcare system in the United States spends about 16.7 billion dollars annually 
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to treat this condition.194 
LPS is a potential drug target since it plays a prominent role in raising the 
immune response that causes sepsis.185 LPS itself is chemically inert. The presence of 
LPS in blood, often a consequence of antibiotic therapy of preexisting bacterial 
infections, sets off a cascade of exaggerated host responses.195 Thus, it would be 
challenging to prevent mortality from Gram-negative shock by the development of 
antimicrobial agents.  
 The total synthesis of lipid A has established that lipid A is the toxic center of 
LPS.196 The receptors capable of recognizing the pathogen-associated molecular 
patterns are Toll-like receptors (TLRs) and scavenger receptors, thereby providing 
immunity against infection.197 TLRs are on the surface of immune cells, heart muscle 
cells, and cells that line blood vessels. Ten members of the TLR family have been 
identified in humans.  
 LPS stimulation of mammalian cells involves several proteins including LPS 
binding protein (LBP), CD14, MD-2 and TLR4.198-201 LBP protein directly binds to 
LPS and facilitates the association between LPS and CD14.202 CD14 is responsible 
for transferring LPS to the TLR4/MD-2 receptor complex.203 It has been shown that 
mutation of the TLR4 gene leads to low response to LPS.204, 205 TLR4 requires the 
MD-2 protein to form a complex at the cell surface to promote the physiological 
recognition of LPS. This was supported by the crystal structure of the TLR4-MD-2-
LPS dimerized complex at 3.1 '° resolution of the extracellular region, a leucine-rich 
domain.206 The TLR4-MD-2-LPS complex is believed to play a role in  the 
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recruitment of specific proteins to initiate the signaling cascade. TLR signaling 
involves the activation of transcription factors such as nuclear factor-(B (NF-$B) and 
members of the interferon (IFN)-regulatory factor (IRF) family.207, 208 
 Since TLR4 is the central signaling mediator for LPS in mammals, this 
finding has opened the possibilty of developing new drug targets to fight sepsis. Our 
approach has been focused on neutralizing LPS in order to block the initial LPS-
signaling events by preventing the generation of cell-surface signals.209 Polymyxin B 
(PMB), a cationic amphiphilic cyclic decapeptide antibiotic isolated from Bacillus 
polymyxa has been known to bind lipid A and to neutralize of LPS.210 PMB also has 
antimicrobial activity particularly against Gram-negative bacteria.211 It is only 
suitable for topical applications, but polymyxin B is extensively used as a standard for 
experimental studies conducted to identify novel compounds able to neutralize 
endotoxins. 
 
3.2 Development of Endotoxin-Sequestering Agents 
 Due to the cytotoxicity of PMB, our focus is to target circulatory LPS using 
small molecules.209 The bis-anionic, amphiphilic nature of lipid A (Figure 23) enables 
it to interact with a variety of bis-cationic hydrophobic ligands. We have found that 
linear bis-cationic amphipathic molecules possessing terminal, protonatable cationic 
groups positioned optimally (N–N distance:  ~14 Å) so as to be able to 
simultaneously interact with the glycosidic phosphates on lipid A as well as 
appropriately positioned lipophilic moieties, enable hydrophobic interactions with the 
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polyacyl domain of lipid A, Table 15.212, 213 Noteworthy examples of such molecules 
displaying potent in vitro and in vivo LPS-sequestering properties are acyl-
polyamines which afford protection in animal models of sepsis. 209, 212-215 
 
Table 15. Acyl compounds for LPS neutralization212 
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Figure 24. Bodipy-cadaverine (BC) 
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 While members of the acylpolyamines undergo exhaustive preclinical 
characterization,212 we have recently identified several bis-guanylhydrazones as 
potent LPS binders from an automated rapid-throughput screen on of focused 
libraries using the Bodipy-cadaverine (BC) displacement assay.214, 216 
 
Table 16. HTS of Bodipy-cadaverine (BC) displacement assay216 
___________________________________________________________________ 
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NH2           51.68                 25.59 
_____________________________________________________________________ 
 
In silico docking of bis-guanylhydrazones indicates excellent charge 
complementarity between the guanylhydrazone moieties and lipid A phosphates, 
Figure 25.217 However, binding to lipid A mediated via electrostatic interactions alone 
does not necessarily manifest in neutralization of endotoxicity, and we have shown 
that additional hydrophobic interactions with the polyacyl domain of the toxin via 


























































Figure 25. Salt bridges of bis-Guanylhydrazones with lipid A, in silico docking 
(SYBYL, using Surflex-Dock) and designed analogues (right) 
 
3.2.1 Preparations of terepthalaldehyde-bis-guanylhydrazones 
We now describe the syntheses and preliminary structure–activity 
relationships in a homologous series of bis-guanylhydrazone compounds decorated 
with hydrophobic functionalities, Figure 25. These first-generation compounds bind 
and neutralize LPS with a potency comparable to that of polymyxin B (PMB), a 
peptide antibiotic known to sequester LPS. 
The syntheses of the target compounds are summarized in Scheme 44 and 45. 
2,3-Dimethoxyterephthalaldehyde 256 was prepared according to the procedure 
described by Kuhnert et al.218 by double directed ortho-lithiation of 1,2-
dimethoxybenzene with n-BuLi/TMEDA under reflux in ether, followed by 
quenching with DMF in THF. Treatment of the resulting aldehyde 256 with boron 
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tribromide in CH2Cl2 afforded 257 in 86% yield.
219 The terephthalaldehydes 258a–





















1. n-BuLi (5 equiv)
    TMEDA (5 equiv)
    Et2O









Scheme 44. Synthesis of alkylated terephthalaldehydes 
 
 The aromatic guanylhydrazones 262a–262k were obtained by condensing the 
terephthalaldehydes with aminoguanidine hydrochloride in refluxing ethanol/HCl, 
Scheme 45.221 Pure aminoguanylhydrazones (as HCl salts) were isolated as 
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Scheme 45. Synthesis of terepthalaldehyde-bis-guanylhydrazone analogues 
 
3.2.2 Biological Assay 
 The final compounds 262a-262k were tested for their ability to bind to LPS 
using an automated fluorescence displacement assay. The assay was performed in a 
three step automated sequence which included plating the compounds in serial 
dilution, adding LPS and BODPIY cadaverine (BC) and recording the resulting 
fluorescence in a plate reader at a fixed wavelength (620 nM).222 When the test 
compounds bind to LPS, displacing BC, the fluorescence of LPS-bound BC is 
dequenched, and the intensity of light emitted is enhanced.  
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 After we established the binding ability of the compounds to LPS and identified 
the most active analogues, we tested the guanylhydrazones for their biological 
efficacy in terms of NF-(B and Nitric oxide (NO) inhibitions.212  
 The induction of NF-$B is a key transcriptional activator of the innate immune 
system, leading to uncontrolled cytokine release which ultimately leads to multiple 
organ failure and the shock syndrome. The in vitro activity of our compounds was 
measured as IC50 values, since sequestering LPS in a concentration dependent 
manner, the tested compounds would interfere with the nuclear translocation of NF-
$B. The resulting NF-$B nuclear translocation was quantified using human 
embryonic kidney 293 cells cotransfected with TLR4 (LPS receptor), CD14 and MD2 
(co-receptors), available from InvivoGen, Inc., (HEK-Blue™, San Diego, CA) as per 
protocols  provided by the vendor.212 
 The ability of the bisguanylhydrazone compounds to inhibit the LPS-
stimulated production of nitric oxide (NO) was tested with the murine macrophage-
like cell line J774.A1 (American Tissue Type Collection, Washington, D.C.), seeded 
in a 96-well tissue culture plate at 5x105 cells/well.214 Activation of macrophages by 
the immune system results in the production of inducible nitric oxide synthase (iNOS) 
enzyme, with consequent release of nitric oxide.  Following overnight culture in 
RPMI 1640 supplemented with L-glutamine, 10% fetal bovine serum, penicillin, and 
streptomycin, the cells were stimulated for 8 h with LPS alone (20 ng/ml) or LPS 
preincubated with graded concentrations of DOSPER, DOGS, or polymyxin B 
(control). The nitric oxide (NO) level was measured by the Griess assay.223 The 
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mechanism is summarized as the cascade reaction of NO with oxygen under acidic 
condition to produce nitrite ion which was further reacted with sulfanilamide to 
generate diazonium species, catalyzed by nitrate reductase. The resulting diazonium 
intermediate was coupled with naphthylethylenediamine to produce azo compound 




 H2NO2SNO2 + N H2NO2S N
1-Napthylethylene-
diamine
N H2NO2S N NHCH2CH2NH2
azo compound, lmax: 540 nm
NO 1/2O2 NO2
(1)
2 NO2 N2O4 (2)
N2O4
+
+ H2O NO2 + NO3 + 2H
N2O3 + H2O 2NO2 2H



















The concentrations of the bis-guanylhydrazones corresponding to effective 
displacement of 50% of the bound fluorescent probe (ED50; relative affinity of 
binding) and of the inhibition (IC50) of nitric oxide (NO) and NF-(B are summarized 
in Table 17, and Figure 27. As shown in Figure 27, a relationship between the alkyl 
chain length and the binding affinity as well as NO and NF-(B inhibition is evident. 
For binding affinity, the optimal substituent appears to be C5H11 while in both in vitro 
bioassays, the most favorable hydrophobic group is C8H17. This discrepancy is due to 
the fact that in the homogeneous fluorescent displacement assay performed in 
aqueous buffer the ligand must be completely soluble; increasing hydrocarbon chain 
length substituents results in a progressively retarded aqueous solubility, resulting in 
higher ED50 values. In the NO and NF-(B neutralization assays the presence of fetal 
bovine serum in the cell-culture medium ensures complete and uniform solubility and 










Table 17. Summary of binding affinity and biological activity for terepthaldehyde-
bis-guanylhydrazones 262a-262k 














     




     
Polymyxin B 
(Ctrl) 
 1.67 0.98 1.23 
262a H 34.55 24.38 164.07 
262b OH 43.68 26.39 59.14 
262c OCH3 42.28 27.96 175.76 
262d OC2H5 22.84 4.56 35.63 
262e OC3H7 12.73 8.38 27.63 
262f O-allyl 29.85 9.64 61.44 
262g OC4H9 9.44 4.15 9.40 
262h OC5H11 7.82 3.54 10.45 
262i OC6H13 13.23 4.67 6.11 
262j OC8H17 39.48 3.45 4.50 





Figure 27. Relationship of alkyl chain length of 262a-262k with binding affinity in 




Figure 28. BC/LPS Displacement Assay 
 
 The apparent binding affinities (ED50) of the compounds were computed from 
the displacement curves in Figure 28. The increasing concentration of test compounds 
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resulted in the enhancement of the intensity of fluorescence emission at 620 nM. The 
analogue with the C5 alkoxy-chain, 262h, showed the most effective binding to LPS 




Figure 29. NF-(B Assay 
 
 The NF-(B and NO inhibition was reflected by the decrease of fluorescence 
emission as shown in Figures 29 and 30. The potency of compounds (IC50) were 
computed from graphs, showing the analogue bearing the C8H19 alkyl chain as the 






Figure 30. NO Inhibition in Murine J774 cells (Stimulus: 10 ng/ml LPS) 
  
 Given that 262j, (R = C8H17), was the most potent compound in these 
biological assays (Table 17), we elected to characterize this compound in an in vivo 
D-galactosamine-primed mouse model of endotoxic shock. It is worth noting that the 
cytokine response to LPS in mice closely parallels that of humans,224 and is thus a 
well-established confirmatory assay.212, 214 
 
% Alive in Cohorts of 5 mice 
 
            
 
                           Dose of 262j (mg/25g mouse) 
Figure 31. Dose-dependent protective effect of 262j in a murine model of lethality 





The administration of graded doses of 262j resulted in a dose-dependent decrease in 
lethality in mice challenged with supralethal (200 ng/mouse; LD100: 100 ng/mouse) 
doses of LPS (Figure 31).  
 These results support to our strategy of incrementally converting high-affinity 
LPS binders to true LPS sequestrants by appending suitable hydrophobic 
functionalities. Further, these data would suggest that a systematic exploration of the 
bis-guanylhydrazone scaffold may yield useful anti-endotoxin molecules.  
 
3.3 Conclusion 
 Structure-activity relationship (SAR) studies clearly indicated that 
modifications of the aromatic ring with long-chain alkyl groups increased potency of 
terepthalaldehyde-bis-guanylhydrazone analogues. Biological assays revealed that the 
most potent compound contains a C8 alkoxy-chain. Potent anti-endotoxic activity as 
well as the relative ease of synthesis render this class of compounds promising for 













4.1 Materials and Methods 
 All reactions were performed using either standard bench top or inert 
atmosphere techniques. All deuterated solvents were used as purchased from 
Cambridge Isotope Labs. Chemical reagents were used as purchased from Aldrich, 
unless otherwise noted. Flash column chromatography was carried out using silica gel 
60(230-400 mesh), while thin-layer chromatography (TLC) was carried out on silica 
gel HLF, precoated glass plates. All yields reported refer to isolated material judged 
to be homogeneous by TLC and NMR spectroscopy.  
 All reactions were performed under an atmosphere of nitrogen in overnight 
oven-dried glassware unless otherwise indicated. THF, DCM, toluene, Et2O and DMF 
were dried and deoxygenated by passing the nitrogen-purged solvents through 
activated alumina columns on a solvent purification system.  All other reagents and 
solvents were used as purchased.  Reaction progress was monitored by thin layer 
chromatography (TLC, silica gel, 10 % 20 cm, 250 micron) visualizing with UV light 
(254 nm) or developing the plates with bluestain, anisaldehyde, or KMnO4 stains. 
 Melting points were determined using a melting point apparatus and are 
uncorrected.  Infrared spectra were obtained as thin films on NaCl plates using an FT-  
IR instrument.  NMR experiments were performed on a Bruker Avance 400 MHz 
instrument (operating at 400.134 MHz for 1H or 100.614 MHz for 13C) using the 
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residual solvent peak as internal standard unless otherwise indicated. NMR spectra 
were recorded with the chemical shifts (&) reported in relative to TMS (for 1H) and 
CDCl3 (for 
13C) or MeOD (for 13C) as internal standards, respectively. High-
resolution mass spectra were obtained utilizing the electrospray ionization technique 
or FAB/MS, using polyethylene glycol (PEG) as a reference compound. 
 
 
4.2 Experimental Procedures 
 









(133). To a flask containing alcohol45 132 (5.04 g, 17.1 mmol) was added DMSO (75 
mL) and IBX (7.20 g, 25.7 mmol). The mixture was stirred at rt for 1 h and then 
diluted with Et2O (400 mL) and water (400 mL). The organic layer was washed with 
water (5x400 mL) The organic layer was dried over MgSO4 and concentrated in 
vacuo to afford a clear oil of the corresponding aldehyde. The crude aldehyde was 
used directly in the next step without further purification.  
 To a mixture of CH3PPh3Br (9.16 g, 25.7 mmol) in anhydrous THF (50 mL), 
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cooled to 0 °C under N2 atmosphere was added dropwise a solution of n-BuLi in 
hexanes (2.5 M, 10.3 mL, 25.7 mmol). After the addition was completed, the mixture 
turned bright yellow. The mixture was stirred at 0 °C for 1 h, and a solution of the 
crude aldehyde diluted in THF (40 mL) was added dropwise over 10 min. The 
reaction mixture was stirred at rt for 5 h and 30 min and then quenched with water 
(200 mL) and extracted with Et2O (3x200 mL). The combined organic layer was 
washed with brine (250 mL), dried over MgSO4 and concentrated in vacuo. 
Purification on neutralized silica gel, treated with a solution of 1% Et3N in hexanes 
(500 mL), (5% EtOAc in hexanes) provided 3.67 g (12.6 mmol, 74% over two steps) 
of Z-diene 133 as a colorless oil: 1H NMR (400 MHz, CDCl3) ) 1.47 (m, 1H), 1.86 
(m, 1H), 3.37 (s, 3H), 3.96 (m, 2H), 4.28 (ddd, J =1.2, 5.0, 11.4 Hz, 1H), 4.63 (d, J = 
6.8 Hz, 1H), 4.66 (m, 1H), 4.69 (d, J = 6.6 Hz, 1H), 5.25 (d, J = 10.1 Hz, 1H), 5.32 
(d, J = 16.8 Hz, 1H), 5.35 (dd, J = 10.1, 10.1 Hz, 1H), 5.55 (s, 1H), 6.31 (dd, J =11.2, 
11.7 Hz, 1H), 6.74 (td, J = 10.7, 16.7 Hz, 1H), 7.33 (m, 3H), 7.50 (m, 2H); 13C NMR 
(100 MHz, CDCl3) )  129.7, 125.8, 122.9, 119.8, 119.2, 117.7, 117.2, 111.5, 92.2, 
85.1, 70.1, 68.4, 64.2, 57.9, 46.5; HRMS (ESI+): m/z calc’d for C17H22NaO4
+, 











(3S,4S,Z)-1-(Benzyloxy)-4-(methoxymethoxy)octa-5,7-dien-3-ol (127). To a flask 
containing Z-diene 133 (100 mg, 0.34 mmol) was added anhydrous DCM (4 mL). 
After cooling the solution to 0 °C, DIBALH in toluene (1M, 2 mL, 2 mmol) was 
added dropwise and stirred for 10 min. The reaction flask was then cooled to -78 °C, 
prior the addition of 1:1 mixture of EtOAc and EtOH (2 mL). The mixture was stirred 
for 10 min before Rochelle’s salt (0.5 g) was added. After the mixture was continued 
to stir at -78 °C for 30 min, it was warmed to rt. Filtration of the Rochelle’s salt 
followed with an organic wash (EtOAc) to provide crude product. It was concentrated 
in vacuo. Purification on neutralized alumina, (20% EtOAc in hexanes) provided 83.9 
mg (0.287 mmol, 84%) of alcohol 127 as a colorless oil:. 1H NMR (400 MHz, 
CDCl3) ) 1.73 (m, 1H), 1.82 (m, 1H), 2.92 (d, 1H), 3.39 (s, 3H), 3.67 (m, 2H), 3.79 
(m, 1H), 4.40 (q, J = 5.6 Hz, 1H), 4.52 (s, 2H), 4.56 (d, J = 6.7 Hz, 1H), 4.69 (d, J = 
6.7 Hz, 1H), 5.21 (d, J = 10.0 Hz, 1H), 5.30 (m, 2H), 6.29 (dd, J = 11.1, 11.1 Hz, 
1H), 6.65 (td, J = 10.6, 16.8 Hz, 1H), 7.31 (m, 5H); 13C NMR (100 MHz, CDCl3) 
) 138.3, 134.9, 131.7, 128.4, 127.7, 127.6, 127.3, 120.4, 93.7, 74.8 73.2, 71.9, 67.8, 
55.6, 32.7; IR (neat, NaCl): 3512(br), 2930(br), 1620, 1510, 14460, 1350, 1120 cm-1; 
HRMS (ESI+): m/z calc’d for C17H24NaO4









2,2-Dimethyl-5-(phenylselanylmethyl)-4H-benzo[d][1,3]dioxin-4-one (136). To a 
flask containing i-Pr2NH (2.70 mL, 18.8 mmol), dissolved in anhydrous THF (50 mL) 
and cooled to –78 °C, was added dropwise n-BuLi in hexanes (2.5 M, 7.50 mL, 18.8 
mmol). The resulting orange solution was stirred at –78 °C for an additional 30 min, 
and methyl salicylate155 135 (1.50 g, 7.80 mmol) dissolved in anhydrous THF (100 
mL) was added dropwise. After the reaction mixture was stirred at –78 °C for 10 min, 
a solution of PhSeSePh dissolved in anhydrous was added dropwise. The mixture was 
stirred for 2 h at  –78 °C and quenched by the addition of sat. NH4Cl (50 mL). It was 
extracted with Et2O (3x200 mL), washed with brine (100 mL). The organic layer was 
dried over Na2SO4 and concentrated in vacuo. Purification by column 
chromatography on silica gel (10% EtOAc in hexanes) provided 0.96 g (2.7 mmol, 
35%) of phenylselenium salicylate 136 as a bright yellow oil: 1H NMR (400 MHz, 
CDCl3) )  1.52 (s, 3H), 1.68 (s, 3H), 2.76 (t, J = 7.1 Hz, 2H), 4.99 (m, 2H), 5.76 (q, 
1H), 6.08 (s, 1H), 6.77 (q, J = 3.1 Hz, 1H), 7.11 (d, J = 8.0 Hz, 1H), 7.21 (m, J = 3.5 
Hz, 3H), 7.40 (m, J = 4.2 Hz, 3H); HRMS (ESI+): m/z calc’d for C17H16NaO3Se
+, 










(128). To a flask containing i-Pr2NH (0.12 mL, 0.84 mmol), dissolved in anhydrous 
THF (5.0 mL) and cooled at –78 °C, was added n-BuLi in hexanes (2.5 M, 0.34 mL, 
0.84 mmol) dropwise. The resulting orange solution was stirred at –78 °C for an 
additional 30 min, and phenylselenium salicylate 136 (100 mg, 0.288 mmol) 
dissolved in anhydrous THF (1.0 mL) was added dropwise. After the reaction mixture 
was stirred at –78 °C for 10 min, a solution of allyl bromide (60 µL, 0.65 mmol) and 
HMPA (0.16 mL, 0.92 mmol) dissolved in anhydrous THF (5.0 mL) was added 
dropwise. The mixture was stirred for 30 min at  –78 °C and quenched by the addition 
of sat. NH4Cl (15 mL). It was extracted with Et2O (3x60 mL), washed with brine 
(2x30 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. 
Purification by column chromatography on silica gel (5% EtOAc in hexanes) 
provided 73.2 mg (0.189 mmol, 66%) of alkene acetonide 128 as a bright yellow oil: 
1H NMR (400 MHz, CDCl3) ) 1.52 (s, 3H), 1.68 (s, 3H), 2.76 (t, J = 7.1 Hz, 2H), 
4.99 (m, 2H), 5.76 (q, 1H), 6.08 (s, 1H), 6.77 (q, J = 3.1 Hz, 1H), 7.11 (d, J = 8.0 Hz, 
1H), 7.21 (m, J = 3.5 Hz, 3H), 7.40 (m, J = 4.2 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) ) 160.5, 147.5, 135.8, 135.6, 134.9, 133.2, 128.7, 127.9, 123.2, 117.1, 115.7, 












Butyldimethylsilyloxy)-6-(1-(phenylselanyl)but-3-enyl)benzoate (126). Alcohol 
127 (120 mg, 0.410 mmol) was azeotroped in vacuo with benzene (2x3 mL), 
dissolved in anhydrous THF (1.0 mL) and cooled to 0 °C. NaHMDS (1.0 M, 0.90 
mL, 0.90 mmol) was added dropwise. After stirring at 0 °C for 30 min, salicylate 128 
(166 mg, 0.429 mmol) dissolved in distilled THF (1.0 mL) was added dropwise. The 
reaction was warmed to rt and stirred for 2 h, and then TBSCl (618 mg, 4.10 mmol) 
and imidazole (280 mg, 4.10 mmol) were added to the reaction mixture as solids. The 
reaction was stirred overnight, filtered through a silica gel plug and rinsed with Et2O 
(10 mL) and dried over MgSO4. The organic layer was concentrated in vacuo. 
Purification by column chromatography on silica gel (7% EtOAc in hexanes) 
provided inseparable diastereomers 173.4 mg (0.2356 mmol, 57%) of ester 126 as a 
bright yellow oil: 1H NMR (400 MHz, CDCl3): & 7.27-7.48 (m, 7H), 7.10-7.24 (m, 
4H), 6.96 (dd, J = 14.4, 8.2 Hz, 1H), 6.68 (d, J = 8.51 Hz, 1H), 6.54-6.65 (m, 1H), 
6.12-6.31 (m, 1H), 5.61-5.80 (m, 1H), 5.24-5.54 (m, 3H), 5.08-5.20 (m, 1H), 4.98(dd, 
J = 16.4, 8.93 Hz, 2 H), 4.63-4.84 (m, 1H), 4.57-4.65 (m, 1H), 4.42-4.57 (m, 4H), 
3.62 (m, 2H), 3.28 (m, 3H), 2.60-2.86 (m, 2H), 2.10-2.25 (m, 1H), 1.82-2.04 (m, 1H), 
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0.97 (s, 9H), 0.22 (m, 6H); 13C NMR (100.6 MHz, CDCl3): & 166.99, 166.91, 152.4, 
140.5, 140.3, 138.4, 136.0, 135.5, 135.4, 135.2, 134.6, 131.7, 131.6, 129.8, 129.7, 
129.2, 129.1, 128.7, 128.6, 128.4, 127.8, 127.7, 127.6, 127.5, 126.9, 126.8, 126.2, 
126.1, 120.6, 120.4, 120.1, 117.6, 117.1, 117.0, 93.7, 74.7, 73.1, 73.0, 71.2, 71.1, 
67.1, 67.0, 55.6, 43.2, 43.1, 41.2, 30.9, 30.8, 29.7, 25.9, 18.4, -4.11, -4.14; HRMS 
(ESI+): m/z calc’d for C40H52NaO6SeSi








Butyldimethylsilyloxy)-6-((1E,3E)-penta-1,3-dienyl)benzoate (137). ). Alcohol 127 
(120 mg, 0.410 mmol) was azeotroped in vacuo with benzene (2x3 mL), dissolved in 
anhydrous THF (1.0 mL) and cooled to 0 °C. NaHMDS (1.0 M, 0.90 mL, 0.90 mmol) 
was added dropwise. After stirring at 0 °C for 1 min, salicylate13 50 (101 mg, 0.414 
mmol) dissolved in distilled THF (1.0 mL) was added dropwise. The reaction was 
warmed to rt and stirred for 2 h, and then TBSCl (618 mg, 4.10 mmol) and imidazole 
(279 mg, 4.10 mmol) were added to the reaction mixture as solids. The reaction was 
stirred overnight, filtered through a silica gel plug and rinsed with Et2O (10 mL) and 
dried over MgSO4. The organic layer was concentrated in vacuo. Purification by 
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column chromatography on silica gel (7% EtOAc in hexanes) provided 115.9 mg 
(0.1955 mmol, 48%) of ester 137 as a yellow oil: 1H NMR (400 MHz, CDCl3) ) 
1H 
NMR (400 MHz, CDCl3) ) 0.22 (s, 6H), 0.95 (s, 9H), 1.61 (m, 1H), 1.77 (m, 1H), 
1.76 (d, J = 7.0 Hz, 3H), 3.27 (s, 3H), 3.46 (m, 2H), 3.72 (dd, J = 4.8, 10.4 Hz, 1H), 
3.83 (dd, J = 5.0, 10.4 Hz, 1H), 4.51 (s, 2H), 4.63 (d, J = 4.6 Hz, 1H), 4.71 (d, J = 4.5 
Hz, 1H), 5.01 (dd, J = 5.8, 9.8 Hz, 1H), 5.19 (d, J = 10.0 Hz, 1H), 5.30 (tdd, J = 0.9, 
6.4, 16.8 Hz, 1H), 5.34 (dd, J = 4.9, 10.7 Hz, 1H), 5.40 (t, J = 10.3 Hz, 1H), 5.80 (m, 
1H), 6.04 (ddd, J = 1.3, 10.3, 14.7 Hz, 1H), 6.24 (td, J = 11.1, 14.0 Hz, 1H), 6.50 (d, J 
= 15.5 Hz, 1H), 6.63 (m, 3H), 7.11 (d, J = 7.0 Hz, 1H), 7.15 (dd, J = 7.92, 12.8 Hz, 
1H), 7.31 (m, 5H); 13C NMR (100 MHz, CDCl3) )  169.7, 152.5, 134.8, 133.4, 
131.0, 131.9, 131.8, 131.6, 131.1, 129.7, 129.3, 127.7, 127.6, 127.6, 126.5, 120.3, 
119.6, 117.4, 93.9, 75.0, 74.3, 72.4, 71.9, 69.9, 55.5, 55.1, 25.8, 25.8, 18.3, -4.1, -4.2; 
HRMS (ESI+): m/z calc’d for C35H48NaO6Si
















(methoxymethoxy)-3,4-dihydro-1H-benzo[c][1]oxacyclododecin-1-one (124).  
 
Procedure A 
To a flask containing bis-diene 137  (53.9 mg, 0.0909 mmol) was added anhydrous 
and degassed toluene (50 mL). Ruthenium Grubbs 2nd generation catalyst (7.7 mg, 
0.0091 mmol) in degassed toluene (3 mL) was added in one portion under a nitrogen 
atmosphere. The solution was heated at 80 °C and stirred for 17 h. The reaction 
mixture was allowed to cool to room temperature and filtered through a silica gel plug 
and was rinsed with 50% DCM in hexanes (20 mL). The combined organic layer was 
removed in vacuo. Purification by column chromatography on silica gel (5% EtOAc 
in hexanes) provided 4.9 mg (0.0089 mmol, 10%) of macrocyclic triene 124 as a 
yellow oil: 1H NMR (400 MHz, CDCl3) ) 0.18 (s, 3H), 0.20 (s, 3H), 0.95 (s, 9H), 
2.15 (m, 1H), 2.30 (m, 1H), 3.35 (s, 3H), 350 (m, 2H), 3.82 (d, J = 5.0 Hz, 2H), 4.54 
(s, 2H), 4.62 (s, 2H), 4.64 (dd, J = 3.0, 10.8 Hz, 1H), 5.55 (m, 2H), 5.85 (dd, J = 3.9, 
10.8 Hz, 1H), 6.11 (dd, J = 4.1, 11.9 Hz, 1H), 6.25 (t, J = 11.3 Hz, 1H), 6.70 (d, J = 
15.8 Hz, 1H), 6.77 (dd, J = 7.9, 13.3 Hz, 2H), 7.02 (dd, J = 11.4, 15.9 Hz, 1H), 7.17 
(t, J = 7.9 Hz, 1H), 7.33 (m, 5H); 13C NMR (100 MHz, CDCl3) )  168.1, 152.2, 
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138.4, 137.8, 132.0, 132.1, 131.1, 130.3, 129.2, 128.2, 127.4, 127.4, 127.1, 126.9, 
121.2, 117.9, 93.1, 77.4, 73.2, 68.2, 67.9, 55.2, 29.0, 25.8, 18.2, -4.0, -4.5; IR (neat, 
NaCl): 2930, 2870, 1735, 1613, 1510, 1475, 1250, 1090 cm-1; HRMS (ESI+): m/z 
calc’d for C32H42NaO6Si
+, 573.2643; found 573.2645. 
 
Procedure B 
To a flask containing macrocyclic selenium-diene 125  (3.3 mg, 0.0047 mmol) was 
added THF (0.1 mL) and 3.5% H202 (0.9 µL, 0.0094 mmol). The resulting mixture 
was stirred at rt for 3 h and quenced with a mixture of 2.5% NaHCO3 (1 mL) and 5% 
Na2S2O3 (1 mL) and then extracted with EtOAc (3x3 mL) and dried over MgSO4. 
Purification on preparative silica-TLC (5% EtOAc in hexanes) provided 0.7 mg 
(0.00127 mmol, 27%) of macrocyclic triene 124 as yellow oil. The 1H NMR is 
identical with the previous method: HRMS (ESI+): m/z calc’d for C32H42NaO6Si
+, 



















oxacyclododecin-1-one (125). To a flask containing intermediate 126  (60.4 mg, 
0.0821 mmol) was added anhydrous and degassed toluene (46 mL). Ruthenium 
Grubbs 2nd generation catalyst (7.0 mg, 0.0082 mmol) in degassed toluene (2 mL) 
was added in one portion under a nitrogen atmosphere. The solution was heated at 80 
°C and stirred for 17 h. The reaction mixture was allowed to cool to room 
temperature and filtered through a silica gel plug. It was rinsed with 50% DCM in 
hexanes (20 mL). The combined organic layer was removed in vacuo. Purification by 
column chromatography on silica gel (5% EtOAc in hexanes) provided 12.7 mg 
(0.0179 mmol, 22%) of macrocyclic selenium-diene 125 as a yellow oil: HRMS 
(ESI+): m/z calc’d for C38H48NaO6SeSi












(3S,4S)-7-(4-Methoxybenzyloxy)-3-(methoxymethoxy)hept-1-en-4-ol (139). To a 
flask containing 3-(methoxymethoxy)prop-1-ene (4.98 g, 48.8 mmol) dissolved in 
anhydrous THF (100 mL) was added sec-butyllithium in cyclohexane (1.40 M, 29.0 
mL, 40.7 mmol) at –78 °C dropwise. The resulting orange solution was stirred at –78 
°C for an additional 30 min, and (+)-B-methoxydiisopinocamphenylborane (12.9 g, 
40.7 mmol) dissolved in THF (100 mL) was added dropwise. After the reaction 
mixture was stirred at –78 °C for 1 h, it was cooled to –90 °C (using MeOH and 
liquid N2 to prepare the cooling bath). The boron trifluoride etherate (6.80 mL, 54.1 
mmol) was added dropwise. Immediately afterwards, aldehyde 138 (7.90, 40.7 mmol) 
was added dropwise and the mixture kept at –90 °C for 3 h. The reaction was warmed 
to rt over 18 h to give a clear colorless solution, and quenched with a mixture of 35% 
H2O2 (30 mL) and sat. NaHCO3 solution (60 mL). After stirring at rt for 30 min, the 
mixture was extracted with EtOAc (3x200 mL). The combined organic extracts were 
washed with brine, dried over Na2SO4, and concentrated in vacuo. Purification by 
column chromatography on silica gel (30% EtOAc in hexanes) provided 11.14 g 
(35.89 mmol, 88%) of alcohol 139 as a colorless oil: 1H NMR (400 MHz, CDCl3) 
) 1.48 (m, J = 4.9 Hz, 1H), 1.69 (m, J = 3.0 Hz, 2H), 1.83 (m, J = 3.1 Hz, 1H), 3.05 
(brs, 1H), 3.39 (s, 3H), 3.48 (t, J = 6.1 Hz, 2H), 3.58 (m, 1H), 3.80 (s, 3H), 3.88 (t, J 
= 7.3 Hz, 1H), 4.45 (s, 2H), 4.59 (d, J = 6.6 Hz, 1H), 4.74 (d, J = 6.6 Hz, 1H), 5.31 
(d, J = 16.8 Hz, 1H), 5.32 (d, J = 10.3 Hz, 1H), 5.69 (m, 1H), 6.87 (d, J = 8.6 Hz, 
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2H), 7.25 (d, J = 8.5 Hz, 2H);13C NMR (100 MHz, CDCl3) )  159.2, 134.6, 130.3, 
129.4, 120.1, 113.8, 94.0, 81.3, 73.3, 72.6, 69.9, 55.8, 55.3, 29.5, 25.8; IR (neat, 
NaCl):, 3450 (br), 2950 (br), 1610, 1580, 1455, 1420, 1302, 1240 cm-1; [%]D 
23  = 
+44.1 (c = 1.31, CHCl3); HRMS (ESI








trioxa-8-siladecane (140). To a stirred solution of alcohol 139 (3.00 g, 9.65 mmol) 
dissolved in anhydrous DMF (5.0 mL) were added TBSCl (10.5 g, 69.7 mmol) and 
imidazole (4.74 g, 69.6 mmol) as solids. The resulting mixture was heated at 75 °C 
for 4 h. The reaction mixture was cooled to rt and it was quenched with phosphate 
buffer pH 7 (100 mL). The mixture was extracted with DCM (3x100 mL). The 
combined organic layer was dried over Na2SO4 and concentrated in vacuo. 
Purification by column chromatography on silica gel (30% EtOAc in hexanes) 
provided 2.90 g (6.84 mmol, 71% yield) of alkene 140 as a colorless oil: 1H NMR 
(400 MHz, CDCl3) )  0.06 (s, 3H), 0.08 (s, 3H), 0.89 (s, 9H), 1.39 (m, 1H), 1.66 (m, 
3H), 3.35 (s, 3H), 3.42 (t, J = 6.5 Hz, 1H), 3.72 (ddd, J = 3.3, 4.9, 8.0 Hz, 1H), 3.80 
(s, 3H), 3.99 (dd, J = 5.4, 6.5 Hz, 1H), 4.42 (s, 2H), 4.58 (d, J = 6.6 Hz, 1H), 4.67 (d, 
J = 6.6 Hz, 1H), 5.25 (d, J = 10.5 Hz, 1H), 5.27 (d, J = 16.7 Hz, 1H), 5.78 (m, 1H), 
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6.87 (t, J = 4.3 Hz, 2H), 7.25 (d, J = 8.2 Hz, 2H); 13C NMR (100 MHz, CDCl3) )  
159.1, 134.8, 130.8, 129.2, 117.9, 113.7, 94.6, 79.9, 74.0, 72.4, 70.3, 55.5, 55.3, 29.1, 
25.9, 25.6, -4.3, -4.7; IR (neat, NaCl): 2930, 2880, 2853, 1620, 1510, 1471, 1250, 
1100 cm-1; [%]D 
22  = +3.86 (c = 1.01, CHCl3); HRMS (ESI
+): m/z calc’d for 
C23H40NaO5Si






To a stirred solution of alkene 140 (2.90 g, 6.84 mmol) dissolved in THF (54 mL) and 
H2O (27 mL) was added NMO (0.96 g, 8.2 mmol) and OsO4 in toluene (1.0 M, 0.74  
mL, 0.74 mmol). The resulting solution was stirred at rt for 24 h, then quenched with 
a sat. Na2S2O3 solution (20 mL) and extracted with EtOAc (3x50 mL). The combined 
organic extracts were dried over Na2SO4 and concentrated in vacuo. The crude 
product was dried under high vacuum for 4 h before use in the next step.   
 To a flask containing the crude diol was added anhydrous MeOH (60 mL) and 
the reaction was cooled to 0 °C. To this mixture was added K2CO3 (1.54 g, 11.1 
mmol) and Pb(OAc)4 (3.96 g, 8.93 mmol) and the resulting solution was stirred at 0 
°C for 15 min before being quenched with sat. NaHCO3 (40 mL). The reaction 
mixture was extracted with EtOAc (3x50 mL), and the combined organic extracts 
were washed with brine (20 mL), dried over Na2SO4, and concentrated in vacuo. The 
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crude aldehyde was used directly in next step without further purification.  
 To a flask containing allyldiphenylphosphine (2.62 mL, 8.21 mmol) dissolved 
in anhydrous THF (30 mL) was added tert-butyllithium (1.70 M, 4.83 mL, 8.21 
mmol) dropwise at –78 °C, and the mixture was stirred at 0 °C for 30 min. Ti(OiPr)4 
(2.63 mL, 8.90 mmol) was added dropwise at –78 °C, and the resulting solution was 
stirred for 5 min. The crude aldehyde, dissolved in THF (3.0 mL), was added over 4 
min via syringe at –78 °C, and the mixture was stirred at –78 °C for 10 min and then 
at 0 °C for 1h. Methyl iodide (1.28 mL, 20.6 mmol) was added at 0 °C and the 
reaction mixture was stirred at rt overnight. The reaction mixture was diluted with 
hexanes (130 mL), filtered through a silica gel plug (13 g), washed with 20% EtOAc 
in hexanes (100 mL), and concentrated in vacuo. The resulting cis-diene was used 
directly in the next step without further purification.  
 The crude cis-diene was dissolved in anhydrous THF (18 mL) and treated with 
TBAF in THF (1.0 M, 10.3 mL, 10.3 mmol). The reaction mixture was stirred at rt for 
25 h before being diluted with water (20 mL) and extracted with EtOAc (3x20 mL). 
The combined organic extracts were washed with brine (20 mL), dried over Na2SO4, 
and concentrated in vacuo. Purification by column chromatography on silica gel (30% 
EtOAc in hexanes) provided 0.43 g (1.3 mmol, 19%) of cis-dienol 142 as a colorless 
oil: 1H NMR (400 MHz, CDCl3) ) 1.43 (m, 1H), 1.63 (m, 1H), 1.72 (m, 1H), 1.82 
(m, 1H), 2.86 (brs, 1H), 3.38 (s, 3H), 3.46 (m, 2H), 3.57 (m, 1H), 3.80 (s, 3H), 4.36 
(dd, J = 7.10, 9.70 Hz, 1H), 4.42 (s, 2H), 4.54 (d, J = 6.64 Hz, 1H), 4.69 (d, J = 6.7 
Hz, 1H), 5.27 (m, 2H), 6.29 (dd, J = 11.1, 11.8 Hz, 1H), 6.67 (ddd, J = 10.31, 11.7, 
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16.7 Hz, 1H), 6.86 (d, J = 8.7 Hz, 2H), 7.24 (d, J = 8.6 Hz, 2H); 13C NMR (100 
MHz, CDCl3) )  159.1, 134.9, 131.7, 130.6, 129.2, 127.5, 120.4, 113.7, 93.6, 74.8, 
73.5, 72.4, 69.9, 55.6, 55.2, 29.6, 26.0; IR (neat, NaCl): 3430 (br), 2940 (br), 1630, 
1509, 1473, 1250, 1120 cm-1; [%]D 
22  = +46.9  (c = 1.30, CHCl3); HRMS (ESI
+): m/z 
calc’d for C19H28NaO5








(tert-Butyldimethylsilyloxy)-6-((1E,3E)-penta-1,3-dienyl)benzoate (143). Alcohol 
142 (350 mg, 1.04 mmol) was azeotroped in vacuo with benzene (2x4 mL), dissolved 
in anhydrous THF (4.0 mL) and cooled to 0 °C. NaHMDS (1.0 M, 1.98 mL, 1.98 
mmol) was added dropwise. After stirring at 0 °C for 30 min, salicylate 50 (242 mg, 
0.991 mmol) dissolved in distilled THF (4.0 mL) was added dropwise. The reaction 
was warmed to rt and stirred for 2 h, and then TBSCl (298 mg, 1.98 mmol) and 
imidazole (135 mg, 1.98 mmol) were added to the reaction mixture as solids. The 
reaction was stirred overnight and then quenched by an ice-cold solution of 5% HCl 
(30 mL). The mixture was extracted with Et2O (2x30 mL) and the combined organic 
layer was washed with 10% NaHCO3 (50 mL). The organic layer was washed with 
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brine (30 mL), dried over MgSO4 and concentrated in vacuo. Purification by column 
chromatography on silica gel (20% EtOAc in hexanes) provided 0.578 g (0.907 
mmol, 91% yield) of ester 143 as a colorless oil: 1H NMR (400 MHz, CDCl3) )  0.22 
(s, 6H), 0.96 (s, 9H), 1.61 (m, 1H), 1.77 (m, 1H), 1.78 (d, J = 6.88 Hz, 3H), 1.92 (m, 
1H), 3.27 (s, 3H), 3.46 (m, 2H), 3.79 (s, 3H), 4.42 (s, 2H), 4.50 (d, J = 6.72 Hz, 1H), 
4.63 (d, J = 6.76 Hz, 5H), 4.72 (dd, J = 5.54, 9.66 Hz, 1H), 5.20 (m, 2H), 5.28 (d, J = 
16.69 Hz, 1H), 5.39 (dd, 1H), 5.81 (m, 1H), 6.15 (dd, J = 10.50, 14.98 Hz, 1H), 6.27 
(dd, J = 11.10, 11.10 Hz, 1H), 6.46 (d, J = 15.53 Hz, 1H), 6.69 (m, 3H), 6.86 (d, J = 
8.60 Hz, 2H), 7.13 (m, 2H), 7.24 (d, J = 8.52 Hz, 2H); 13C NMR (100 MHz, CDCl3) 
)  171.1, 167.8, 159.1, 152.5, 136.4, 134.7, 131.9, 131.7, 131.6, 131.2, 130.7, 129.6, 
129.1, 126.9, 126.7, 120.4, 117.6, 117.4, 113.7, 93.4, 76.4, 72.4, 70.5, 69.7, 55.5, 
55.2, 27.5, 25.8, 25.6, 25.5, 18.3, -4.1, -4.2; IR (neat, NaCl): 2950, 2873, 1720, 1565, 
1505, 1440, 1280, 1100 cm-1; [%]D 
21  = + 32.9 (c = 1.50, CHCl3); HRMS (ESI
+): m/z 
calc’d for C37H52NaO7Si








(144). To a flask containing bis-diene 143 (100 mg, 0.157 mmol) was added 
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anhydrous and degassed toluene (80 mL). Ruthenium Grubbs 2nd generation catalyst 
(6.7 mg, 0.0079 mmol) in degassed toluene was added in one portion under a nitrogen 
atmosphere. The solution was heated to reflux and stirred for 60 min. The reaction 
mixture was allowed to cool to room temperature and DMSO (5mL) was added into 
the reaction flask prior to the removal of toluene in vacuo to obtain dark brown liquid. 
The crude product was loaded directly on to a silica column for combi-flash 
purification (0% to 10% EtOAc in hexanes) to afford 20.6 mg (0.0346 mmol, 22%) of 
the macrocyclic triene as a light-yellow oil: 1H NMR (400 MHz, CDCl3) ) 0.19 (s, 
3H), 0.20 (s, 3H), 0.96 (s, 9H), 1.73 (m, 1H), 1.86 (m, 1H), 1.97 (m, 1H), 2.07 (m, 
1H), 3.35 (s, 3H) , 3.49 (m, 2H), 3.80 (s, 3H), 4.52 (d, J = 6.6 Hz, 1H), 4.55 (d, J = 
6.4 Hz, 1H), 4.60 (dd, J = 2.9, 10.7 Hz, 1H), 5.32 (ddd, J = 2.9, 2.88, 10.3 Hz, 1H), 
5.68 (dd, J = 11.4, 11.4 Hz, 2H), 5.87 (dd, J = 4.1, 11.0 Hz, 1H), 6.18 (dd, J = 4.1, 
12.0 Hz, 1H), 6.34 (t, J = 11.2 Hz, 1H), 6.64 (d, J = 16.0 Hz, 1H), 6.74 (d, J = 8.20 
Hz, 1H), 6.78 (d, J = 7.7 Hz, 1H), 6.87 (d, J = 8.5 Hz, 2H), 7.01 (dd, J = 11.5, 16.01 
Hz, 1H), 7.16 (dd, J = 7.9, 7.9 Hz, 1H), 7.26 (t, J = 4.3 Hz, 2H); 13C NMR (100 
MHz, CDCl3) ) 168.4, 159.0, 152.3, 137.9, 132.2, 131.9, 131.0, 130.8, 129.9, 129.2, 
129.1, 127.2, 127.1, 126.6, 121.2, 117.9; IR (neat, NaCl): 2930, 2857, 1730, 1612, 
1570, 1513, 1463, 1362, 1292, 1250, 1172, 1155, 1102, 1032, 1001, 927, 863, 839, 
807, 783, 753, 714, 670 cm-1; [%]D 
20 = -81.9  (c= 1.03, CHCl3); HRMS (ESI
+): m/z 
calc’d for C34H46NaO7Si









(2R,3S,Z)-1-(Benzyloxy)-3-(methoxymethoxy)hepta-4,6-dien-2-ol (147). To a flask 
containing ethyl 6-O-benzyl-2,3-dideoxyhex-2-enopyranoside, 146, (11.42 g, 43.86 
mmol) was added anhydrous DCM (120 mL) and cooled to 0 °C. i-Pr2NEt (23.0 mL, 
131.6 mmol) was added dropwise and stirred for 10 min. To the mixture was added 
MOMCl (13.4 mL, 176.4 mmol) dropwise over 40 min at 0 °C and stirred overnight. 
The reaction mixture was poured into a sat. NaHCO3 (50 mL) and extracted with Et2O 
(3x50 mL). The combined organic layer washed with brine (50 mL) and dried over 
Na2SO4, concentrated in vacuo. The crude product, a colorless oil, was used in the 
next step without further purification.  
 To a flask containing the crude product from the previous step dissolved in 
acetonitrile (300 mL) was added Zn(NO3)2•6H2O (26 g, 88 mmol). The mixture was 
heated at 60 °C for 45 min. It was allowed to cool to rt, and then added a 1:1 mixture 
of sat. Na(HCO3) (50 mL) and sat. Rochelle’s salt (50 mL). The mixture was washed 
with brine, and dried over Na2SO4. The organic layer was concentrated in vacuo to 
afford crude pyran-2-ol as colorless oil. The crude product was used in the next step 
without further purification. 
 To a mixture of CH3PPh3Br (34.6 g, 96.8 mmol) in anhydrous THF (50 mL), 
cooled at 0 °C under a N2 atmosphere, was added dropwise a solution of t-BuOK (9.9 
g, 88 mmol) dissolved in THF (200 mL). After the addition was completed, the 
mixture turned bright yellow. The mixture was stirred at 0 °C for 1.5 h, and a solution 
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of crude pyran-2-ol diluted in THF (100 mL) was added dropwise over 10 min. The 
reaction mixture was stirred at 0 °C and warmed to rt overnight and then quenched 
with water (200 mL) and extracted with Et2O (2x200 mL). The combined organic 
layer was washed with brine (250 mL), dried over MgSO4, and concentrated in vacuo. 
Purification by column chromatography on silica gel (40% EtOAc in hexanes) 
provided 4.70 g (16.8 mmol, 38% over three steps) of Z-dienol 147 as a colorless oil: 
1H NMR (400 MHz, CDCl3) ) 2.51 (d, J = 4.1 Hz, 1H), 3.34 (s, 3H), 3.55 (d, J = 1.2 
Hz, 1H), 3.56 (s, 1H), 3.96 (m, J = 5.0 Hz, 1H), 4.54 (s, 2H), 4.54 (d, J = 6.5 Hz, 1H), 
4.63 (dd, J = 4.1, 9.1 Hz, 1H), 4.66 (d, J = 6.6 Hz, 1H), 5.22 (d, J = 10.1 Hz, 1H), 
5.30 (d, J = 16.8 Hz, 1H), 5.42 (dd, J = 10.3, 10.3 Hz, 1H), 6.32 (dd, J = 11.1, 11.1 
Hz, 1H), 6.66 (td, J = 10.8, 16.8 Hz, 1H), 7.31 (m, 5H); 13C NMR (100 MHz, 
CDCl3) )  137.9, 135.0, 131.7, 128.4, 127.8, 127.7, 126.7, 120.3, 93.7, 73.5, 72.5, 
71.7, 70.8, 55.5; IR (neat, NaCl): 3520 (br), 2970 (br), 1650, 1529, 1483, 1239, 1120, 
957 cm-1; HRMS (ESI+): m/z calc’d for C16H22NaO4







(148). To a flask containing Z-dienol 147 (4.70 g, 16.8 mmol) dissolved in anhydrous 
THF (100 mL) was added PPh3 (6.61 g, 25.2 mmol). The mixture was added 
dropwise to a solution of DEAD and PNBA dissolved in THF (200 mL) at 0 °C. The 
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resulting mixture was stirred at 0 °C for 30 min, and stirred overnight at rt and 
concentrated in vacuo and loaded on a silica column. Purification by column 
chromatography on silica gel (30% EtOAc in hexanes) provided 5.77 g (13.5 mmol, 
80%) of Z-diene 148 as a colorless oil: 1H NMR (400 MHz, CDCl3) ) 3.26 (s, 3H), 
3.70 (dd, J = 5.5, 10.8 Hz, 1H), 3.78 (dd, J = 3.5, 10.8 Hz, 1H), 4.51 (m, 3H), 4.64 (d, 
J = 6.8 Hz, 1H), 4.97 (dd, J = 7.0, 9.6 Hz, 1H), 5.23 (d, J = 10.1 Hz, 1H), 5.31 (d, J = 
7.8 Hz, 1H), 5.33 (d, J = 16.5 Hz, 1H), 5.43 (m, J = 2.3 Hz, 1H), 6.31 (dd, J = 11.2, 
11.2 Hz, 1H), 6.71 (td, J = 10.5, 16.4 Hz, 1H), 7.29 (m, 5H), 8.27 (m, 4H); 13C NMR 
(100 MHz, CDCl3) )  164.1, 150.6, 137.7, 135.6, 135.3, 131.5, 130.9, 128.3, 127.7, 
127.7, 125.8, 123.5, 120.9, 93.6, 75.5, 73.3, 69.7, 68.4, 55.5; [%]D 
21  = +39.5   (c = 
1.24, CHCl3); HRMS (ESI
+): m/z calc’d for C23H25NNaO7







(2S,3S,Z)-1-(Benzyloxy)-3-(methoxymethoxy)hepta-4,6-dien-2-ol (149). To a flask 
containing Z-diene 148 (3.0 g, 7.0 mmol) dissolved in MeOH (75 mL) was added 
K2CO3 (7.5 g, 54 mmol). The mixture was stirred for 1 h at rt . The solid K2CO3 were 
filtered out using filtered paper and was rinsed with Et2O (20 mL). The combined 
organic layer was concentrated in vacuo and loaded to a silica column. Purification by 
column chromatography on silica gel (30% EtOAc in hexanes) provided 1.60 g (5.74 
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mmol, 82%) of Z-dienol 149 as a colorless oil: 1H NMR (400 MHz, CDCl3) )  2.81 
(d, J = 4.3 Hz, 1H), 3.37 (s, 3H), 3.47 (dd, J = 5.6, 9.9 Hz, 1H), 3.59 (dd, J = 3.7, 9.9 
Hz, 1H), 3.79 (m, 1H), 4.52 (s, 2H), 4.56 (d, J = 6.6 Hz, 1H), 4.63 (dd, J = 6.8, 9.8 
Hz, 1H), 4.68 (d, J = 6.7 Hz, 1H), 5.21 (d, J = 10.1 Hz, 1H), 5.29 (d, J = 16.7 Hz, 
1H), 5.33 (dd, J = 10.4, 10.4 Hz, 1H), 6.26 (dd, J = 11.1, 11.8 Hz, 1H), 6.69 (td, J = 
10.2, 16.8 Hz, 1H), 7.29 (m, 5H); 13C NMR (100 MHz, CDCl3) )  138.0, 134.7, 
131.7, 128.3, 127.8, 127.6, 127.1, 120.3, 93.8, 73.5, 73.1, 72.0, 70.7, 55.6; IR (neat, 
NaCl): 3545 (br), 2930 (br), 1670, 1549, 1485, 1259, 1117 cm-1; [%]D 
21  = + 60.3   (c 
= 1.25, CHCl3); HRMS (ESI










Butyldimethylsilyloxy)-6-((1E,3E)-penta-1,3-dienyl)benzoate (150). Alcohol 149 
(1.60 g, 5.74 mmol) was azeotroped in vacuo with benzene (2x10 mL), dissolved in 
anhydrous THF (20.0 mL) and cooled to 0 °C. NaHMDS (1.0 M, 12.1 mL, 12.1 
mmol) was added dropwise. After stirring at 0 °C for 30 min, salicylate 50  (1.42 g, 
5.80 mmol) dissolved in distilled THF (20.0 mL) was added dropwise. The reaction 
was warmed to rt and stirred for 2 h, and then TBSCl (1.82 g, 12.1 mmol) and 
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imidazole (0.82 g, 12.1 mmol) were added to the reaction mixture as solids. The 
reaction was stirred overnight, filtered through a silica gel plug and rinsed with Et2O 
(40 mL) and dried over MgSO4. The organic layer was concentrated in vacuo. 
Purification by column chromatography on silica gel (10% EtOAc in hexanes) 
provided 1.44 g (2.489 mmol, 43%) of ester 150 as a colorless oil: 1H NMR (400 
MHz, CDCl3) ) 0.21 (s, 3H), 0.22 (s, 3H), 0.97 (s, 9H), 1.75 (d, J = 7.40 Hz, 3H), 
3.27 (s, 3H), 3.72 (dd, J = 4.7, 10.4 Hz, 1H), 3.83 (dd, J = 5.0, 10.4 Hz, 1H), 4.52 (s, 
2H), 4.63 (d, J = 4.6 Hz, 1H), 4.65 (d, J = 4.5 Hz, 1H), 4.95 (dd, J = 5.8, 9.8 Hz, 1H), 
5.19 (d, J = 10.0 Hz, 1H), 5.28 (tdd, J = 0.9, 6.4, 16.8 Hz, 1H), 5.34 (dd, J = 4.9, 10.7 
Hz, 1H), 5.39 (t, J = 10.3 Hz, 1H), 5.79 (m, 1H), 6.04 (ddd, J = 1.3, 10.4, 15.0 Hz, 
1H), 6.24 (td, J = 11.1, 14.0 Hz, 1H), 6.50 (d, J = 15.5 Hz, 1H), 6.67 (m, 3H), 7.14 (d, 
J = 7.0 Hz, 1H), 7.15 (dd, J = 7.92, 12.8 Hz, 1H), 7.31 (m, 5); 13C NMR (100 MHz, 
CDCl3) )  167.7, 152.5, 134.8, 133.4, 132.0, 131.9, 131.8, 131.7, 131.1, 129.7, 128.3, 
127.7, 127.6, 127.6, 126.5, 120.3, 119.6, 117.4, 93.9, 75.0, 74.3, 73.4, 71.9, 68.9, 
55.5, 25.8, 25.8, 18.3, -4.2, -4.2; IR (neat, NaCl): 2920. 2875, 1720, 1568. 1503, 
1465, 1280, 1237, 1083, 985 cm-1; [%]D 
21  = +23.5  (c = 1.50, CHCl3); HRMS (ESI
+): 
m/z calc’d for C34H46NaO6Si









(methoxymethoxy)-3,4-dihydro-1H-benzo[c][1]oxacyclododecin-1-one (151). To a 
flask containing ester 150 (70 mg, 0.12 mmol) was added anhydrous and degassed 
DCM (65 mL). Ruthenium Grubbs 2nd generation catalyst (17 mg, 0.020 mmol) in 
degassed DCM (1.0 mL) was added in one portion under a nitrogen atmosphere. The 
solution was heated to reflux at 47 °C for 80 min. The reaction mixture was allowed 
to cool to room temperature and DMSO (5 mL) was added into the reaction flask. The 
mixture was stirred overnight, and then concentrate in vacuo. The crude product was 
loaded directly on to a silica column for combi-flash purification (0% to 10% EtOAc 
in hexanes) to afford 10.9 mg (0.0203 mmol, 17%) of macrocyclic triene 151 as a 
light-yellow oil: 1H NMR (400 MHz, CDCl3) ) 0.17 (s, 3H), 0.21 (s, 3H), 0.92 (s, 
9H), 3.36 (s, 3H), 3.92 (d, J = 5.0 Hz, 2H), 4.54 (s, 2H), 4.62 (s, 2H), 4.64 (dd, J = 
3.0, 10.8 Hz, 1H), 5.57 (m, 2H), 5.85 (dd, J = 3.9, 10.8 Hz, 1H), 6.13 (dd, J = 4.1, 
11.9 Hz, 1H), 6.35 (t, J = 11.3 Hz, 1H), 6.65 (d, J = 16.0 Hz, 1H), 6.77 (dd, J = 7.9, 
13.4 Hz, 2H), 7.02 (dd, J = 11.4, 16.0 Hz, 1H), 7.17 (t, J = 8.0 Hz, 1H), 7.33 (m, 5H); 
13C NMR (100 MHz, CDCl3) )  168.3, 152.5, 138.2, 138.0, 132.1, 132.1, 131.2, 
130.2, 129.4, 128.3, 127.7, 127.5, 127.2, 126.9, 121.1, 117.8, 93.2, 77.4, 73.2, 68.2, 
67.9, 55.5, 25.7, 18.2, -4.0, -4.5; IR (neat, NaCl): 2950, 2859, 1732, 1620, 1590, 
1587, 1480, 1260, 1038 cm-1; [%]D 
21  = -78  (c = 0.50, CHCl3); HRMS (ESI
+): m/z 
calc’d for C31H40NaO6Si







 (5S,6S)-10,10,11,11-Tetramethyl-5-vinyl-2,4,9-trioxa-10-siladodecan-6-ol (153). 
To a flask containing 3-(methoxymethylthoxy)prop-1-ene (4.00 g, 39.2 mmol) 
dissolved in anhydrous THF (80 mL) was added sec-butyllithium in cyclohexane 
(1.40 M, 23.3 mL, 32.6 mmol) at –78 °C dropwise. The resulting orange solution was 
stirred at –78 °C for an additional 30 min, and (+)-B-
methoxydiisopinocamphenylborane (10.3 g, 32.6 mmol) dissolved in THF (80 mL) 
was added dropwise. After the reaction mixture was stirred at –78 °C for 1 h, it was 
cooled to -90 °C (using MeOH and liquid N2 to prepare the cooling bath). Boron 
trifluoride etherate (5.45 mL, 43.4 mmol) was added dropwise. Immediately 
afterwards, 3-(tert-butyldimethylsilyloxy)propanal, 152, (6.14 g, 32.6 mmol) was 
added dropwise and the mixture kept at -90 °C for 3 h. The reaction was warmed to rt 
over 15 h to give a clear colorless solution, and quenched with a mixture of 35% 
H2O2 (23 mL) and sat. NaHCO3 solution (45 mL). After stirring at rt for 30 min, the 
mixture was extracted with EtOAc (3x50 mL). The combined organic extracts were 
washed with brine, dried over Na2SO4, and concentrated in vacuo. Purification by 
column chromatography on silica gel (15% EtOAc in hexanes) provided 7.64 g (26.3 
mmol, 81%) of alcohol 153 as a colorless oil: 1H NMR (400 MHz, CDCl3) )  0.05 (s, 
6H), 0.88 (s, 9H), 1.69 (m, 2H), 3.12 (brs, 1H), 3.38 (s, 3H), 3.82 (m, 3H), 3.92 (dd, J 
= 6.90, 6.90 Hz, 1H), 4.59 (d, J = 6.64 Hz, 1H), 4.72 (d, J = 6.64 Hz, 1H), 5.30 (d, J = 
15.73 Hz, 1H), 5.30 (d, J = 11.60 Hz, 1H), 5.74 (m, J = 3.54 Hz, 13H); 13C NMR 
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(100 MHz, CDCl3) )  134.8, 119.6, 94.0, 80.9, 72.2, 61.2, 55.6, 34.9, 25.9, 18.2, -5.5, 
-5.5; IR (neat, NaCl): 3450 (br), 2890 (br), 1630, 1598, 1473, 1290, 1157 cm-1; [%]D 
21  
= +61.4 (c = 1.31, CHCl3); HRMS (ESI









trioxa-10-siladodecane (154). Alcohol 153 (1.65 g, 5.68 mmol) was azeotroped in 
vacuo with benzene (2x5 mL), and dissolved in anhydrous DCM (75.0 mL). To the 
mixture was added 2,6-lutidine (1.32 mL, 11.36 mmol) and cooled to –78 °C. TBSOTf 
(1.32 mL, 11.36 mmol) was added dropwise at –78 °C and stirred overnight while the 
reaction slowly warmed to rt. The reaction mixture was quenched with cold water (2 
mL) and extracted with DCM (3x30 mL). The combined organic layer was dried over 
Na2SO4 and concentrated in vacuo. Purification by column chromatography on silica 
gel (5% Et2O in hexanes) provided 2.30 g (5.68 mmol, quantitative yield) of alkene 
154 as a colorless oil: 1H NMR (400 MHz, CDCl3) )  0.04 (s, 6H), 0.08 (s, 3H), 0.09 
(s, 3H), 0.88 (s, 9H), 0.89 (s, 9H), 1.56 (m, 1H), 1.80 (m, 1H), 3.36 (s, 3H), 3.68 (m, 
2H), 3.92 (m, 1H), 4.02 (q, 1H), 4.59 (d, J = 6.64 Hz, 1H), 4.67 (d, J = 6.60 Hz, 1H), 
5.25 (d, J = 9.40 Hz, 1H), 5.28 (d, J = 16.85 Hz, 1H), 5.82 (m, 1H); 13C NMR (100 
MHz, CDCl3) )  134.8, 117.6, 94.7, 79.6, 70.6, 59.5, 55.4, 35.4, 25.9, 18.2, 18.1, -
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4.4, -4.9, -5.3, -5.3; IR (neat, NaCl): 2968, 2945, 2849, 1608, 1520, 1469, 1246, 1093 
cm-1; [%]D 
21  = +7.90   (c =  1.50, CHCl3); HRMS (ESI
+): m/z calc’d for 
C20H44NaO4Si2







(triisopropylsilyl) but-1-en-3-ynyl)-2,4,9-trioxa-10-siladodecane (156). To a stirred 
solution of alkene 154 (0.47 g, 1.16 mmol) dissolved in THF (10 mL) and H2O (5 
mL) was added NMO (163 mg, 1.40 mmol) and OsO4 in toluene (1.0 M, 0.13 mL, 
0.13 mmol). The resulting solution was stirred at rt for 41 h, then quenched with a sat. 
Na2S2O3 solution (20 mL) and extracted with EtOAc (3x50 mL). The combined 
organic extracts were dried over Na2SO4 and concentrated in vacuo. The crude 
product was dried under high vacuum for 4 h before use in the next step.   
 To a flask containing the crude diol was added anhydrous MeOH (10 mL) and 
the reaction was cooled to 0 °C. To the mixture was added K2CO3 (0.26 g, 1.9 mmol) 
and Pb(OAc)4 (0.67 g, 1.5 mmol) and the resulting solution was stirred at 0 °C for 15 
min before being quenched with sat. NaHCO3 (20 mL). The reaction mixture was 
extracted with EtOAc (3x20 mL), and the combined organic extracts were washed 
with brine (20 mL), dried over Na2SO4, and concentrated in vacuo. The crude 
aldehyde was used directly in next step without further purification.  
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 To a flask containing prop-1-yne-1,3-diylbis(triisopropylsilane), 120, (0.71 g, 
2.0 mmol) was added anhydrous THF (16 mL) and cooled to -20 °C. To the resulting 
mixture was added n-BuLi in hexanes (1.6 M, 1.25 mL, 2.00 mmol) dropwise over 5 
min, stirred for 30 min, and then cooled to -78 °C.  The crude aldehyde dissolved in 
THF (11 mL) was added dropwise to the anion solution over 1.5 h.  After additional 
stirring for 30 min, the reaction was quenched at -78 °C with saturated NH4Cl 
solution (25 mL) and warmed to rt. The mixture was extracted with EtOAc (3x30 
mL), and washed with brine. The combined organic layer was dried over MgSO4 and 
concentrated in vacuo. Purification by column chromatography on silica gel (5% 
EtOAc in hexanes) provided 0.21 g (0.36 mmol, 31% over three steps) of the enyne 
product as an inseparable 10:1 Z:E olefin mixture, as determined by 1H NMR. 1H 
NMR (400 MHz, CDCl3) ) 0.03 (s, 6H), 0.07 (s, 3H), 0.09 (s, 3H), 0.88 (s, 9H), 0.89 
(s, 9H), 1.09 (s, 21H), 1.65 (m, 1H), 1.87 (m, 1H), 3.33 (s, 3H), 3.69 (m, 2H), 3.88 
(m, 1H), 4.53 (dd, J = 5.78, 9.34 Hz, 1H), 4.58 (d, J = 6.36 Hz, 1H), 4.69 (d, J = 6.40 
Hz, 1H), 5.76 (d, J = 11.12 Hz, 1H), 5.88 (dd, J = 9.32, 11.08 Hz, 1H); 13C NMR (100 
MHz, CDCl3) &  140.7, 113.6, 107.1, 96.9, 95.1, 78.6, 71.0, 59.7, 55.6, 36.6, 26.0, 
25.9, 25.9, 25.8, 18.6, 18.6, -4.7, -4.7, -5.2, -5.3; IR (neat, NaCl): 2950, 2878, 2157, 
1630, 1529, 1276, 1108, 973 cm-1; [%]D 
21  = +5.35  (c = 1.44 , CHCl3); HRMS (ESI
+): 
m/z calc’d for C31H64NaO4Si3










 The eneyne 156 (110 mg, 0.188 mmol) was dissolved in anhydrous THF (18 
mL), cooled to 0 °C and treated with TBAF in THF (1.0 M, 0.51 mL, 0.51 mmol). 
The reaction mixture was stirred at rt for 38 h before being diluted with phosphate 
buffer pH 7 (3 mL) and extracted with EtOAc (3x5 mL). The combined organic 
extracts were washed with brine (5 mL), dried over Na2SO4, and concentrated in 
vacuo. Purification by column chromatography on silica gel (70% EtOAc in hexanes) 




 A stirred solution of alkene 154 (1.40 g, 3.45 mmol) dissolved in anhydrous 
DCM (60 mL) was cooled to -78 °C and ozone was introduced for 3-5 min until the 
solution turned a deep blue color. The reaction was flushed with N2 until the solution 
became colorless, and then Me2S (13.5 mL) was added to a reaction mixture at -78 
°C. The resulting mixture was stirred overnight and dried over Na2SO4. The organic 
layer was concentrated in vacuo to afford the aldehyde as a light yellow oil. The 
crude aldehyde was used directly in the next step without further purification.   
 To a flask containing prop-1-yne-1,3-diylbis(triisopropylsilane), 120, (2.3 g, 6.5 
mmol) dissolved in anhydrous THF (45 mL) at -20 °C was added n-BuLi in hexanes 
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(1.6 M, 4.1 mL, 6.5 mmol) dropwise over 5 min. The reaction mixture was stirred for 
30 min, and then cooled to -78 °C.  The crude aldehyde, dissolved in THF (11 mL), 
was added dropwise to the anion solution over 1.5 h.  After additional stirring for 30 
min, the reaction was quenched at -78 °C with saturated NH4Cl solution (40 mL) and 
warmed to rt. The mixture was extracted with EtOAc (3x30 mL), and washed with 
brine. The combined organic layer was dried over MgSO4 and concentrated in vacuo. 
The crude enyne was used directly in the next step without further purification. 
 The crude enyne was dissolved in anhydrous THF (30 mL), cooled to 0 °C and 
treated with TBAF in THF (1.0 M, 26.04 mL, 26.04 mmol). The reaction mixture was 
stirred at rt for 22 h before it was quenched with sat. NH4Cl (40 mL) and extracted 
with EtOAc (3x40 mL). The combined organic extracts were washed with brine (20 
mL), dried over Na2SO4, and concentrated in vacuo. Purification by column 
chromatography on silica gel (70% EtOAc in hexanes) provided 352.9 mg (1.762 
mmol, 51% over three steps) of diol 157 as a pure Z-enyne light yellow product: 1H 
NMR (400 MHz, CDCl3) ) .74 (m, 1H), 2.85 (brs, 1H), 3.17 (d, J = 2.2 Hz, 1H), 
3.23 (brs, 1H), 3.39 (s, 3H), 3.81 (m, 3H), 4.50 (dd, J = 7.1, 9.2 Hz, 1H), 4.61 (d, J = 
6.6 Hz, 1H), 4.70 (d, J = 6.6 Hz, 1H), 5.73 (dd, J = 2.4, 11.1 Hz, 1H), 5.87 (dd, J = 
9.0, 11.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) )  141.0, 113.3, 95.1, 83.4, 79.2, 
78.3, 73.1, 60.9, 56.0, 34.1; IR (neat, NaCl): 3557 (br), 3300, 3078, 2953, 2870, 1635, 
1463, 1298, 1107 cm-1; [%]D 
21  = +37.1  (c = 1.58, CHCl3); HRMS (ESI
+): m/z calc’d 
for C10H16NaO4









siladodecan-6-ol (114). To a stirred solution of diol 157 (85.0 mg, 0.424 mmol) 
dissolved in anhydrous DMF (2.0 mL) were added imidazole (72.0 mg, 1.06 mmol) 
and DMAP (3.7 mg, 0.030 mmol) as solids. To the mixture was added TBDPSCl 
(110 µL, 0.429 mmol) at rt, stirred overnight, and quenched with sat. NaHCO3 (5 mL) 
, and extracted with DCM (2x5 mL). The combined organic layer was washed with 
brine (2 mL), dried over Na2SO4, and concentrated in vacuo. Purification by column 
chromatography on silica gel (20% EtOAc in hexanes) provided 149.5 mg (0.3408 
mmol, 80%) of alcohol 157 as a light yellow oil: 1H NMR (400 MHz, CDCl3) ) 1.05 
(s, 9H), 1.78 (m, 2H), 3.03 (d, 1H), 3.11 (q, 1H), 3.40 (s, 3H), 3.84 (m, 1H), 3.92 (m, 
2H), 4.53 (dd, 1H), 4.63 (d, J = 6.7 Hz, 1H), 4.73 (d, J = 6.6 Hz, 1H), 5.73 (dd, J = 
2.2, 11.0 Hz, 1H), 5.95 (d, J = 9.4 Hz, 1H), 5.98 (d, J = 10.2 Hz, 1H), 7.39 (m, 6H), 
7.67 (m, 4H); 13C NMR (100 MHz, CDCl3) )  141.7, 135.6, 135.6, 129.7, 127.7, 
112.7, 95.0, 83.1, 79.3, 77.9, 71.8, 60.4, 55.9, 35.0, 26.8, 21.0; IR (neat, NaCl): 3489 
(br), 3290, 3071, 2927, 2855, 1609, 1591, 1472, 1425, 1258, 1111, 1029 cm-1; [%]D 
21  
= +39.6  (c = 1.18, CHCl3); HRMS (ESI
+): m/z calc’d for C26H34NaO4Si












siladodecan-6-yl 2-((E)-2-iodovinyl)-6-methoxybenzoate (111). Alcohol 114 (550 
mg, 1.25 mmol) was azeotroped in vacuo with benzene (2x5 mL), dissolved in 
anhydrous THF (15.0 mL) and cooled to 0 °C. NaHMDS (1.0 M, 2.50 mL, 2.50 
mmol) was added dropwise. After stirring at 0 °C for 30 min, salicylate61 115 (432 
mg, 1.31 mmol) dissolved in distilled THF (12.0 mL) was added dropwise. The 
reaction was warmed to rt and stirred for 2 h, and then Me2SO4 (0.52 mL, 5.5 mmol) 
was added. The reaction was stirred at rt for 5 h, and then quenched with phosphate 
buffer pH 7. The mixture was extracted with EtOAc (3x20 mL) and washed with 
brine (20 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. 
Purification by column chromatography on silica gel (10% EtOAc in hexanes) 
provided 735 mg (1.01 mmol, 81%) of ester 111 as a light yellow oil: 1H NMR (400 
MHz, CDCl3) ) 1.07 (s, 9H), 2.04 (m, 2H), 3.13 (m, 1H), 3.32 (s, 3H), 3.56 (s, 3H), 
3.88 (m, 2H), 4.64 (d, J = 6.8 Hz, 1H), 4.73 (d, J = 6.8 Hz, 1H), 4.82 (dd, J = 5.4, 9.0 
Hz, 1H), 5.69 (m, 1H), 5.85 (dd, J = 2.6, 11.3 Hz, 1H), 6.02 (dd, J = 9.1, 11.0 Hz, 
1H), 6.79 (d, J = 8.2 Hz, 1H), 6.87 (d, J = 14.8 Hz, 1H), 7.00 (d, J = 7.8 Hz, 1H), 7.28 
(t, J = 8.6 Hz, 1H), 7.38 (m, 6H), 7.50 (d, J = 14.8 Hz, 1H), 7.71 (m, 4H); 13C NMR 
(100 MHz, CDCl3) )  166.8, 156.3, 141.7, 141.0, 136.1, 135.7, 135.6, 130.4, 129.5, 
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127.6, 122.3, 117.5, 113.4, 110.5, 94.7, 83.8, 80.2, 79.1, 74.8, 73.1, 59.7, 55.8, 55.5, 
34.1, 26.8, 19.2; IR (neat, NaCl): 3291, 3068, 2927, 2853, 1730, 1607, 1591, 1573, 
1475, 1271, 1111 cm-1; [%]D 
21  = -4.60 (c = 3.70, CHCl3); HRMS (ESI
+): m/z calc’d 
for C36H41INaO6Si







(methoxymethoxy)-3,4-dihydro-1H-benzo[c][1]oxacyclododecin-1-one (110). To a 
flask containing Cu(OAc)2 (13.8 mg, 0.0760 mmol), P(OMe)3 (9.0 µL, 0.076 mmol), 
K2CO3 (14.4 mg, 0.104 mmol) and NaHCO3 (19.0 mg, 0.279 mmol) was added 
anhydrous DMF (7 mL) and stirred at 110 °C for 30 min, during which time a dark 
black solution formed.  The intermediate 111 (50 mg, 0.0690 mmol) dissolved in 
DMF (7.0 mL) was added dropwise over 10 min.  The reaction mixture was stirred 
for an additional 1 h and 15 min at 110 °C, and then cooled to rt. The mixture was 
diluted with Et2O (5.0 mL) and sat. NH4Cl (5.0 mL). The organic layer was 
separated, and the aqueous layer was extracted with Et2O (2x5.0 mL). The combined 
organic layer was washed with brine (5 mL), dried over Na2SO4, and concentrated in 
vacuo. Purification by column chromatography on silica gel (10% EtOAc in hexanes) 
provided 25.7 mg (0.0429 mmol, 62%) of macrocyclic triene 110 as a light yellow 
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oil: 1H NMR (400 MHz, CDCl3) )  1.07 (s, 9H), 2.09 (m, 1H), 2.30 (m, 1H), 3.36 (s, 
3H), 3.40 (s, 3H), 3.90 (m, 2H), 4.55 (d, J = 6.5 Hz, 1H), 4.58 (d, J = 6.5 Hz, 1H), 
4.63 (dd, J = 3.4, 10.8 Hz, 1H), 5.56 (dd, J = 1.78, 11.5 Hz, 1H), 5.69 (dd, J = 11.3, 
11.3 Hz, 1H), 5.89 (dd, J = 4.2, 10.6 Hz, 1H), 6.18 (dd, J = 4.0, 11.9 Hz, 1H), 6.35 
(dd, J = 11.3, 11.3 Hz, 1H), 6.66 (d, J = 16.0 Hz, 1H), 6.70 (d, J = 8.3 Hz, 2H), 6.79 
(d, J = 7.7 Hz, 1H), 7.01 (dd, J = 11.5, 16.0 Hz, 1H), 7.23 (t, J = 8.1 Hz, 1H), 7.38 
(m, 6H), 7.70 (d, J = 2.8 Hz, 4H); 13C NMR (100 MHz, CDCl3) )  168.4, 156.0, 
138.3, 135.5, 134.0, 133.0, 132.1, 130.8, 129.5, 129.5, 127.7, 127.6, 127.4, 123.7, 
120.4, 109.2, 93.4, 74.2, 68.5, 60.6, 55.4, 55.3, 31.2, 26.8, 19.2; IR (neat, NaCl): 
2930, 1732, 1572, 1468, 1427, 1271, 1111, 1030, 853, 822, 742, 703 cm-1; [%]D 
21  = -
139 (c = 2.37, CHCl3); HRMS (ESI







(E)-5-(Hexa-1,5-dienyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (177). To a 
flask containing Pd2dba3 (50.3 mg, 0.0549 mmol), tricyclohexylphosphonium 
tetrafluoroborate (79.2 mg, 0.215 mmol) and i-Pr2NEt (0.30 mL, 1.7 mmol) was 
added DCM (100 mL) and the resulting mixture was stirred at rt for 10 min. 4-
Pentyn-1-ol (1 mL, 11 mmol) was added and the reaction mixture was cooled to 0 °C. 
Bu3SnH (3.45 mL, 13.0 mmol) diluted in DCM (30 mL) was added dropwise via 
 
141 
syringe over 15 min. The reaction was then allowed to stir at 0 °C for 4 h. The 
reaction mixture was condensed to approximately 30 mL of organic mixture and was 
used directly to the next step without any workup. The crude product showed only 
(E)-5-(tributylstannyl)pent-4-en-1-ol, identical with 1H NMR and 13C properties as 
reported by Chong.90 
 To the crude (E)-5-(tributylstannyl)pent-4-en-1-ol was added Et3N (7.6 mL, 54 
mmol) and DMSO (30 mL). The mixture was cooled to 0 °C, and SO3•Py (52.0 mg, 
0.324 mmol) was added in portions over 2 min. The mixture was stirred at 0 °C for 15 
min, and then diluted with hexanes (100 mL) and phosphate buffer pH 7 (20 mL). 
The organic layer was separated, and then the aqueous layer was extracted with (3x30 
mL of hexanes). The combined organic layer was concentrated in vacuo to afford a 
bright yellow crude product. The crude aldehyde was used directly in the next step 
without further purification.  
 To a mixture of CH3PPh3Br (8.50g, 23.8 mmol) in anhydrous THF (30 mL), 
cooled at 0 °C under N2 atmosphere, was added dropwise a solution of t-BuOK (2.42 
g, 21.6 mmol) over 3 min. After the addition was completed, the mixture turned 
bright yellow. The mixture was stirred at 0 °C for 30 min and a solution of crude 
aldehyde diluted in THF (30 mL) was added dropwise over 10 min. The reaction 
mixture was stirred at 0 °C and warmed to rt overnight, an then diluted with hexanes 
(100 mL) and quenched with phosphate buffer pH 7 (50 mL). The organic layer was 
separated and the aqueous layer was extracted with hexanes (3x100 mL), dried over 
NaSO4 and concentrated in vacuo to afford crude stannyl-diene as a yellow oil. The 
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crude product was divided into four portions equally and used directly for Stille 
coupling in procedure A and procedure B without further purification. 
 
Stille Coupling Procedure A 
 To a flask containing Pd2dba3 (103.0 mg, 0.1125 mmol), tri-(2-furyl)-phosphine 
(79.0 mg, 0.340 mmol), LiCl (475.0 mg, 11.21 mmol), and  triflate 57 (731.0 mg, 
2.241 mmol) was added anhydrous and degassed DMF (20 mL) and stirred at rt for 
15 min under a N2 atmosphere. Then the crude stannyl-diene (~ 2.7 mmol), dissolved 
in anhydrous and degassed DMF, was added dropwise. The resulting mixture was 
stirred and heated at 80 °C for 16 h, and then cooled to rt. After 10% NH4OH (15 
mL) was added, the mixture was extracted with hexanes (5x50 mL), washed with 
brine (20 mL), dried over Na2SO4 and concentrated in vacuo. Purification by column 
chromatography on silica gel (10% EtOAc in hexanes) provided 327.2 mg (1.267 
mmol, 57%) of dienyl acetonide 177 as an opaque oil. 
 
Stille Coupling Procedure B 
 To a flask containing Pd(PPh3)4 (129.0 mg, 0.1116 mmol), LiCl (475.0 mg, 
11.21 mmol), and  triflate 57 (731.0 mg, 2.241 mmol) was added anhydrous and 
degassed THF (10 mL) at rt under a N2 atmosphere. Then the crude stannyl-diene (~ 
2.7 mmol) dissolved in anhydrous and degassed DMF was added dropwise over 15 
min. The resulting mixture was stirred and heated at 70 °C for 90 h, and then cooled 
to rt. After 10% NH4OH (15 mL) was added, the mixture was extracted with hexanes 
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(5x50 mL), washed with brine (20 mL), dried over Na2SO4, and concentrated in 
vacuo. Purification by column chromatography on silica gel (10% EtOAc in hexanes) 
provided 538.4 mg (2.084 mmol, 93%) of dienyl acetonide 177 as an opaque oil: 1H 
NMR (400 MHz, CDCl3) ) 1.71 (s, 6H), 2.27 (m, 2H), 2.39 (m, 2H), 5.00 (dd, J = 
1.86, 10.2 Hz, 1H), 5.08 (dd, J = 1.7, 17.1 Hz, 1H), 5.88 (tdd, J = 6.6, 10.4, 17.0 Hz, 
1H), 6.23 (td, J = 6.8, 15.6 Hz, 1H), 6.82 (dd, J = 0.9, 8.1 Hz, 1H), 7.22 (d, J = 7.8 
Hz, 2H), 7.42 (t, J = 8.0 Hz, 1H), 7.48 (d, J = 15.7 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) )  160.4, 156.8, 142.5, 138.0, 135.0, 134.6, 128.5, 121.3, 115.6, 115.0, 110.6, 
105.1, 33.3, 32.5, 25.6; IR (neat, NaCl): 2990, 1735, 1598, 1467, 1320 cm-1; HRMS 
(ESI+): m/z calc’d for C16H18NaO3






(3S,4S)-1-(4-Methoxybenzyloxy)-4-(methoxymethoxy)hex-5-en-3-ol (53). To a 
flask containing 3-(methoxymethoxy)prop-1-ene (1.27 g, 12.4 mmol) dissolved in 
anhydrous THF (25 mL) was added sec-butyllithium in cyclohexane (1.40 M, 7.3 mL, 
10.3 mmol) at –78 °C dropwise. The resulting orange solution was stirred at –78 °C 
for an additional 30 min, and (+)-B-methoxydiisopinocamphenylborane (3.26 g, 10.3 
mmol) dissolved in THF (25 mL) was added dropwise. The reaction mixture was 
stirred at –78 °C for 1 h, then cooled to -90 °C (using MeOH and liquid N2 to prepare 
the cooling bath). The boron trifluoride etherate (1.72 mL, 13.7 mmol) was added 
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dropwise. Immediately afterwards, 3-(4-methoxybenzyloxy)propanal (2 g, 10.3 
mmol) was added dropwise and the mixture kept at -90 °C for 3 h. The reaction was 
warmed to rt over 15 h to give a clear colorless solution, and quenched with a mixture 
of 35% H2O2 (12.5 mL) and sat. NaHCO3 solution (20.0 mL). After stirring at rt for 
30 min, the mixture was extracted with Et2O (2x15 mL). The combined organic 
extracts were washed with brine, dried over Na2SO4, and concentrated in vacuo. 
Purification by column chromatography on silica gel (30% EtOAc in hexanes) 
provided 2.44 g (8.23 mmol, 80%) of alcohol 53 as a colorless oil: 1H NMR (400 
MHz, CDCl3) ) 1.79 (m, 2H), 3.22 (brs, 1H), 3.39 (s, 1H), 3.66 (m, 2H), 3.80 (s, 3H), 
3.82 (m, 1H), 3.92 (dd, J = 7.0, 7.0 Hz, 1H), 4.46 (s, 2H), 4.60 (d, J = 6.7 Hz, 1H), 
4.73 (d, J = 6.7 Hz, 1H), 5.31 (d, J = 16.9 Hz, 1H), 5.31 (d, J = 11.0 Hz, 1H), 5.72 
(ddd, J = 7.7, 11.4, 16.3 Hz, 1H), 6.87 (q, J = 2.9 Hz, 2H), 7.26 (t, J = 5.9 Hz, 1H); 
13C NMR (100 MHz, CDCl3) )  159.2, 134.4, 130.1, 129.4, 120.1, 113.8, 94.0, 81.0, 
72.8, 71.8, 67.5, 55.7, 55.3, 32.4; IR (neat, NaCl): 2955 (br), 2953 (br), 1613, 1515, 
1460, 1249, 1170 cm-1;    [%]D 
21  = +50.6   (c = 1.50, CHCl3), (90% ee)
13; HRMS 
(ESI+): m/z calc’d for C16H24NaO5













(183). Alcohol 53 (500 mg, 1.69 mmol) was azeotroped in vacuo with benzene (2x5 
mL), dissolved in anhydrous THF (5.0 mL) and cooled to 0 °C. NaHMDS (1.0 M, 
3.20 mL, 3.20 mmol) was added dropwise. After stirring at 0 °C for 30 min, salicylate 
177 (413 mg, 1.60 mmol) dissolved in distilled THF (5.0 mL) was added dropwise. 
The reaction was warmed to rt and stirred for 2 h, and then TBSCl (482 mg, 3.20 
mmol) and imidazole (218 mg, 3.20 mmol) were added to the reaction mixture as 
solids. The reaction was stirred overnight and diluted with hexanes (30 mL). The 
mixture was filtered through a thin silica gel plug, which was rinsed with 20% Et2O 
in hexanes (2x35 mL). The combined organic layer was concentrated in vacuo and 
azeotroped with benzene (2x5 mL). The crude ester was used directly in the next step 
without further purification. 
 To a flask containing crude ester was added anhydrous and degassed toluene 
(1L). Ruthenium Grubbs 2nd generation catalyst (50.0 mg, 0.0589 mmol) in degassed 
toluene (1.0 mL) was added in one portion under a nitrogen atmosphere. The solution 
was heated to reflux and stirred for 20 h. The reaction mixture was allowed to cool to 
room temperature and DMSO (15 mL) was added into the reaction flask prior the 
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removal of toluene in vacuo to obtain a dark brown liquid. The crude product was 
loaded directly on to a silica column for combi-flash purification (0% to 20% EtOAc 
in hexanes) to afford 553.3 mg (0.9528 mmol, 60%) of macrocyclic diene as a light-
yellow oil: 1H NMR (400 MHz, CDCl3) ) 0.23 (s, 3H), 0.24 (s, 3H), 0.98 (s, 9H), 
2.18 (m, 4H), 2.36 (m, 2H), 3.35 (s, 3H), 3.64 (m, 2H), 3.81 (s, 3H), 4.39 (q, J = 2.6 
Hz, 1H), 4.43 (d, J = 11.4 Hz, 1H), 4.51 (d, J = 11.4 Hz, 1H), 4.57 (d, J = 6.8 Hz, 
1H), 4.67 (d, J = 6.8 Hz, 1H), 5.29 (td, J = 3.35, 6.7 Hz, 1H), 5.32 (dd, J = 5.5, 15.9 
Hz, 1H), 5.50 (ddd, J = 5.6, 6.3, 15.9 Hz, 1H), 5.77 (td, J = 6.2, 15.9 Hz, 1H), 6.22 (d, 
J = 15.9 Hz, 1H), 6.68 (d, J = 8. Hz, 1H), 6.87 (q, J = 5.0 Hz, 3H), 7.13 (t, J = 7.8 Hz, 
1H), 7.29 (q, J = 2.9 Hz, 2H); 13C NMR (100 MHz, CDCl3) )  168.2, 159.1, 152.1, 
137.6, 132.2, 131.5, 130.9, 130.6, 129.9, 129.6, 129.3, 125.7, 118.7, 117.1, 113.8, 
94.9, 76.3, 75.3, 72.4, 66.6, 56.1, 55.3, 30.6, 30.6, 30.0, 25.8, 18.3, -4.0, -4.2; IR 
(neat, NaCl): 2910, 2857, 1730, 1613, 1600, 1565, 1505, 1463, 1250, 1160, 1033 cm -
1; [%]D 
21  = +76.3  (c = 1.53, CHCl3); HRMS (ESI
+): m/z calc’d for C33H46NaO7Si
+, 













(184). Alcohol 139 (1.19 g, 3.83 mmol) was azeotroped in vacuo with benzene (2x10 
mL), dissolved in anhydrous THF (15.0 mL) and cooled to 0 °C. NaHMDS (1.0 M, 
7.26 mL, 7.26 mmol) was added dropwise. After stirring at 0 °C for 30 min, salicylate 
177 (0.93 g, 3.63 mmol) dissolved in distilled THF (15.0 mL) was added dropwise. 
The reaction was warmed to rt and stirred for 2 h, and then TBSCl (1.09 g, 7.26 
mmol) and imidazole (0.50 g, 7.26 mmol) were added to the reaction mixture as solids. 
The reaction was stirred overnight and filtered through a thin silica gel plug, which 
was rinsed with 20% Et2O in hexanes (2x50 mL). The combined organic layer was 
concentrated in vacuo and azeotroped with benzene (2x10 mL). The crude ester was 
used directly in the next step without further purification. 
 To a flask containing crude ester was added anhydrous and degassed toluene 
(2L). Ruthenium Grubbs 2nd generation catalyst (98.0 mg, 0.116 mmol) in degassed 
toluene (3.0 mL) was added in one portion under a nitrogen atmosphere. The solution 
was heated to reflux and stirred for 4 h. The reaction mixture was allowed to cool to 
room temperature and DMSO (20 mL) was added into the reaction flask prior the 
 
148 
removal of toluene in vacuo to obtain a dark brown liquid. The crude product was 
loaded directly on to silica column for combi-flash purification (0% to 10% EtOAc in 
hexanes) to afford 1.321 g ( 2.212 mmol, 61%) of macrocyclic diene 184 as a light-
yellow oil: 1H NMR (400 MHz, CDCl3) ) 0.21 (s, 3H), 0.22 (s, 3H), 0.95 (s, 9H), 
1.81 (m, 3H), 2.00 (m, 1H), 2.29 (m, 4H), 3.37 (s, 3H), 3.49 (m, 2H), 3.79 (s, 3H), 
4.40 (m, 1H), 4.43 (s, 2H), 4.57 (d, J = 6.8 Hz, 1H), 4.68 (d, J = 6.8 Hz, 1H), 5.17 (m, 
1H), 5.32 (dd, J = 4.8, 15.7 Hz, 1H), 5.47 (td, J = 6.0, 15.7 Hz, 1H), 5.76 (td, J = 5.9, 
15.9 Hz, 1H), 6.24 (d, J = 15.9 Hz, 1H), 6.67 (d, J = 8.2 Hz, 1H), 6.85 (t, J = 7.3 Hz, 
3H), 7.11 (t, J = 8.0 Hz, 1H), 7.25 (t, J = 4.8 Hz, 2H); 13C NMR (100 MHz, CDCl3) 
)  168.2, 159.1, 152.1, 137.5,132.3, 131.6, 130.7, 129.5, 129.4, 129.2, 125.8, 118.9, 
117.1, 113.7, 94.9, 77.1, 75.9, 72.5, 69.9, 60.4, 56.1, 55.2, 30.6, 30.1, 27.4, 25.9, 25.8, 
18.3, -4.1, -4.3; IR (neat, NaCl): 2915, 2865, 1735, 1620, 1600, 1565, 1525, 1460, 
1245, 11450, 1083 cm -1; [%]D 
21  = +97.7  (c = 1.33, CHCl3); HRMS (ESI
+): m/z 
calc’d for C34H48NaO7Si















one (185). To a solution of macrocyclic diene 184 (200.0 mg, 0.3356 mmol) 
dissolved in i-PrOH (5.7 mL) was added CBr4 (398 mg, 1.20 mmol). The resulting 
solution was heated to 75 °C for 4 h at which time the reaction mixture was cooled to 
rt and concentrated in vacuo. Purification by column chromatography on silica gel 
(15 % EtOAc in hexanes) provided 99.6 mg (0.180 mmol, 54%) of secondary alcohol 
185 as a yellowish oil: 1H NMR (400 MHz, CDCl3) & 0.18 (s, 3H), 0.22 (s, 3H), 0.95 
(s, 9H), 1.86 (m, 2H), 1.97 (m, 2H), 2.23 (m, 2H), 2.34 (m, 2H), 3.50 (m, 2H), 3.80 
(s, 3H), 4.30 (d, J = 5.1 Hz, 1H), 4.42 (s, 2H), 5.2 (t, J = 5.0 Hz, 1H), 5.50 (m, 2H), 
5.76 (dd, J = 10.3, 17.2 Hz, 1H), 6.30 (d, J  = 16.0 Hz, 1H), 6.87 (d, J  = 4.6 Hz, 1H), 
7.12 (m, 3H), 7.25 (t, J = 4.6 Hz, 1H), 7.26 (m, 2H); 13C NMR (100 MHz, CDCl3) )  
168.0, 159.0, 152.2, 137.2, 133.1, 132.7, 130.4, 130.0, 129.7, 129.4, 129.1, 125.5, 
118.9, 117.2, 113.7, 77.5, 77.1, 76.8, 72.6, 71.9, 69.7, 55.3, 30.6, 29.9, 27.7, 25.9, 
25.8, 18.4, -4.0, -4.2; ; IR (neat, NaCl): 3430 (br), 2935, 1733, 1460, 1350, 1250 cm-1; 
HRMS (ESI+): m/z calc’d for C32H44NaO6Si









3,4,7,8-tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one (186). To a solution of 
macrocyclic diene 184 (200.0 mg, 0.3356 mmol) dissolved in i-PrOH (5.7 mL) was 
added CBr4 (398 mg, 1.20 mmol). The resulting solution was heated to 75 °C for 4 h 
at which time the reaction mixture was cooled to rt and concentrated in vacuo. 
Purification by column chromatography on silica gel (15 % EtOAc in hexanes) 
provided 64.9 mg (0.150 mmol, 45%) of diol 186 as a white solid: MP = 107-108 °C;  
1H NMR (400 MHz, CDCl3) & 0.19 (s, 3H), 0.20 (s, 3H), 0.94 (s, 9H), 1.43 (m, 1H), 
1.46 (m, 1H), 1.80 (m, 2H), 2.22 (m, 2H), 2.36 (m, 2H), 3.58 (m, 2H), 4.15 (d, J = 7.9 
Hz, 1H), 5.02 (t, J  = 6.7 Hz, 1H), 5.4 (s, 2H), 5.7 (dq, J  = 3.1, 16.0 Hz, 1H), 6.23 (d, 
J  = 16.1 Hz, 1H), 6.68 (d, J  = 8.2 Hz, 1H), 6.87 (d, J  = 7.7 Hz, 1H), 7.16 (t, J  = 8.0, 
1H); 13C NMR (100 MHz, CDCl3) )  168.0, 152.2, 136.9, 132.8, 132.4, 129.8, 129.7, 
128.9, 125.5, 118.4, 117.3, 77.2, 71.7, 62.2, 30.1, 29.7, 28.7, 25.7, 25.7, 18.4, -4.0, -
4.2; ; IR (neat, NaCl): 3450 (br), 3010, 2945, 2859, 1733, 1465, 1370, 1250, 1110 cm-
1; HRMS (ESI+): m/z calc’d for C24H36NaO5Si















(232). To a flask containing macrocyclic diene 183 (177.7 mg, 0.3049 mmol) was 
added DCM (10.0 mL) and H2O (1.0 mL). The mixture was cooled to 0 °C, and DDQ 
(74.9 mg, 0.330 mmol) was added in one portion. The cooling bath was removed and 
the reaction was stirred at rt for 1 h. The reaction mixture was diluted with sat. 
NaHCO3 20 mL, and then extracted with DCM (2x20 mL). The organic layer was 
washed with sat. NaHCO3 (10 mL) and brine (10 mL). The crude mixture was dried 
over Na2SO4, and concentrated in vacuo. Purification by column chromatography on 
silica gel (30% EtOAc in hexanes) provided 70.9 mg (0.153 mmol, 50%) of alcohol 
232 as a colorless oil: 1H NMR (400 MHz, CDCl3) ) 0.24 (s, 3H), 0.27 (s, 3H), 0.98 
(s, 9H), 2.09 (m, 2H), 2.18 (m, 2H), 2.39 (m, 2H), 3.39 (s, 3H), 3.78 (m, 2H), 4.39 (s, 
1H), 4.58 (d, J = 6.8 Hz, 1H), 4.69 (d, J = 6.8 Hz, 1H), 5.31 (d, J = 4.2 Hz, 1H), 5.34 
(dd, J = 5.04, 15.8 Hz, 1H), 5.54 (td, J = 5.9, 15.8 Hz, 1H), 5.80 (td, J = 5.9, 15.9 Hz, 
1H), 6.21 (d, J = 15.9 Hz, 1H), 6.70 (d, J = 8.2 Hz, 1H), 6.90 (d, J = 7.7 Hz, 1H), 7.14 
(t, J = 8.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) )  169.4, 152.1, 137.5, 132.2, 
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131.4, 130.8, 130.1, 129.9, 125.2, 118.6, 117.2, 94.8, 77.2, 75.5, 58.8, 56.1, 34.0, 
30.4, 29.8, 25.8, 18.5, -4.0, -4.1; IR (neat, NaCl): 3450 (br), 3005, 2930, 1731, 1460, 
1380 cm-1; [%]D 
21  =  +108  (c = 2.86, CHCl3); HRMS (ESI
+): m/z calc’d for 
C25H38NaO6Si









(233). To a flask containing macrocyclic diene 184 (404.6 mg, 0.6779 mmol) was 
added DCM (15.0 mL) and H2O (1.5 mL). The mixture was cooled to 0 °C, and DDQ 
(185.0 mg, 0.8149 mmol) was added in one portion. The cooling bath was removed 
and the reaction was stirred at rt for 1 h and 10 min. The reaction mixture was diluted 
with EtOAc 100 mL, and then washed with 10% NaHCO3 solution (2x15 mL). The 
organic layer was washed with brine, dried over Na2SO4, and concentrated in vacuo. 
Purification by column chromatography on silica gel (30% EtOAc in hexanes) 
provided 204.5 mg (0.4290 mmol, 63%) of alcohol 233 as a colorless oil: 1H NMR 
(400 MHz, CDCl3) ) 0.22 (s, 3H), 0.22 (s, 3H), 0.96 (s, 9H), 1.71 (m, 3H), 1.87 (m, 
2H), 2.00 (m, 1H), 2.22 (m, 2H), 2.34 (m, 2H), 3.39 (s, 3H), 3.69 (m, 2H), 4.42 (t, 
1H), 4.58 (d, J = 6.8 Hz, 1H), 4.69 (d, J = 6.8 Hz, 1H), 5.16 (td, J = 3.47, 9.9 Hz, 
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1H), 5.33 (dd, J = 5.0, 15.7 Hz, 1H), 5.50 (td, J = 6.2, 15.1 Hz, 1H), 5.77 (td, J = 6.2, 
15.9 Hz, 1H), 6.23 (d, J = 15.9 Hz, 1H), 6.67 (d, J = 8.1 Hz, 1H), 6.85 (d, J = 7.7 Hz, 
1H), 7.12 (t, J = 8.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) )  168.4, 152.1, 137.6, 
132.3, 131.8, 130.8, 129.7, 129.3, 125.6, 118.9, 117.1, 94.9, 77.2, 76.0, 62.7, 56.1, 
30.6, 30.1, 28.7, 26.7, 25.7, 18.3, -4.1, -4.3; IR (neat, NaCl): 3455 (br), 3015, 2935, 
1733, 1466, 1380, 1115 cm-1 [%]D 
22  = +112   (c = 1.51, CHCl3); HRMS (ESI
+): m/z 
calc’d for C26H40NaO6Si













(234). To a flask containing alcohol 232 (50.0 mg, 0.108 mmol) was added DCM (0.5 
mL), Et3N (75.0 µL, 0.540 mmol) and DMSO (0.5 mL). The mixture was cooled to 0 
°C, and SO3•Py (52.0 mg, 0.324 mmol) was added in one portion. The mixture was 
stirred at 0 °C for 20 min, diluted with Et2O (4 mL) and phosphate buffer pH 7 (2 
mL). The organic layer was separated, and then the aqueous layer was extracted with 
Et2O (3x4 mL). The combined organic layer was washed with sat. NH4Cl (4 mL), and 
then with sat. CuSO4 (2x4 mL). The organic layer was concentrated in vacuo to 
afford an opaque oil of the corresponding aldehyde. The crude aldehyde was used 
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directly in the next step without further purification.  
 To a solution of diethyl [(phenylsulfonyl)methyl]phosphonate (31.4 mg, 0.108 
mmol) in anhydrous THF (1.0 mL) was added 60% NaH (5.0 mg, 0.12 mmol). The 
mixture was cooled to 0 °C, and was stirred for 5 min. The aldehyde in THF (1.0 mL) 
was added dropwise over 3 min. The mixture was stirred at 0 °C for 40 min, and then 
diluted with 10 % HCl (0.25 mL) and buffer pH 7 (2.0 mL). The crude mixture was 
extracted with EtOAc (2.0 mL).  The organic layer was separated, and washed with 
sat. NaHCO3 (1.0 mL). The organic layer was washed with brine (1.0 mL), dried over 
MgSO4, and concentrated in vacuo. Purification by column chromatography on silica 
gel (20% EtOAc in hexanes) provided 31.0 mg (0.0518 mmol, 48%) of phenylsulfone 
234 as an opaque oil: 1H NMR (400 MHz, CDCl3) ) 0.21 (s, 3H), 0.22 (s, 3H), 0.94 
(s, 9H), 2.10 (m, 2H), 2.37 (m, 2H), 2.72 (m, 1H), 2.94 (m, 1H), 3.30 (s, 3H), 4.35 (q, 
J = 3.0 Hz, 1H), 4.49 (d, J = 6.7 Hz, 1H), 4.63 (d, J = 6.7 Hz, 1H), 5.08 (m, J = 2.9 
Hz, 1H), 5.25 (dd, J = 6.1, 15.8 Hz, 2H), 5.52 (td, J = 6.2, 15.4 Hz, 1H), 5.75 (td, J = 
6.2, 15.7 Hz, 1H), 6.12 (d, J = 15.9 Hz, 1H), 6.47 (td, J = 1.31, 15.2 Hz, 1H), 6.68 (t, 
J = 4.0 Hz, 1H), 6.87 (d, J = 7.7 Hz, 2H), 7.05 (td, J = 7.4, 14.9 Hz, 1H), 7.15 (t, J = 
8.0 Hz, 1H), 7.56 (m, 3H), 7.88 (m, 2H); 13C NMR (100 MHz, CDCl3) )  168.1, 
152.0, 141.5, 140.4, 137.7, 133.4, 133.2, 132.4, 132.2, 131.0, 130.1, 129.6, 129.3, 
127.7, 125.1, 118.8, 117.0, 94.6, 75.9, 75.5, 56.2, 32.3, 30.8, 30.1, 25.7, 18.2, -4.0, -
4.5; IR (neat, NaCl): 2935, 1731, 1570, 1460, 1292, 1270, 1148, 1101 cm-1;  [%]D 
21  =  
+100.3 (c = 1.20, CHCl3); HRMS (ESI















1-one (235). To a flask containing alcohol 233 (70.3 mg, 0.147 mmol) was added 
DCM (1.0 mL), Et3N (0.15 mL, 1.07 mmol) and DMSO (1.0 mL). The mixture was 
cooled to 0 °C, and SO3•Py (73.0 mg, 0.459 mmol) was added in three portions over 
3 min. The mixture was stirred at 0 °C for 30 min, and then diluted with Et2O (2.5 
mL) and phosphate buffer pH 7 (2.5 mL). The organic layer was separated, and then 
the aqueous layer was extracted with Et2O (5x1 mL). The combined organic layer 
was washed with sat. NH4Cl (5 mL), and then washed with water (2x5 mL) and sat. 
CuSO4 (2x5 mL). The organic layer was dried over MgSO4 and concentrated in vacuo 
to afford an opaque oil of the corresponding aldehyde. The crude aldehyde was used 
directly in the next step without further purification.  
 To a solution of diethyl [(phenylsulfonyl)methyl]phosphonate (43.7 mg, 0.179 
mmol) in anhydrous THF (2.0 mL) was added 60% NaH (6.8 mg, 0.17 mmol). The 
mixture was cooled to 0 °C, and stirred for 10 min. The aldehyde in THF (1.0 mL) 
was added dropwise over 3 min. The mixture was stirred at 0 °C for 40 min, and then 
diluted with 10 % HCl (0.5 mL) and phosphate buffer pH 7 (4.0 mL). The crude 
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mixture was extracted with Et2O (3x15 mL).  The combined organic layer was 
washed with 10% NaHCO3 (20.0 mL) and brine (10.0 mL), dried over MgSO4, and 
concentrated in vacuo. Purification by column chromatography on silica gel (30% 
EtOAc in hexanes) provided 60.1 mg (0.0959 mmol, 65%) of phenylsulfone 235 as 
an opaque oil: 1H NMR (400 MHz, CDCl3) ) 0.18 (s, 3H), 0.19 (s, 3H), 0.89 (s, 9H), 
1.98 (m, 2H), 2.19 (m, 2H), 2.38 (m, 4H), 3.34 (s, 3H), 4.37 (t, 1H), 4.55 (d, J = 6.8 
Hz, 1H), 4.67 (d, J = 6.8 Hz, 1H), 5.09 (td, J = 3.4, 10.0 Hz, 1H), 5.27 (dd, J = 5.4, 
15.6 Hz, 1H), 5.48 (td, J = 6.3, 15.2 Hz, 2H), 5.75 (td, J = 6.1, 15.9 Hz, 2H), 6.19 (d, 
J = 15.9 Hz, 1H), 6.36 (td, J = 1.5, 15.0 Hz, 1H), 6.67 (d, J = 7.7 Hz, 1H), 6.85 (d, J = 
7.7 Hz, 1H), 7.02 (td, J = 6.4, 15.1 Hz, 1H), 7.13 (t, J = 8.0 Hz, 1H), 7.56 (m, J = 4.5 
Hz, 3H), 7.88 (m, J = 2.1 Hz, 2H); 13C NMR (100 MHz, CDCl3) )  168.2, 152.0, 
145.8, 140.6, 137.6, 133.3, 132.5, 132.4, 130.9, 130.8, 129.8, 129.3, 128.8, 127.6, 
125.3, 119.0, 117.2, 94.8, 76.2, 76.0, 56.2, 30.5, 30.1, 28.2, 27.7, 25.7, 18.3, -4.1, -
4.3; IR (neat, NaCl): 2933, 1735, 1550, 1480, 1282, 1255, 1138, 1111 cm-1; [%]D 
22  = 
+90.3 (c = 2.43, CHCl3); HRMS (ESI



















1H-benzo[c][1]oxacyclododecin-1-one (223). To a flask containing phenylsulfone 
234 (19.0 mg, 0.0318 mmol) was added 4M HCl in MeOH (1.0 mL). The mixture 
was stirred at rt for 120 h, and then concentrated in vacuo. Purification by column 
chromatography on silica gel (50% EtOAc in hexanes) provided 11.5 mg (0.0262 
mmol, 82%) of the desired analogue 223 as a colorless oil: 1H NMR (400 MHz, 
CDCl3) ) 2.20 (m, 2H), 2.41 (m, 2H), 2.72 (m, 1H), 2.95 (m, 1H), 4.38 (brs, 1H), 
5.27 (m, J = 2.4 Hz, 1H), 5.45 (dd, J = 5.8, 15.9 Hz, 1H), 5.62 (qd, J = 4.49, 15.8 Hz, 
2H), 6.44 (q, J = 5.4 Hz, 1H), 6.52 (d, J = 15.8 Hz, 1H), 6.74 (d, J = 7.4 Hz, 1H), 6.85 
(q, J = 3.1 Hz, 1H), 7.05 (ddd, J = 7.1, 8.0, 15.1 Hz, 1H), 7.30 (t, J = 7.9 Hz, 1H), 
7.46 (m, 3H), 7.81 (q, J = 2.8 Hz, 2H), 10.41 (s, 1H); 13C NMR (100 MHz, CDCl3) 
)  170.5, 161.5, 142.1, 141.7, 140.0, 135.0, 134.8, 134.3, 133.3, 133.1, 129.7, 129.2, 
128.8, 127.5, 120.0, 116.3, 111.4, 75.0, 72.5, 32.4, 31.7, 29.8; IR (neat, NaCl): 
3415(br), 3050, 2920, 2865, 1737, 1630, 1464, 1406, 1044 cm-1;  [%]D 
21  =  -35 (c = 
0.58, CHCl3); HRMS (ESI
+): m/z calc’d for C24H24NaO6S
















tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one (234). To a flask containing 
phenylsulfone 235 (48.7 mg, 0.0777 mmol) was added 4M HCl in MeOH (5.0 mL). 
The mixture was stirred at rt for 99 h, and then concentrated in vacuo. Purification by 
column chromatography on silica gel (50% EtOAc in hexanes) provided 31.0 mg 
(0.0662 mmol, 85%) of the desired analogue 234 as a colorless oil: 1H NMR (400 
MHz, CDCl3) & 1.78 (brs, 1H), 1.91 (m, 1H), 2.20 (m, 3H), 2.40 (m, 4H), 4.33 (t, J = 
4.8  Hz, 1H), 5.18 (m, J = 4.19 Hz, 1H), 5.47 (dd, J = 6.10, 15.6 Hz, 1H), 5.61 (m, 
2H), 6.41 (d, J = 15.2 Hz, 1H), 6.61 (d, J = 15.7 Hz, 1H), 6.78 (d, J = 7.5 Hz, 4H), 
6.86 (d, J = 8.3 Hz, 1H), 7.02 (td, J = 6.7, 14.7 Hz, 1H), 7.31 (t, J = 7.9 Hz, 1H), 7.57 
(m, 3H), 7.88 (d, J = 7.9 Hz, 2H), 10.47 (s, 1H); 13C NMR (100 MHz, CDCl3) )  
169.7, 160.4, 144.5, 140.7, 139.4, 134.2, 133.8, 133.3, 132.3, 130.2, 128.7, 128.3, 
128.0, 126.6, 119.0, 115.2, 110.6, 75.1, 71.6, 31.5, 28.7, 26.9, 26.2; IR (neat, NaCl): 
3415(br), 3055, 2910, 2855, 1735, 1632, 1484, 1426, 1134 cm-1; [%]D 
21  = -14 (c = 
0.98, CHCl3); HRMS (ESI
+): m/z calc’d for C25H26NaO6S











dihydro-1H-benzo[c][1]oxacyclododecin-1-one (236). To a flask containing 
macrocyclic triene 110 (47.4 mg, 0.0792 mmol) was added anhydrous THF (1.0 mL), 
and TBAF 1 M in THF (87.0 µL, 0.0870 mmol) was added dropwise over 5 min at rt. 
The mixture was stirred at rt for 1.5 h, and then concentrated in vacuo. Purification by 
column chromatography on silica gel (40% EtOAc in hexanes) provided 26.6 mg 
(0.0694 mmol, 88%) of alcohol 235 as a colorless oil: 1H NMR (400 MHz, CDCl3) 
) 2.18 (m, 2H), 3.37 (s, 3H), 3.84 (s, 3H), 3.90 (s, 2H), 4.53 (d, J = 6.4 Hz, 1H), 4.58 
(d, J = 6.4 Hz, 1H), 4.66 (dd, J = 3.4, 10.8 Hz, 1H), 5.55 (ddd, J = 3.2, 3.2, 10.7 Hz, 
1H), 5.71 (dd, J = 11.3, 11.3 Hz, 1H), 5.90 (dd, J = 3.9, 11.0 Hz, 1H), 6.21 (dd, J = 
3.8, 11.9 Hz, 1H), 6.36 (dd, J = 11.3, 11.3 Hz, 1H), 6.68 (d, J = 15.9 Hz, 1H), 6.82 (t, 
J = 8.3 Hz, 1H), 6.99 (d, J = 15.9 Hz, 1H), 7.01 (d, J = 15.9 Hz, 1H), 7.27 (d, J = 5.0 
Hz, 1H); 13C NMR (100 MHz, CDCl3) &  168.2, 155.7, 138.5, 133.3, 132.6, 130.7, 
129.9, 129.5, 127.8, 126.9, 123.3, 120.8, 109.4, 93.3, 77.3, 68.4, 61.2, 55.8, 55.5, 
30.7; IR (neat, NaCl): 3432 (br), 3010, 2943,1729, 1599, 1571, 1468, 1438, 1154, 
1089, 1058 cm-1; [%]D 
21 = -207  (c= 1.33, CHCl3); HRMS (ESI
+): m/z calc’d for 
C20H24NaO6










To a flask containing alcohol 236 (25.0 mg, 0.0694 mmol) was added anhydrous 
DCM (1.2 mL) and molecular sieve 4 Å (70 mg). The mixture was cooled to 0 °C, 
and PDC (104.0 mg, 0.2764 mmol) was added in one portion. The cooling bath was 
removed and the reaction was stirred at rt for 1.5 h The reaction mixture was diluted 
with hexanes 3 mL, then filtered through a silica gel plug and rinsed with 40% EtOAc 
in hexanes (20 mL). The combined organic layer was concentrated in vacuo to afford 
an opaque oil of the corresponding aldehyde. The crude aldehyde was used directly in 
the next step without further purification.  
 To a solution of diethyl [(phenylsulfonyl)methyl]phosphonate (22.0 mg, 0.0759 
mmol) in anhydrous THF (1.0 mL) was added 60% NaH (3.4 mg, 0.086 mmol). The 
mixture was cooled to 0 °C, and was stirred for 5 min. The aldehyde in THF (1.0 mL) 
was added dropwise over 3 min. The mixture was stirred at 0 °C for 30 min, and then 
diluted with sat. NH4Cl (3.0 mL) and phosphate buffer pH 7 (4.0 mL). The crude 
mixture was extracted with EtOAc (3x4 mL).  The combined organic layer was 
washed with brine (5 mL), dried over Na2SO4, and concentrated in vacuo. 
 
161 
Purification by column chromatography on silica gel (30% EtOAc in hexanes) 
provided 17.8 mg (0.0358 mmol, 47%) of phenylsulfone 237 as an opaque oil: 1H 
NMR (400 MHz, CDCl3) )  2.83 (m, J = 3.0 Hz, 2H), 3.33 (s, 3H), 3.95 (s, 3H), 4.49 
(d, J = 6.52 Hz, 1H), 4.54 (d, J = 6.5 Hz, 1H), 4.66 (dd, J = 3.36, 10.8 Hz, 1H), 5.44 
(ddd, J = 3.1, 3.1, 10.8 Hz, 1H), 5.59 (dd, J = 11.3, 11.3 Hz, 1H), 5.88 (dd, J = 3.7, 
11.4 Hz, 1H), 6.2 (dd, J = 3.8, 11.8 Hz, 1H), 6.37 (dd, J = 11.3, 11.3 Hz, 1H), 6.52 (d, 
J = 15.2 Hz, 1H), 6.69 (d, J = 16.0 Hz, 1H), 6.83 (dd, J = 8.0, 13.8 Hz, 1H), 6.99 (dd, 
J = 11.7, 15.7 Hz, 1H), 7.16 (d, J = 5.5 Hz, 1H), 7.18 (d, J = 5.6 Hz, 1H), 7.21 (dd, J 
= 5.5, 7.8 Hz, 1H), 7.29 (t, J = 8.0 Hz, 1H), 7.57 (m, J = 7.5 Hz, 3H), 7.90 (t, J = 4.3 
Hz, 2H); 13C NMR (100 MHz, CDCl3) & 168.3, 156.4, 143.0, 140.6, 138.1, 133.3, 
133.3, 132.8, 132.3, 131.1, 130.0, 129.9, 129.3, 127.6, 127.3, 126.0, 123.0, 120.4, 
109.5, 93.3, 75.5, 68.3, 56.0, 55.6, 30.0;  IR (neat, NaCl): 3012, 2945, 2842, 1732, 
1635, 1572, 1469,  1318, 1305, 1105, 1087, 1059, 953, cm-1; [%]D 
20 = -178 (c= 0.89, 
CHCl3); HRMS (ESI
+): m/z calc’d for C27H28NaO7S














dihydro-1H-benzo[c][1]oxacyclododecin-1-one (238). To a flask containing phenyl 
sulfone 237 (17.0 mg, 0.0359 mmol) was added i-PrOH (0.37 mL), and CBr4 (48.0 
mg, 0.144 mmol) in one portion. The mixture was heated at 75 °C for 2 h, and then 
concentrated in vacuo. Purification by column chromatography on silica gel (40% 
EtOAc in hexanes) provided 12.6 mg (0.0278 mmol, 78%) of alcohol 238 as a bright 
yellow oil: 1H NMR (400 MHz, CDCl3) )  2.78 (m, J = 3.50 Hz, 1H), 2.93 (q, J = 
7.84 Hz, 1H), 3.95 (s, 3H), 4.77 (dd, J = 3.2, 10.5 Hz, 1H), 5.40 (td, J = 2.6, 11.5 Hz, 
2H), 5.76 (t, J = 11.22 Hz, 1H), 5.87 (dd, J = 3.8, 11.0 Hz, 1H), 6.10 (dd, J = 3.8, 
11.9 Hz, 1H), 6.34 (t, J = 11.2 Hz, 1H), 6.52 (d, J = 15.2 Hz, 1H), 6.69 (d, J = 15.9 
Hz, 1H), 6.83 (dd, J = 8.0, 15.0 Hz, 3H), 6.98 (dd, J = 11.6, 15.9 Hz, 1H), 7.18 (ddd, 
J = 5.4, 8.1, 15.1 Hz, 2H), 7.29 (t, J = 8.0 Hz, 1H), 7.57 (q, J = 10.3 Hz, 3H), 7.89 (t, 
J = 4. Hz, 2H); 13C NMR (100 MHz, CDCl3) &  168.5, 156.3, 143.1, 140.6, 138.0, 
133.3, 132.8, 132.3, 131.6, 131.1, 130.1, 130.0, 129.3, 128.7, 127.6, 127.2, 122.9, 
120.4, 109.6, 76.3, 65.5, 56.0, 29.3; IR (neat, NaCl): 3470, 3014, 2927, 1731, 1634, 
1572, 1469, 1305, 1271, 1107, 1060, 961 cm-1; [%]D 
20 = -180  (c= 0.63, CHCl3); 
HRMS (ESI+): m/z calc’d for C25H24NaO6S










benzo[c][1]oxacyclododecin-1-one (225). To a flask containing alcohol 238 (10.0 
mg, 0.0221 mmol) was added anhydrous DCM (2.2 mL). The mixture was cooled to -
78 °C, and BCl3 1M in DCM (0.22 mL, 0.22 mmol) was added dropwise over 1 min. 
The mixture was stirred at -78 °C for 10 min, and warmed to rt and stirred for 15 min. 
The reaction mixture was quenched with water (2 mL) and extracted with EtOAc 
(3x5 mL). The combined organic layer was washed with brine and dried over MgSO4. 
The crude mixture was concentrated in vacuo. Purification by column 
chromatography on silica gel (50% EtOAc in hexanes) provided 7.2 mg (0.016 mmol, 
75%) of the desired analogue 225 as a bright yellow oil: 1H NMR (400 MHz, 
MeOD) )  2.70 (m, 1H), 2.82 (q, 1H), 4.53 (dd, J = 3.32, 10.52 Hz, 1H), 5.18 (td, J = 
2.75, 10.86 Hz, 1H), 5.69 (dd, J = 11.22, 11.22 Hz, 1H), 5.81 (dd, J = 3.94, 11.10 Hz, 
1H), 5.98 (dd, J = 3.84, 11.92 Hz, 1H), 6.25 (dd, J = 11.24, 11.24 Hz, 1H), 6.56 (d, J 
= 15.97 Hz, 1H), 6.65 (m, 3H), 6.90 (dd, J = 11.44, 15.93 Hz, 1H), 7.08 (ddd, J = 
7.17, 7.17, 15.15 Hz, 2H), 7.51 (m, 3H), 7.82 (m, 2H); 13C NMR (100 MHz, MeOD) 
&  170.8, 155.6, 145.2, 142.1, 139.4, 134.5, 133.9, 133.8, 131.6, 131.6, 131.1, 
130.9, 130.5, 130.5, 130.4, 128.7, 123.1, 120.2, 115.1, 78.6, 66.3, 30.3; IR (neat, 
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NaCl): 3408(br), 3052, 3014, 2927, 2854, 1727, 1635, 1464, 1219, 1144, 1085, 1057 
cm-1; [%]D 
20 = -133  (c= 0.36, CHCl3); HRMS (ESI
+): m/z calc’d for C24H22NaO6S
+, 







(methoxymethoxy)-3,4-dihydro-1H-benzo[c][1]oxacyclododecin-1-one (239). To a 
flask containing macrocyclic triene 144 (15.9 mg, 0.0274 mmol) was added DCM 
(1.0 mL) and H2O (0.1 mL). The mixture was cooled to 0 °C, and DDQ (7.5 mg, 
0.033 mmol) was added in one portion. The cooling bath was removed and the 
reaction was stirred at rt for 1 h. The reaction mixture was diluted with EtOAc (10 
mL), and then washed with 10% NaHCO3 solution (2x5 mL). The organic layer was 
washed with brine, dried over Na2SO4, and concentrated in vacuo. Purification by 
column chromatography on silica gel (30% EtOAc in hexanes) provided 12.7 mg 
(0.0267 mmol, 98%) of alcohol 239 as a colorless oil: 1H NMR (400 MHz, CDCl3) 
) 0.20 (s, 3H), 0.21 (s, 3H), 0.97 (s, 9H), 1.66 (m, 2H), 1.91 (m, 2H), 3.36 (s, 3H), 
3.72 (m, 2H), 4.53 (d, J = 6.44 Hz, 1H), 4.56 (d, J = 6.5 Hz, 1H), 4.61 (dd, J = 2.9, 
10.7 Hz, 1H), 5.34 (td, J = 2.8, 10.3 Hz, 1H), 5.68 (dd, J = 11.3, 11.3 Hz, 1H), 5.87 
(dd, J = 3.6, 11.1 Hz, 1H), 6.19 (dd, J = 4.1, 12.0 Hz, 1H), 6.35 (dd, J = 11.2, 11.2 
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Hz, 1H), 6.64 (d, J = 16.0 Hz, 1H), 6.75 (d, J = 8.2 Hz, 1H), 6.79 (d, J = 7.6 Hz, 1H), 
7.01 (qd, J = 3.9, 16.0 Hz, 1H), 7.16 (t, J = 8.0 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) ) 168.3, 152.3, 137.9, 132.2, 132.1, 131.1, 129.9, 129.2, 128.5, 127.2, 127.0, 
121.3, 117.9, 93.2, 78.1, 69., 62.7, 55.5, 29.9, 25.8, 25.0, 18.4; IR (neat, NaCl): 
3438.92(br), 2931, 2859, 1731, 1570, 1255, 1153, 1102, 1030 cm-1; [%]D 
22 = -88  (c= 
0.63, CHCl3); HRMS (ESI
+): m/z calc’d for  C26H38NaO6Si










(240). To a flask containing alcohol 239 (10.0 mg, 0.0210 mmol) was added 
anhydrous DCM (0.4 mL) and molecular sieve 4 Å (21 mg). The mixture was cooled 
to 0 °C, and PDC (32.0 mg, 0.0842 mmol) was added in one portion. The cooling 
bath was removed and the reaction was stirred at rt for 1.5 h. The reaction mixture 
was diluted with hexanes (1 mL), and then filtered through silica gel plug and rinsed 
with 40% EtOAc in hexanes (7 mL). The combined organic layer was concentrated in 
vacuo to afford an opaque oil of the corresponding aldehyde 6.0 mg. The crude 
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aldehyde was used directly in the next step without further purification.  
 To a solution of diethyl [(phenylsulfonyl)methyl]phosphonate (6.7 mg, 0.023 
mmol) in anhydrous THF (0.3 mL) was added 60% NaH (1.0 mg, 0.026 mmol). The 
mixture was cooled to 0 °C, and was stirred for 5 min. The aldehyde in THF (1.0 mL) 
was added dropwise over 3 min. The mixture was stirred at 0 °C for 30 min, and then 
diluted with sat. NH4Cl (4.0 mL) and phosphate buffer pH 7 (4.0 mL). The crude 
mixture was extracted with EtOAc (3x4 mL).  The combined organic layer was 
washed with brine (5.0 mL), dried over Na2SO4, and concentrated in vacuo. 
Purification by column chromatography on silica gel (30% EtOAc in hexanes) 
provided 6.0 mg (0.0098 mmol, 47%) of phenylsulfone 240 as an opaque oil: 1H 
NMR (400 MHz, CDCl3) ) 0.17 (s, 3H), 0.19 (s, 3H), 0.93 (s, 9H), 1.97 (m, 1H), 
2.11 (m, 1H), 2.37 (m, 1H), 2.63 (m, 1H), 3.30 (s, 3H), 4.47 (d, J = 6.5 Hz, 1H), 4.51 
(d, J = 6.5 Hz, 1H), 4.59 (dd, J = 2.9, 10.7 Hz, 1H), 5.29 (td, J = 2.9, 10.4 Hz, 1H), 
5.60 (dd,  J = 11.3, 11.3 Hz, 1H), 5.87 (dd, J = 3.9, 11 Hz, 1H), 6.20 (dd, J = 4.0, 
11.84 Hz, 1H), 6.33 (d, J = 11.3 Hz, 1H), 6.39 (d, J = 15.1 Hz, 1H), 6.64 (d, J = 16.0 
Hz, 1H), 6.74 (d, J = 8.2 Hz, 2H), 6.79 (d, J = 7.6 Hz, 5H), 6.95 (dd, J = 11.5, 16.0 
Hz, 1H), 7.05 (td, J = 6.4, 15.1 Hz, 1H), 7.17 (t, J = 8.0 Hz, 1H), 7.56 (m, 3H), 7.88 
(d, J = 7.2 Hz, 2H); 13C NMR (100 MHz, CDCl3) ) 168.2, 152.2, 145.7, 140.6, 
137.9, 133.3, 132.6, 132.2, 131.1, 130.9, 129.9, 129.4, 129.2, 127.6, 127.1, 126.4, 
126.1, 121.3, 117.9, 93.1, 77.2, 68.7,55.5, 28.5, 26.4, 25.8, 18.4, -4.0, -4.1; IR (neat, 
NaCl): 2930, 1731, 1570, 1463, 1292, 1252, 1148, 1101, 1027 cm-1; [%]D 
20 = -66  (c= 
0.30, CHCl3); HRMS (ESI
+): m/z calc’d for C33H42NaO7SSi














dihydro-1H-benzo[c][1]oxacyclododecin-1-one (226). To a flask containing 
phenylsulfone 240 (6.0 mg, 0.0098 mmol) was added 4M HCl in MeOH (0.7 mL). 
The mixture was stirred at rt for 211 h, and then concentrated in vacuo. Purification 
by column chromatography on silica gel (60% EtOAc in hexanes) provided 3.0 mg 
(0.0066 mmol, 68%) of the desired analogue 226 as a colorless oil: 1H NMR (400 
MHz, MeOD) & 1.87 (m, 1H), 2.03 (m, 1H), 2.38 (m, 1H), 2.48 (m, 1H), 4.48 (dd, J = 
3.6, 10.5 Hz, 1H), 5.07 (td, J = 2.7, 11.8 Hz, 1H), 5.72 (dd, J = 11.3, 11.3 Hz, 1H), 
5.81 (dd, J = 4.0, 11.0 Hz, 1H), 5.96 (dd, J = 4.0, 12.0 Hz, 1H), 6.23 (dd, J = 11.4, 
11.4 Hz, 1H), 6.53 (d, J = 15.9 Hz, 1H), 6.61 (t, J = 7.1 Hz, 3H), 6.88 (dd, J = 11.5, 
15.8 Hz, 1H), 6.95 (ddd, J = 6.1, 8.5, 14.8 Hz, 1H), 7.05 (t, J = 7.9 Hz, 1H), 7.51 (m, 
J = 5.0 Hz, 3H), 7.77 (m, J = 2.2 Hz, 2H); 13C NMR (100 MHz, MeOD) )  170.8, 
155.3, 147.7, 142.1, 139.4, 134.5, 134.1, 132.9, 131.5, 131.2, 130.9, 130.8, 130.8, 
130.5, 128.9, 128.5, 123.4, 120.3, 115.0, 78.6, 66.4, 28.6, 26.3; IR (neat, NaCl): 
3440(br), 3060, 2950, 2854, 1730, 1640, 1457, 1115, 1070 cm-1; [%]D 
20 = -118 (c= 
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0.15, CHCl3);  HRMS (ESI














benzo[c][1]oxacyclo dodecin-1-one (244). To a flask containing alcohol 233 (70.3 
mg, 0.147 mmol) was added DCM (1.0 mL), Et3N (0.15 mL, 1.07 mmol) and DMSO 
(1.0 mL). The mixture was cooled to 0 °C, and SO3.Py (73.0 mg, 0.459 mmol) was 
added in three portions over 3 min. The mixture was stirred at 0 °C for 30 min, and 
then was diluted with Et2O (2.5 mL) and phosphate buffer pH 7 (2.5 mL). The 
organic layer was separated, and then the aqueous was extracted with Et2O (5x1 mL). 
The combined organic layer was washed with sat. NH4Cl (5 mL), and then washed 
with water (2x5 mL) and sat. CuSO4 (2x5 mL). The organic layer was dried over 
MgSO4 and concentrated in vacuo to afford an opaque oil of the desired aldehyde. 
The crude aldehyde was used directly in the next step without further purification.  
   In a different reaction flask, a solution of 2-phenyl-1,3,4-oxadiazole (43.8 mg, 
0.30 mmol) was cooled with a dry ice bath and treated with a n-BuLi (1.6 M in 
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hexanes, 188 µL, 0.30 mmol). The mixture was stirred at this ambient temperature for 
1 h before the addition of MgBr2 diethyl etherate (77.5 mg, 0.30 mmol) as solid in 
one portion. The mixture was stirred for an additional 1 h at this low temperature 
before the freshly prepared aldehyde was added as a solution in THF (1 mL). The 
mixture was stirred for an additional 1.5 h, and then quenched by the addition of 1M 
HCl (5 mL). The organic layer was transferred to a separatory funnel and diethyl 
ether was used to extract the desired crude material. The combined organic phase was 
washed with 10% NaHCO3, and brine and then dried over MgSO4. The TLC and 
crude NMR showed high conversion of the desired product. The combined organic 
layer was concentrated in vacuo, and was used in the next step without further 
purification. 
  The crude alcohol was dissolved in DCM and cooled to 0 °C. DMP was added 
in one portion and the mixture was allowed to stir for 1 hour at 0 °C. The reaction 
was quenched with phosphate buffer pH 7 (10 mL). The crude product was extracted 
with diethyl acetate, washed with brine, dried over MgSO4 and concentrated in vacuo. 
Purification by column chromatography on silica gel (20% EtOAc in hexanes) 
provided 27.6 mg (0.0446 mmol, 38% over three steps) of %-keto oxadiazole 244 as a 
colorless foam. 1H NMR (400 MHz, CDCl3) )  0.24 (s, 3H), 0.24 (s, 3H), 0.96 (s, 
9H), 2.17 (m, 2H), 2.37 (m, 4H), 3.39 (m, 2H), 3.39 (s, 3H), 4.52 (t, J = 4.54 Hz, 1H), 
4.58 (d, J = 6.76 Hz, 1H), 4.71 (d, J = 6.76 Hz, 1H), 5.23 (m, 1H), 5.35 (dd, J = 5.94, 
15.67 Hz, 1H), 5.55 (td, J = 6.25, 15.67 Hz, 1H), 5.76 (td, J = 6.46, 15.85 Hz, 1H), 
6.20 (d, J = 15.89 Hz, 1H), 6.68 (d, J = 8.20 Hz, 2H), 6.85 (d, J = 7.64 Hz, 1H), 7.12 
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(t, J = 7.96 Hz, 1H), 7.56 (m, 3H), 8.16 (m, 2H); 13C NMR (100 MHz, CDCl3) )  
186.5, 168.3, 166.3, 160.7, 152.0, 137.6, 132.8, 132.8, 132.3, 131.0, 129.8, 129.2, 
129.2, 127.8, 125.4, 122.8, 118.8, 117.1, 94.7, 76.4, 76.2, 56.2, 36.1, 30.6, 30.2, 25.7, 
24.3, 18.3, -4.1, -4.3;    [%]D 
21  =  +98.5 (c = 1.38, CHCl3); HRMS (ESI
+): m/z calc’d 
for C34H42N2NaO7Si












3,4,7,8-tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one (227). To a flask 
containing %-keto oxadiazole (20.0 mg, 0.0323 mmol) was added a solution of 4M 
HCl in MeOH (5 mL). The mixture was stirred at rt for 46 h, and then washed with 
diethyl ether and concentrated in vacuo to provide 9.97 mg (0.0216 mmol, 67%) of 
desired analogue 227 as an oily white solid. HRMS (ESI+): m/z calc’d for 
C26H24N2NaO6

















oxacyclododecin-3-yl)acetamido)-3-methylbutylboronic Acid (228). Alcohol 232 
(18.5 mg, 0.0400 mmol) was dissolved in a 1:1 mixture of MeCN/water (0.1 mL)  
and cooled to 0 °C, following the addition of BAIB (41 mg, 0.127 mmol) and 
TEMPO (1.98 mg, 0.0127 mmol). The mixture was allowed to warm to rt and stirred 
for 1 h, and then quenched by the addition of sat. Na2S2O3 (1 mL), extracted with 
EtOAc (3 x 5 mL). The combined organic layer was dried over Na2SO4, and 
concentrated in vacuo. The crude product was used in the next step without further 
purification. 
 To a flask containing amine179 249 (10 mg, 0.040 mmol) in anhydrous DCM 
(0.12 mL) at 0 °C, diisopropylethylamine was added dropwise. Following the 
addition of the crude acid  and TBTU (13.5mg, 0.0420 mmol) as solid, the mixture 
was stirred at 0 °C for 8 h before it was concentrated in vacuo. The crude was 
dissolved in EtOAc (2 mL) and washed with water (2 x1 mL), and brine (2 mL). The 
organic layer was dried over Na2SO4, and concentrated in vacuo. The crude was used 
in the next step by the addition of 4M HCl/MeOH (2 mL). 
 2-Methylpropaneboronic acid (13.4 mg, 0.131 mmol) and hexanes (0.5 mL) 
were added to the solution of the crude amide product. This mixture was stirred 
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vigorously for 90 h and the pentane layer was removed to provide 12.1 mg (0.0280 
mmol, 70% over three steps) of desired analogue 228 as a colorless oil. HRMS 




4.2.3 Biological Evaluation  
 
Cytotoxicity Assay.225   The human cancer cell lines leukemia (HL-60), breast 
(MCF-7), melanoma (SK-MEL-28 and SK-MEL-5) were grown in normal RPMI 
1640 culture medium containing 10% fetal bovine serum.  The cells, in exponential-
phase maintenance culture, were dissociated with 0.25% trypsin and harvested at 
125%g for 5 min.  Trypsin was removed and the cells were re-suspended in new 
culture medium.  The cell density was adjusted to 1 x 105 and dispensed in triplicate 
on 96-well plates in 50 'L volumes.  After incubation overnight at 37 °C under 5% 
CO2, 50 'L of culture medium containing various concentrations of the test 
compounds was added. Paclitaxel and colchicine were used as positive controls.  
After 48 h incubation, the relative cell viability in each well was determined by using 
the AlamarBlue Assay Kit. The IC50 of each compound was determined by fitting the 







4.2.4 Chapter 3 
 
2,3-Dihydroxyterephthalaldehyde (257).
219 To a solution of 256 (400 mg, 2 mmol) 
in anhydrous DCM (1 mL; at r.t.) was added dropwise a 1.0 M boron tribromide 
solution in anhydrous DCM (20 mL, 20 mmol). The reaction mixture was stirred for 1 
h, followed by quenching of the reaction by addition of 1 M of aq. HCl (20 mL). The 
mixture was extracted with DCM (100 mL x 3). The combined organic extracts were 
washed with brine (50 mL x 2) and dried over Na2SO4 and the solvent was removed 
under reduced pressure. The resulting viscous liquid was purified by flash column 
chromatography (1% MeOH, 1% AcOH and DCM) on silica gel to obtain compound 
257 (239 mg, 86%) as a yellowish powder. 1H NMR (400 MHz, CDCl3): & 7.30 (s, 
4H), 10.05 (s, 2H). 13C NMR (100.6 MHz, CDCl3): & 122.28, 123.17, 150.86, 196.39; 
GC-MS (EI+) calc’d for C8H6O4 m/z 166.1, found 166.1 (M)
+. 
 
General Procedure for the Synthesis of 258a-258h.
220 To a solution of 2 (10 mg, 
0.06 mmol) in anhydrous dimethylformamide (4 mL) were added the respective alkyl 
halides (25 equiv) [C2H5I, C3H7I, C3H5I, C4H9Cl, C5H11I, C6H13Cl, C8H17Cl, and 
C14H29Cl] and K2CO3 (67 mg, 0.48 mmol). The reaction mixture was stirred for 15 h 
at r.t. The reaction was quenched with water (5 mL), and the resulting solution was 
extracted with DCM, and the combined organic extracts were washed with brine and 
dried over Na2SO4. The resulting viscous liquids were purified by flash column 
chromatography (CH2Cl2/hexane=6:4) to obtain the terephthalaldehyde analogues 
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258a-258h (258a, R=C2H5; 258b, R=C3H7; 258c, R= allyl; 258d, R=C4H9; 258e, 








2,3-Diethoxyterephthalaldehyde (258a). viscous oil; yield 49%; 1H NMR (400 
MHz, CDCl3): & 1.46 (t, 6H), 4.26 (q, 4H), 7.65 (s, 2H), 10.48 (s, 2H). 
13C NMR 
(100.6 MHz, CDCl3): & 15.89, 71.52, 122.99, 135.04, 156.36, 190.04; MS (FAB) 
calc’d for C12H14O4 m/z 222.1, found 223.3 (MH)+. 
2,3-Di-n-propoxyterephthalaldehyde (258b). viscous oil; yield 37%; 1H NMR (500 
MHz, CDCl3): & 1.09 (t, 6H), 1.84 (m, 4H), 4.09 (t, 4H), 7.63 (s, 2H), 10.46 (s, 2H). 
13C NMR (125.8 MHz, CDCl3): & 10.46, 23.32, 77.21, 122.56, 134.52, 156.25, 
189.61; MS (FAB) calc’d for C14H18O4 m/z 250.1, found 250.1 (MH)+. 
2,3-Diallyloxyterephthalaldehyde (258c). viscous oil; yield 43%; 1H NMR (400 
MHz, CDCl3): & 4.74 (d, J = 6.1 Hz, 4H), 5.34 (dd, J = 1.0, 10.2 Hz, 2H), 5.41 (dd, J 
= 1.3, 17.1 Hz, 2H), 5.34 (ddt, J = 6.1, 10.2, 16.5 Hz, 2H), 7.67 (s, 2H), 10.69 (s, 2H). 
13C NMR (100.6 MHz, CDCl3): & 76.13, 120.40, 123.27, 132.63, 135.05, 155.74, 
189.92. 
2,3-Di-n-butoxyterephthalaldehyde (258d). viscous oil; yield 63%; 1H NMR (400 
MHz, CDCl3): & 1.01 (t, 6H), 1.55 (m, 4H), 1.83 (m, 4H), 4.20 (t, 4H), 7.64 (s, 2H), 
10.53 (s, 2H). 13C NMR (100.6 MHz, CDCl3): & 14.29, 19.60, 32.48, 75.89, 122.95, 
 
175 
134.92, 156.68, 190.03; GC-MS (EI+) calc’d for C16H22O4 m/z 278.3, found 278.3 
(M)+. 
2,3-Di-n-pentoxyterephthalaldehyde (258e). viscous oil; yield 58%; 1H NMR (400 
MHz, CDCl3): & 0.96 (t, 6H), 1.46 (m, 8H), 1.84 (m, 4H), 4.20 (t, 4H), 7.60 (s, 2H), 
10.48 (s, 2H). 13C NMR (100.6 MHz, CDCl3): & 14.41, 22.89, 28.50, 30.14, 76.20, 
122.95, 134.91, 156.70, 190.06; MS (FAB) calc’d for C18H26O4 m/z 306.2, found 
307.2 (MH)+. 
2,3-Di-n-hexoxyterephthalaldehyde (258f). viscous oil; yield 65%; 1H NMR (400 
MHz, CDCl3): & 0.94 (t, 6H), 1.37 (m, 12H), 1.84 (m, 4H), 4.20 (t, 4H), 7.71 (s, 2H), 
10.47 (s, 2H). 13C NMR (100.6 MHz, CDCl3):& 14.42, 22.99, 26.04, 30.42, 31.99, 
76.22, 122.94, 134.91, 156.70, 190.03; MS (ESI+) calc’d for C20H30O4 m/z 334.2, 
found 335.2 (MH)+. 
2,3-Di-n-octoxyterephthalaldehyde (258g). viscous oil; yield 57%; 1H NMR (400 
MHz, CDCl3): & 0.91 (t, 6H), 1.35 (m, 20H), 1.84 (m, 4H), 4.20 (t, 4H), 7.61 (s, 2H), 
10.47 (s, 2H). 13C NMR (100.6 MHz, CDCl3): & 14.49, 23.05, 26.38, 29.63, 29.79, 
30.46, 32.19, 76.23, 122.95, 134.92, 156.69, 190.03; MS (ESI+) calc’d for C24H38O4 
m/z 390.3, found 391.3 (MH)+. 
2,3-Di-n-tetradecyloxyterephthalaldehyde (258h). viscous oil; yield 56%; 1H NMR 
(400 MHz, CDCl3): & 0.91 (t, 6H), 1.28 (m, 44H), 1.84 (m, 4H), 4.19 (t, 4H), 7.64 (s, 
2H), 10.50 (s, 2H). 13C NMR (100.6 MHz, CDCl3): & 14.55, 23.11, 26.39, 29.79, 
29.85, 29.99, 30.02, 30.08, 30.10, 30.11, 30.12, 30.47, 32.34, 76.23, 122.94, 134.91, 




General Procedure for the Synthesis of 262a-262k.221 To a hot solution of 
aminoguanidine hydrochloride (13.7 mg, 0.12 mmol) in EtOH (1 mL) was added a 
solution of the respective terephthalaldehyde (259, 260, 261, and 258a-258h) (0.5 
equiv, in 0.5 mL EtOH) and conc. HCl (0.1 mL). The reaction mixture was heated up 
to 80 °C for 1 h, and then cooled to 0 °C. The resultant white solid HCl salts were 
filtered and washed with cold ether (2 mL) to give bis-guanylhydrazone analogues 















Terephthaldehyde-1,4-bis-guanylhydrazone Dihydro Dichloride (262a). yield 
66%; 1H NMR (500 MHz, DMSO-d6): & 8.10 (s, 4H), 8.21 (s, 2H).
 13C NMR (125.8 
MHz, DMSO-d6):& 128.20, 135.54, 146.55, 155.69; MS (ESI+) calc’d for C10H14N8 














2,3-Dihydroxyterephthaldehyde-1,4-bis-guanylhydrazone Dihydro Dichloride 




NMR (125.8 MHz, DMSO-d6): & 117.62, 122.40, 144.07, 145.86, 155.12; MS (ESI+) 















2,3-Dimethoxyterephthaldehyde-1,4-bis-guanylhydrazone Dihydro Dichloride 
(262c). yield 44%; 1H NMR (400 MHz, DMSO-d6): & 3.86 (s, 6H), 7.93 (s, 2H), 8.42 
(s, 2H). 13C NMR (125.8 MHz, DMSO-d6): & 61.71, 117.62, 121.30, 129.24, 141.44, 















2,3-Diethoxyterephthaldehyde-1,4-bis-guanylhydrazone Dihydro Dichloride 
(262d). yield 67%; 1H NMR (500 MHz, DMSO-d6): & 1.38 (t, 6H), 4.07 (q, 4H), 7.95 
(s, 2H), 8.44 (s, 2H). 13C NMR (125.8 MHz, DMSO-d6): & 15.28, 69.77, 121.05, 



















2,3-Dipropoxyterephthaldehyde-1,4-bis-guanylhydrazone Dihydro Dichloride 
(262e). yield 64%; 1H NMR (500 MHz, DMSO-d6): & 1.01 (t, 6H), 1.75 (m, 4H), 3.95 
(t, 4H), 7.95 (s, 2H), 8.41 (s, 2H). 13C NMR (125.8 MHz, DMSO-d6): & 10.42, 22.84, 
75.82, 121.21, 129.50, 141.67, 151.34, 155.19; MS (ESI+) calc’d for C16H26N8O2 m/z 
















2,3-Diallyloxyterephthaldehyde-1,4-bis-guanylhydrazone Dihydro Dichloride 
(262f). yield 70%; 1H NMR (500 MHz, DMSO-d6): & 4.56 (d, J = 6.0 Hz, 4H), 5.28 
(d, J = 10.4 2H), 5.40 (dd, J = 1.3, 16.1 Hz, 2H), 6.80 (ddt, J= 6.0, 10.7, 16.1 Hz, 
2H), 7.97 (s, 2H), 8.42 (s, 2H). 13C NMR (125.8 MHz, DMSO-d6): & 74.53, 118.71, 
121.28, 129.55, 133.30, 141.54, 150.61, 155.15; MS (FAB) calc’d for C16H22N8O2 



















2,3-Dibutoxyterephthaldehyde-1,4-bis-guanylhydrazone Dihydro Dichloride 
(262g). yield 78%; 1H NMR (500 MHz, DMSO-d6): & 0.90 (t, 6H), 1.47 (m, 4H), 1.74 
(m, 4H), 4.00 (t, 4H), 8.11 (s, 2H), 8.41 (s, 2H). 13C NMR (125.8 MHz, DMSO-d6): & 
13.79, 18.71, 31.60, 74.06, 121.21, 129.51, 141.58, 151.34, 155.31; MS (ESI+) calc’d 















2,3-Dipentoxyterephthaldehyde-1,4-bis-guanylhydrazone Dihydro Dichloride 
(262h). yield 65%; 1H NMR (500 MHz, DMSO-d6): & 0.90 (t, 6H), 1.39 (m, 8H), 
1.76 (m, 4H), 3.96 (t, 4H), 7.94 (s, 2H), 8.40 (s, 2H). 13C NMR (125.8 MHz, DMSO-
d6):& 14.27, 22.37, 27.97, 29.59, 74.83, 121.66, 129.92, 142.08, 151.81, 155.59; MS 




















2,3-Dihexoxyterephthaldehyde-1,4-bis-guanylhydrazone Dihydro Dichloride 
(262i). yield 66%; 1H NMR (500 MHz, DMSO-d6): & 0.89 (t, 6H), 1.32 (m, 12H), 
1.74 (m, 4H), 3.97 (t, 4H), 7.94 (s, 2H), 8.42 (s, 2H). 113C NMR (125.8 MHz, 
DMSO-d6): & 14.29, 22.42, 25.47, 29.89, 31.50, 76.22, 121.66, 129.91, 142.09, 















2,3-Dioctoxyterephthaldehyde-1,4-bis-guanylhydrazone Dihydro Dichloride 
(262j). yield 90%; 1H NMR (500 MHz, DMSO-d6): & 0.86 (t, 6H), 1.30 (m, 20H), 
1.72 (m, 4H), 3.94 (t, 4H), 7.94 (s, 2H), 8.42 (s, 2H). 13C NMR (125.8 MHz, DMSO-
d6): & 13.84, 22.00, 25.37, 28.57, 29.71, 29.44, 31.17, 74.39, 121.17, 129.43, 141.49, 





















Dichloride (262k). yield 59%; 1H NMR (500 MHz, DMSO-d6): & 0.85 (t, 6H), 1.30 
(m, 44H), 1.76 (m, 4H), 3.94 (t, 4H), 7.95 (s, 2H), 8.40 (s, 2H). 13C NMR (125.8 
MHz, DMSO-d6): & 13.83, 22.00, 25.38, 28.63, 28.83, 28.91, 28.94, 29.46, 31.21, 
74.45, 121.21, 129.43, 141.54, 151.39, 155.14; MS (ESI+) calc’d for C38H70N8O2 m/z 















4.2.5 Crystal structure data for 185 
 
Data collection 
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A crystal (approximate dimensions 0.45x 0.45 x 0.25mm3) was placed onto the 
tip of a 0.1 mm diameter glass capillary and mounted on a CCD area detector  
diffractometer for a data collection at 123(2) K.1  A preliminary set of cell 
constants was calculated from reflections harvested from three sets of 20 
frames.  These initial sets of frames were oriented such that orthogonal wedges 
of reciprocal space were surveyed.  This produced initial orientation matrices 
determined from 84 reflections.  The data collection was carried out using 
MoK% radiation (graphite monochromator) with a frame time of 60 seconds 
and a detector distance of 4.8 cm.  A randomly oriented region of reciprocal 
space was surveyed to the extent of one sphere and to a resolution of 0.82 Å.  
Four major sections of frames were collected with 0.30º steps in * at four 
different + settings and a detector position of -28º in 2,.  The intensity data 
were corrected for absorption and decay (SADABS).2 Final cell constants were 
calculated from 2990 strong reflections from the actual data collection after 
integration (SAINT).3 Please refer to Table 1 for additional crystal and 
refinement information. 
 
Structure solution and refinement 
The structure was solved using Bruker SHELXTL4 and refined using Bruker 
SHELXTL.4 The space group I4 was determined based on systematic absences and 
 
186 
intensity statistics.  A direct-methods solution was calculated which provided most 
non-hydrogen atoms from the E-map.  Full-matrix least squares / difference Fourier 
cycles were performed which located the remaining non-hydrogen atoms.  All non-
hydrogen atoms were refined with anisotropic displacement parameters.  All 
hydrogen atoms were placed in ideal positions and refined as riding atoms with 
relative isotropic displacement parameters.  The final full matrix least squares 
refinement converged to R1 = 0.1047 and wR2 = 0.2871 (F2, all data). 
 
Structure description 
The structure is the one suggested. This result is provided to determine the correct 
connectivity and relative stereochemistry only. This result is not considered 
publishable due to a number of factors. The thermal ellipsoid drawing shows atoms 
C8 – C13 with oblate ellipsoids. This appears to be due to disordered solvent within 
pockets centered on the 4-fold axis. The crystal diffracted very poorly given the 
specimen size. Platon/Squeeze5 was used to quantify the disordered solvent and 
provide a correction for the effects of diffuse scattering. 408.6Å3, or 7.9% of the total 
volume was occupied by disordered solvent. 87 electrons were attributed to 
disordered solvent.  
 
 
If a high-resolution crystal structure determination is needed for publication, then 
please consider recrystallization from other solvents besides DEE and hexane. 
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Interrupting the hydrogen bonding pattern would present an opportunity to make a 
new crystal form with alcohols, perhaps. Another alternative would to form a 
derivative with the two –OH groups. This result is certainly acceptable to the point of 
the determination of connectivity and relative stereochemistry, however the quality is 
not acceptable for the determination of absolute configuration. This was selected 
based on use of reference materials. 
 
Data collection and structure solution were conducted at the X-Ray Crystallographic 
Laboratory, 192 Kolthoff Hall, Department of Chemistry, University of Minnesota.  
All calculations were performed using Pentium computers using the current 
SHELXTL suite of programs.  All publications arising from this report MUST either 
1) include Victor G. Young, Jr. as a coauthor or 2) acknowledge Victor G. Young, Jr.  





1   SMART V5.054, Bruker Analytical X-ray Systems, Madison, WI (2001). 
2   An empirical correction for absorption anisotropy, R. Blessing, Acta Cryst. A51, 
33-38(1995). 
3   SAINT+ V6.45, Bruker Analytical X-Ray Systems, Madison, WI (2003). 
4   SHELXTL V6.14, Bruker Analytical X-Ray Systems, Madison, WI (2000). 
7   A. L. Spek, Acta. Cryst.A46, C34 (1990).  PLATON, A Multipurpose 








Some equations of interest:  
 
Rint = -|Fo2-< Fo2>| / -|Fo2| 
R1 = -||Fo|-|Fc|| / -|Fo| 
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wR2 = [-[w(Fo2-Fc2)2] / -[w(Fo2)2]]1/2 
where w = q / ["2(Fo2) + (a*P)2 + b*P + d + e*sin(,)] 
GooF = S = [-[w(Fo2-Fc2)2] / (n-p)]1/2 
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Table 1.  Crystal data and structure refinement for 09113bs. 
________________________________________________________________________________ 
Identification code  09113bs 
Empirical formula  C24 H36 O5 Si 
Formula weight  432.62 
Temperature  123(2) K 
Wavelength  0.71073 Å 
Crystal system  Tetragonal 
Space group  I4 
Unit cell dimensions a = 19.080(6) Å % = 90° 
 b = 19.080(6) Å . = 90° 
 c = 14.100(9) Å / = 90° 
Volume 5133(4) Å3 
Z 8 
Density (calculated) 1.120 Mg/m3 
Absorption coefficient 0.120 mm-1 
F(000) 1872 
Crystal color, morphology Colorless, Plate 
Crystal size 0.45 x 0.45 x 0.25 mm3 
Theta range for data collection 1.51 to 26.61° 
Index ranges -16 0h 0 23,-14 0k 0 23,-17 0l 0 14 
Reflections collected 11480 
Independent reflections 4732 [R(int) = 0.1673] 
Observed reflections 2272 
Completeness to theta = 26.61° 99.3%  
Absorption correction Multi-scan 
Max. and min. transmission 0.97 and 0.947 
Refinement method Full-matrix least-squares on F2 
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Data / restraints / parameters 4732 / 1 / 278 
Goodness-of-fit on F2 0.970 
Final R indices [I>2sigma(I)] R1 = 0.1047, wR2 = 0.2609 
R indices (all data) R1 = 0.1674, wR2 = 0.2871 
Absolute structure parameter -0.4(4) 
Largest diff. peak and hole 0.473 and -0.318 e.Å-3 
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Table 2.  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 09113bs.  Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z Ueq 
________________________________________________________________________________ 
O1 2933(2) 4969(2) 4943(4) 69(1) 
C1 2255(3) 5121(4) 4919(5) 54(2) 
O2 1805(3) 4691(3) 5047(6) 102(2) 
C2 2121(3) 5867(4) 4789(6) 62(2) 
C3 2028(3) 6121(3) 3866(7) 64(2) 
C4 1903(4) 6818(4) 3748(9) 88(3) 
C5 1873(6) 7270(6) 4480(20) 168(9) 
C6 1980(6) 7016(8) 5448(14) 138(7) 
C7 2107(4) 6332(6) 5601(9) 95(4) 
C8 2233(4) 6051(8) 6496(10) 116(4) 
C9 2537(5) 6352(9) 7245(10) 159(7) 
C10 2706(8) 5961(16) 8145(9) 236(14) 
C11 2752(14) 5175(18) 8077(17) 258(16) 
C12 3236(7) 4862(10) 7392(10) 149(6) 
C13 3077(9) 4405(9) 6753(13) 166(8) 
C14 3527(5) 4174(5) 5984(8) 90(3) 
C15 3152(4) 4245(4) 5070(7) 78(3) 
O3 2076(2) 5659(2) 3149(4) 58(1) 
Si1 1454(1) 5326(1) 2448(2) 65(1) 
C16 1325(4) 4408(4) 2778(9) 97(4) 
C17 628(3) 5843(4) 2625(11) 116(4) 
C18 1792(4) 5425(4) 1222(6) 72(2) 
C19 2462(5) 4985(5) 1076(9) 107(3) 
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C20 1238(5) 5133(6) 492(7) 103(3) 
C21 1949(5) 6153(6) 941(8) 97(3) 
O4 4181(3) 4491(3) 6043(6) 98(2) 
C22 3637(4) 4060(4) 4317(7) 75(2) 
C23 3279(4) 4021(4) 3334(8) 92(3) 
C24 3755(4) 3818(4) 2559(9) 99(3) 




Table 3.   Bond lengths [Å] and angles [°] for 09113bs. 
_____________________________________________________ 
  O(1)-C(1) 1.327(7) 
  O(1)-C(15) 1.454(9) 
  C(1)-O(2) 1.201(7) 
  C(1)-C(2) 1.457(10) 
  C(2)-C(3) 1.400(12) 
  C(2)-C(7) 1.449(12) 
  C(3)-O(3) 1.345(9) 
  C(3)-C(4) 1.360(10) 
  C(4)-C(5) 1.34(2) 
  C(4)-H(4A) 0.9500 
  C(5)-C(6) 1.47(2) 
  C(5)-H(5A) 0.9500 
  C(6)-C(7) 1.345(18) 
  C(6)-H(6A) 0.9500 
  C(7)-C(8) 1.392(16) 
  C(8)-C(9) 1.334(15) 
  C(8)-H(8A) 0.9500 
  C(9)-C(10) 1.51(3) 
  C(9)-H(9A) 0.9500 
  C(10)-C(11) 1.50(4) 
  C(10)-H(10A) 0.9900 
  C(10)-H(10B) 0.9900 
  C(11)-C(12) 1.46(3) 
  C(11)-H(11A) 0.9900 
  C(11)-H(11B) 0.9900 





























  C(20)-H(20C) 0.9800 
  C(21)-H(21A) 0.9800 
  C(21)-H(21B) 0.9800 
  C(21)-H(21C) 0.9800 
  O(4)-H(4B) 0.8400 
  C(22)-C(23) 1.548(14) 
  C(22)-H(22A) 0.9900 









  C(1)-O(1)-C(15) 119.4(5) 
  O(2)-C(1)-O(1) 122.9(7) 
  O(2)-C(1)-C(2) 124.1(6) 
  O(1)-C(1)-C(2) 112.8(5) 
  C(3)-C(2)-C(7) 121.3(8) 
  C(3)-C(2)-C(1) 118.6(6) 
  C(7)-C(2)-C(1) 120.1(9) 
  O(3)-C(3)-C(4) 124.1(9) 
  O(3)-C(3)-C(2) 117.5(6) 
  C(4)-C(3)-C(2) 118.4(8) 
  C(5)-C(4)-C(3) 122.8(14) 
  C(5)-C(4)-H(4A) 118.6 
  C(3)-C(4)-H(4A) 118.6 
  C(4)-C(5)-C(6) 119.8(12) 
  C(4)-C(5)-H(5A) 120.1 
  C(6)-C(5)-H(5A) 120.1 
  C(7)-C(6)-C(5) 119.7(11) 
  C(7)-C(6)-H(6A) 120.2 
  C(5)-C(6)-H(6A) 120.2 























  C(13)-C(12)-C(11) 126.1(14) 
  C(13)-C(12)-H(12A) 117.0 
  C(11)-C(12)-H(12A) 117.0 
  C(12)-C(13)-C(14) 126.0(13) 
  C(12)-C(13)-H(13A) 117.0 
  C(14)-C(13)-H(13A) 117.0 
  O(4)-C(14)-C(13) 110.7(10) 
  O(4)-C(14)-C(15) 116.6(8) 
  C(13)-C(14)-C(15) 109.7(8) 
  O(4)-C(14)-H(14A) 106.4 
  C(13)-C(14)-H(14A) 106.4 
  C(15)-C(14)-H(14A) 106.4 
  O(1)-C(15)-C(22) 108.9(6) 
  O(1)-C(15)-C(14) 109.4(8) 
  C(22)-C(15)-C(14) 107.8(7) 
  O(1)-C(15)-H(15A) 110.2 
  C(22)-C(15)-H(15A) 110.2 
  C(14)-C(15)-H(15A) 110.2 
  C(3)-O(3)-Si(1) 130.2(4) 
  O(3)-Si(1)-C(16) 108.0(4) 
  O(3)-Si(1)-C(18) 105.4(3) 
  C(16)-Si(1)-C(18) 112.4(5) 
  O(3)-Si(1)-C(17) 108.5(4) 
  C(16)-Si(1)-C(17) 110.9(4) 
  C(18)-Si(1)-C(17) 111.3(5) 
  Si(1)-C(16)-H(16A) 109.5 
  Si(1)-C(16)-H(16B) 109.5 
  H(16A)-C(16)-H(16B) 109.5 
































  C(18)-C(21)-H(21C) 109.5 
  H(21A)-C(21)-H(21C) 109.5 
  H(21B)-C(21)-H(21C) 109.5 
  C(14)-O(4)-H(4B) 109.5 
  C(15)-C(22)-C(23) 112.6(6) 
  C(15)-C(22)-H(22A) 109.1 
  C(23)-C(22)-H(22A) 109.1 
  C(15)-C(22)-H(22B) 109.1 
  C(23)-C(22)-H(22B) 109.1 
  H(22A)-C(22)-H(22B) 107.8 
  C(24)-C(23)-C(22) 113.8(7) 












  _____________________________________________________________ 




Table 4.   Anisotropic displacement parameters (Å2x 103)for 09113bs.  The anisotropic 
displacement factor exponent takes the form: -2!2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
________________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
________________________________________________________________________________ 
O1 45(2)  70(3) 92(4)  4(3) 6(3)  -15(2) 
C1 43(3)  80(4) 38(4)  -1(3) 8(3)  -18(3) 
O2 56(3)  110(4) 141(6)  -7(4) 21(3)  -31(3) 
C2 36(3)  76(5) 73(6)  -25(4) 6(3)  1(3) 
C3 39(3)  36(3) 118(8)  -19(4) 9(4)  3(3) 
C4 67(5)  53(4) 144(9)  6(5) 6(5)  6(3) 
C5 75(7)  58(6) 370(30)  -92(12) 46(12)  -8(5) 
C6 77(7)  111(11) 227(18)  -111(12) 36(9)  -1(6) 
C7 39(4)  135(9) 112(9)  -71(7) 16(5)  -15(4) 
C8 50(5)  201(12) 98(9)  -52(9) -8(5)  -22(6) 
C9 63(6)  287(17) 128(12)  -124(12) -4(6)  -22(7) 
C10110(10)  570(50) 29(6)  -64(14) 27(6)  -89(18) 
C11200(20)  440(40) 131(19)  -60(20) -95(17)  -140(20) 
C12118(9)  282(16) 46(6)  22(9) -5(7)  -85(10) 
C13159(13)  209(15) 130(13)  86(12) -97(12)  -116(12) 
C14 69(5)  105(7) 96(8)  49(6) -15(5)  -16(5) 
C15 60(4)  69(4) 106(7)  38(5) -18(5)  -24(3) 
O3 45(2)  45(2) 84(4)  -6(2) 3(2)  2(2) 
Si1 42(1)  55(1) 98(2)  3(1) -4(1)  -1(1) 
C16 58(4)  55(4) 179(11)  3(5) -25(5)  -1(3) 
C17 36(3)  78(5) 233(13)  0(7) -20(6)  12(3) 
C18 61(4)  88(5) 69(5)  -1(4) -32(4)  -7(4) 
C19105(7)  104(7) 110(9)  -21(6) -42(6)  14(5) 
C20101(7)  139(8) 68(7)  -3(6) -40(5)  0(5) 
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C21 87(6)  120(8) 84(7)  20(6) -12(5)  -11(5) 
O4 64(3)  97(4) 133(6)  16(4) -34(3)  -9(3) 
C22 57(4)  57(4) 111(7)  14(4) 1(5)  10(3) 
C23 60(4)  46(4) 170(11)  2(5) -10(6)  2(3) 
C24 64(4)  49(4) 182(11)  -9(6) 35(6)  2(3) 




Table 5.   Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 103) 
for 09113bs. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H4A 1833 6992 3124 106 
H5A 1782 7752 4364 201 
H6A 1959 7333 5967 166 
H8A 2083 5581 6586 139 
H9A 2652 6836 7209 191 
H10A 3159 6138 8389 283 
H10B 2343 6079 8622 283 
H11A 2879 4996 8713 309 
H11B 2276 4997 7932 309 
H12A 3711 5008 7421 178 
H13A 2624 4201 6789 199 
H14A 3606 3661 6081 108 
H15A 2735 3927 5056 94 
H16A 1069 4384 3380 146 
H16B 1781 4179 2850 146 
H16C 1055 4170 2282 146 
H17A 466 5788 3281 173 
H17B 266 5672 2190 173 
H17C 720 6340 2498 173 
H19A 2683 5114 473 160 
H19B 2340 4486 1064 160 
H19C 2790 5074 1597 160 
H20A 1471 5031 -112 154 
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H20B 870 5484 391 154 
H20C 1029 4702 744 154 
H21A 2019 6175 253 145 
H21B 2375 6311 1264 145 
H21C 1556 6457 1119 145 
H4B 4152 4853 6380 147 
H22A 3852 3600 4463 90 
H22B 4018 4412 4293 90 
H23A 2890 3678 3366 111 
H23B 3073 4484 3185 111 
H24A 4013 3391 2749 118 
H24B 3472 3701 1992 118 




























































Symmetry transformations used to generate equivalent atoms:  
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Table 7.  Hydrogen bonds for 09113bs [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 O4-H4B...O4#1 0.84 2.01 2.601(7) 126.9 
 O5-H5B...O5#1 0.84 2.12 2.664(8) 121.7 
____________________________________________________________________________
Symmetry transformations used to generate equivalent atoms:  
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